Official Protocol Title:  
NCT number:  
Document Date:  A Phase II Study of Navarixin (MK-7123) in Combination 
with Pembrolizumab (MK-3475) in Participants with Selected 
Advanced/Metastatic Solid Tumors
22-March-2018[STUDY_ID_REMOVED]
Product:   MK-7123 SCH 527123 1
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTitle Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A.
(MSD).
Protocol Title: A Phase II Study  of Navarixin (MK -7123) in Combination with 
Pembrolizumab (MK -3475) in Participants with Selected Advanced/Metastatic Solid Tumors
Protocol Number: 034-01
Compound Number: MK-7123
Sponsor Name and Legal Registered Address: 
Merck Sharp & Dohme Corp., a subsidiary  of Merck & Co., Inc. 
(hereafter referred to as the Sponsor or MSD )
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey , 08889 -0100, U.S.A.
Regulatory Agency Ident ifying Number(s):
IND NUMBER:   137,203
EudraCT NUMBER: Not Applicable
Approval Date:  22- Mar -2018 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 2
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialSponsor Signatory
Typed Name:
Title:Date
Protocol -specific Sponsor Contact information can be found in the Investigator Trial 
File Binder (or equivalent). 
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all provisions of this protocol.
Typed Name:
Title:Date 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 3
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialPROTOCOL AMENDMENT S UMMARY OF CHANGES
Amendment 01
Overall Rationale for the Amendment:
Revisions/updates incorporated based on feedback from regulatory agency , data management, and sites.
Summary of Changes Table:
Section # and
NameDescription of Change Brief Rationale
2. Schedule of 
Activities (SoA)Addition of row in Efficacy  Procedures 
section for MSI testing of tumor sample in 
participants with CRPC who show a 
response to treatmentTo assist in interpreting response to tre atment in the CRPC 
participant population.
9.2.3 MSI  Status Information noting that MSI  testing will be 
performed on tumor samples from CRPC 
participants who show a response to 
treatmentTo align with the change made to the Schedule of Activities 
described in the row above .
(To assist in interpreting response to treatment in the CRPC 
participant population )
2. Schedule of 
Activities (SoA)In Notes cell of Hematology  row:
Revision of descr iption of time points for 
collection of hematology (including ANC) 
blood samples.This change is made to remove ambiguity regarding collection of 
ANC samples :
As a safety  lab, hematology  (including ANC) will be collected 
on Day  1 of every  cycle pre -dose as follows:
On day s whe nnavarixin PK samples are collected, 
pre-dose ANC should be collected within 2 h ours prior 
to dosing.
On day s whe nnavarixin PK is not collected, pre -dose 
ANC can be collected within 24 hours prior to dosing
An additional sample ( for pharmacod ynamics assessment )
will be collected between 6- 12 hours after dosing on Day s 1, 
3, and 8 of Cy cle 1, and Day  1 of C ycle 2. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 4
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialSection # and
NameDescription of Change Brief Rationale
9.7 
Pharmacod ynamicsRemoval of the phrase “After C ycle 4: 
Same scheme as Pembro PK” from 
description of when venous sampl es for 
ANC are to be collected.To align with the change made to the Schedule of Activities 
described in the row above.
(To remove ambiguit y regarding collection of ANC samples)
2. Schedule of 
Activities (SoA)In Notes cell of Comprehensive Chemistry 
Panel row:
Revision of description of time points for 
collection of chemistry  panel blood 
samples.The following change is made to allow chemistry  samples to be 
collected at the same time as hematology samples:
Chemistry  panel will be collected on Day 1  ofevery  cycle 
pre-dose as follows:
On days whennavarixin PK samples are collected, pre-
dose sample should be collected within 2 hours prior to 
dosing.
On days whennavarixin PK is notcollected, pre-dose 
sample can be collected within 24 hours prior to dosing.
2. Schedule of 
Activities (SoA)In Notes cell of Th yroid Function (T3, or 
FT3, T4 or  FT4, and TSH) Testing row:
Revision of description of time points for 
collection of thyroid testing blood samples.The following change is made to allow thyroid function samples 
to be collected at the same time as hematology  samples:
Thyroid testing will be collected on Day  1 of every  cycle pre -
dose as follows:
On days whennavarixin PK samples are collected, pre-
dose sample should be collected within 2 hours prior to 
dosing.
On days whennavarixin PK is not collected, pre-dose 
sample can be collected within 24 hours prior to dosing. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 5
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialSection # and
NameDescription of Change Brief Rationale
5.1 Overall Design Added clarify ing language regarding 
discontinuing enrollment in an arm due to 
DLTs in Stage 1.The following sentence is added to ensure participant safet y:
However, during Stage 1, if at any time >3 DLTs are observed 
within the first 10 evaluable participants , enrollment into an 
arm will be discontinued. 
5.1 Overall Design Stopping rule for excessive toxicity  
occurring outside the protocol defined 
window is added.This change is made to ensure participant safet y.
5.1.3 Dose 
Limiting ToxicityDefinition of DLT is modified . The following criteria for anemia are added to expand the 
definition of DLT :
Grade 4 anemia of an y duration
Grade 3 anemia lasting >7 day s or requiring transfusion
6.1 Exclusion 
CriteriaExclusion Criterion #4 is modified, adding 
the sentence
“In addition to active autoimmune disease, 
participants who have previously been 
permanentl y discontinued from PD -(L)1 
therap y due to immune related side effects 
are not eligible for the study .”This change is made for participant safety .
6.1 Exclusion 
CriteriaExclusion criterion #5, “History  of 
vasculitis” is deleted.
(list of criteria has been renumbered)Vasculitis is not a risk for navarixin or pembrolizumab. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 6
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialSection # and
NameDescription of Change Brief Rationale
6.1 Exclusion 
CriteriaExclusion criterion #1 2 (previously
criterion #1 3)is mod ified to include 
history  or evidence of gastrointestinal 
condition(s) or impaired liver function or 
diseases that may  significantly  alter 
absorption or metabolism of oral 
medication.This change is made because navarixin is administered orally .
9.1.12 Calibration 
of EquipmentBulleted list of critical equipment for the 
trial is deleted.This change is made per process update. 
9.2.1.3 End of 
Treatment and 
Follow -up Tumor 
ImagingMonitoring disease status by tumor 
imaging is changed from every  9 weeks to 
every  12 weeks (±7 day s).This change corrects the end of treatment and follow -up tumor 
imaging interval to be consistent with that shown in the Schedule 
of Activities.
9.3.1  Time Period 
and Frequency  for 
Collecting AE, 
SAE and Other 
Reportable Safet y 
Event Information The time period and frequency  for 
collection of AE, SAE and other reportable 
safet y event information is corrected.This correction ensures alignment of the time period and 
frequency  of data collection with pembrolizumab protocol 
standards and is consistent with other sections of the protocol. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 7
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialTable of Contents
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 3
1. Synopsis ....................................................................................................................... 15
2. Schedule of Activities (SoA) ...................................................................................... 19
3. Introduction ................................................................................................................ 29
Study Rationale ....................................................................................................... 29 3.1
Background .............................................................................................................. 29 3.2
Pharmaceutical and Therapeutic Background ..................................................... 30 3.2.1
Navarixin Pharmaceutical and Therapeutic Background ............................. 30 3.2.1.1
Pembrolizumab (MK -3475) Pharmaceutical and Therapeutic 3.2.1.2
Background ................................................................................................... 31
Benefit/Risk Assessment ......................................................................................... 31 3.3
4. Objectives/Hypotheses and Endpoints ..................................................................... 32
5. Study Design ............................................................................................................... 33
Overall Design ......................................................................................................... 33 5.1
Study  Diagram ..................................................................................................... 35 5.1.1
Evaluation of Safet y............................................................................................. 36 5.1.2
Dose L imiting Toxicity ........................................................................................ 37 5.1.3
Futility  Anal ysis................................................................................................... 38 5.1.4
Number of Participants .......................................................................................... 38 5.2
Beginning and End of Study Definition ................................................................ 38 5.3
Clinical Criteria for Early Study Termination ..................................................... 39 5.3.1
Scientific Rationale for Study Design .................................................................... 39 5.4
Rationale for Endpoints ....................................................................................... 39 5.4.1
Efficacy Endpoints ...................................................................................... 39 5.4.1.1
Safety  Endpoints ........................................................................................... 40 5.4.1.2
Pharmacokinetic Endpoints .......................................................................... 40 5.4.1.3
Pharmacod ynamic Endpoints ........................................................................ 40 5.4.1.4
Planned Exploratory  Biomarker Research .................................................... 41 5.4.1.5 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 8
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialPlanned Genetic Anal ysis...................................................................... 42 5.4.1.5.1
Future Biomedical Research ......................................................................... 42 5.4.1.6
Justification for Dose .............................................................................................. 43 5.5
Starting Dose for This Study ................................................................................ 43 5.5.1
Maximum Dose/Exposure for This Study ........................................................... 44 5.5.2
Rationale for Dose Interval and Study Design ..................................................... 44 5.5.3
6. Study Population ........................................................................................................ 45
Inclusion Criteria .................................................................................................... 45 6.1
Exclusion Criteria ................................................................................................... 49 6.2
Lifestyle Restrictions............................................................................................... 51 6.3
Screen Failures ........................................................................................................ 51 6.4
Participant Replacement Strategy ......................................................................... 51 6.5
7. Treatments .................................................................................................................. 52
Treatments Administered ....................................................................................... 52 7.1
Dose Modification ................................................................................................... 53 7.2
Navarixin Dose Modification .............................................................................. 53 7.2.1
Pembrolizumab Dose Modification ..................................................................... 56 7.2.2
Method of Treatment Assignment ......................................................................... 61 7.3
Stratification ......................................................................................................... 61 7.3.1
Blinding .................................................................................................................... 61 7.4
Preparation/Handling/Storage/Accountability .................................................... 61 7.5
Dose Preparation .................................................................................................. 61 7.5.1
Handling, Storage and Accountability ................................................................ .61 7.5.2
Treatment Compliance ........................................................................................... 62 7.6
Concomitant Therapy ............................................................................................. 62 7.7
Rescue Medications and Supportive Care ........................................................... 62 7.7.1
Treatment After the End of the Study .................................................................. 67 7.8
Clinical Supplies Disclosure ................................................................................... 67 7.9
8. Discontinuation/Withdrawal Criteria ...................................................................... 67
Discontinuation of Study Treatment ..................................................................... 67 8.1
Withdrawal from the Study ................................................................................... 67 8.2 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 9
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialLost to Follow Up .................................................................................................... 68 8.3
9. Study Assessments and Procedures.......................................................................... 68
Administrative and General Procedures .............................................................. 69 9.1
Informed Consent ................................................................................................ .69 9.1.1
General Informed Consent ............................................................................ 69 9.1.1.1
Consent and Collection of Specimens for Future Biomedical 9.1.1.2
Research ........................................................................................................ 70
Inclusion/Exclusion Criteria ................................................................................ 70 9.1.2
Participant Identification Card ............................................................................. 70 9.1.3
Medical History ................................................................................................... 70 9.1.4
General Medical History ............................................................................... 70 9.1.4.1
Oncologic Disease Details ............................................................................ 70 9.1.4.2
Prior and Concomitant Medications Review ....................................................... 71 9.1.5
Prior Medications .......................................................................................... 71 9.1.5.1
Prior Oncologic Treatment ........................................................................... 71 9.1.5.2
Concomitant Medications ............................................................................. 71 9.1.5.3
Assignment of Screening Number ....................................................................... 71 9.1.6
Assignment of Treatment/Randomization Number ............................................. 71 9.1.7
Treatment Administration .................................................................................... 72 9.1.8
Timing of Dose Administration .................................................................... 72 9.1.8.1
Discontinuation and Withdrawal ......................................................................... 72 9.1.9
Withdrawal From Future Biomedical Research ........................................... 72 9.1.9.1
Participant Blinding/Unblinding .......................................................................... 72 9.1.10
Domiciling ........................................................................................................... 72 9.1.11
Calibration of Equipment ..................................................................................... 73 9.1.12
Efficacy Assessments............................................................................................... 73 9.2
Tumor I maging and Assessment of Disease ........................................................ 73 9.2.1
Initial Tumor Imaging ................................................................................... 73 9.2.1.1
Tumor Imaging During the Study ................................................................ .74 9.2.1.2
End of Treatment and Follow -up Tumor I maging ........................................ 74 9.2.1.3
RECI ST 1.1 Assessment of Disease ............................................................. 74 9.2.1.4
iRECI ST Assessment of Disease .................................................................. 75 9.2.1.5 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 10
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialProstate -Specific Antigen .................................................................................... 77 9.2.2
MSI Status in CPRC Patients ............................................................................... 77 9.2.3
Adverse Events (AE), Serious Adverse Events (SAE) and Other Reportable 9.3
Safety Events ........................................................................................................... 77
Time Period and Frequency  for Collecting AE, SAE and Other 9.3.1
Reportable Safet y Event Information .................................................................. 78
Method of Detecting AE, SAE and Other Reportable Safet y Events .................. 80 9.3.2
Follow -up of AE, SAE and Other Reportable Safety  Event Information ............ 80 9.3.3
Regulatory  Reporting Requirements for SAE ..................................................... 80 9.3.4
Disease -Related Events and/or Disease -Related Outcomes Not 9.3.5
Qualifying as AEs or SAEs .................................................................................. 80
Pregnancy  and Exposure During Breastfeeding .................................................. 81 9.3.6
Events of Clinical I nterest (ECI ).......................................................................... 81 9.3.7
Treatment of Overdose ........................................................................................... 81 9.4
Safety ........................................................................................................................ 81 9.5
Physical Examinations ......................................................................................... 82 9.5.1
Full Phy sical Exam ....................................................................................... 82 9.5.1.1
Directed Ph ysical Exam ......................................................................... 82 9.5.1.1.1
Vital Signs............................................................................................................ 82 9.5.2
Electrocardiograms .............................................................................................. 82 9.5.3
Clinical Safety  Laboratory  Assessments .............................................................. 82 9.5.4
Pharmacokinetics .................................................................................................... 83 9.6
Blood Collection for Plasma Navarixin ............................................................... 83 9.6.1
Cycle 1 .......................................................................................................... 83 9.6.1.1
Cycles 2 to 4.................................................................................................. 83 9.6.1.2
After C ycle 4 ................................................................................................ .84 9.6.1.3
Blood Collection for Pembrolizumab .................................................................. 84 9.6.2
Pharmacodynamics ................................................................................................ .84 9.7
Biomarkers .............................................................................................................. 84 9.8
Future Biomedical Research Sample Collection .................................................. 85 9.9
Health Economics .................................................................................................... 85 9.10
Visit Requirements .................................................................................................. 85 9.11
Screening .............................................................................................................. 85 9.11.1 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 11
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialTreatment Period .................................................................................................. 86 9.11.2
Post-Study ............................................................................................................ 86 9.11.3
Safety  Follow -up Visit .................................................................................. 86 9.11.3.1
Disease Status Follow -up.............................................................................. 86 9.11.3.2
Survival Follow -up....................................................................................... 86 9.11.3.3
Survival Status ..................................................................................................... 87 9.11.4
10. Statistical Analysis Plan ............................................................................................ 87
Statistical Analysis Plan Summary........................................................................ 87 10.1
Responsibility for Analyses/In -House Blinding .................................................... 89 10.2
Hypotheses/Estimation ........................................................................................... 89 10.3
Analysis Endpoints .................................................................................................. 89 10.4
Efficacy /Pharmacokinetics/Pharmacody namic Endpoints .................................. 89 10.4.1
Safety  Endpoints .................................................................................................. 90 10.4.2
Analysis Populations ............................................................................................... 90 10.5
Efficacy  Anal ysis Po pulations ............................................................................. 90 10.5.1
Safety Anal ysis Populations ................................................................................ 90 10.5.2
Pharmacokinetic Analy sis Populations ................................................................ 90 10.5.3
Statistical Methods .................................................................................................. 90 10.6
Statistical Methods for Efficacy  Anal ysis............................................................ 91 10.6.1
Statistical Methods for Safety Anal ysis............................................................... 91 10.6.2
Summaries of Baseline Characteristics, Demographics, and Other 10.6.3
Analy ses............................................................................................................... 91
Demographic and Baseline Characteristics .................................................. 91 10.6.3.1
Pharmacokinetic and Pharmacod ynamic Modeling Analysis ....................... 91 10.6.3.2
Interim Analyses ..................................................................................................... 91 10.7
Multiplicity .............................................................................................................. 92 10.8
Sample Size and Power Calculations .................................................................... 92 10.9
Subgroup Analyses .................................................................................................. 93 10.10
Compliance (Medication Adherence) .................................................................... 93 10.11
Extent of Exposure .................................................................................................. 93 10.12
11. References ................................................................................................................... 93
12. Appendices .................................................................................................................. 96 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 12
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialAppendix 1: Study Governance Considerations .................................................. 96 12.1
Merck Code of Conduct for Clinical Trials ..................................................................... 96
Financial Disclosure ......................................................................................................... 98
Data Protection ................................................................................................................. 98
Confidentiality  of Data .................................................................................................... 98
Confidentiality  of Participant Records ............................................................................. 98
Confidentiality  of IRB/IEC I nformation .......................................................................... 99
Publication Policy ............................................................................................................ 99
Compliance with Study  Registration and Results Posting Requirements ....................... 99
Compliance with La w, Audit and Debarment ............................................................... 100
Data Qualit y Assurance ................................................................................................ .100
Source Documents ......................................................................................................... 101
Study  and Site Closure ................................................................................................... 101
Appendix 2: Collection and Management of Specimens for Future 12.2
Biomedical Research ............................................................................................. 102
Appendix 3: Contraceptive Guidance and Pregnancy Testing ......................... 106 12.3
Definitions ...................................................................................................................... 106
Contraception Requirements .......................................................................................... 107
Pregnancy  Testing .......................................................................................................... 109
Appendix 4: Adverse Events: Definitions and Procedures for Recording, 12.4
Evaluating, Follow -up, and Reporting ................................................................ 110
Definition of AE ............................................................................................................ 110
Definition of SAE ...................................................................................................... 111
Additional Events report ed in the same manner as SAE ............................................... 112
Recording AE and SAE ................................................................................................ .112
Reporting of AE, SAE, and Other Reportable Safety  Events to the Sponsor ................ 115
Appendix 5: Clinical Laboratory Tests ............................................................... 117 12.5
Appendix 6: Abbreviations and Trademarks ..................................................... 119 12.6
Appendix 7: Description of the iRECIST Process for Assessment of Disease 12.7
Progression ............................................................................................................ 122 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 13
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialLIST OF TABLES
Table 1 Adequate Organ Function L aboratory  Values ................................ ...................... 48
Table 2 Study  Treatment(s) ................................ ................................ ............................... 52
Table 3 Navarixin/Study  Drug Dose Modifications ................................ .......................... 54
Table 4 Dose Modification and Toxicity  Management Guidelines for Immune-
related AEs Associated with Pembrolizumab ................................ ....................... 57
Table 5 Pembrolizumab I nfusion Reaction Treatment Guidelines ................................ ....65
Table 6 Imaging and Treatment After First Radiologic Evidence of Progressive 
Diseas e................................ ................................ ................................ .................. 76
Table 7 Reporting Time Periods and Timeframes for Adverse Events and Other 
Reportable Safet y Events ................................ ................................ ...................... 79
Table 8 Probability  That ORR is Claimed as Clinical I nterest With 20 
Participants in Each Tumor Ty pe of Each Arm ................................ .................... 92
Table 9 The CI  of the True ORR U nder Different Hy pothetical Number of 
Observed Response Scenarios With 20 Participants in Each Tumor 
Type of Each Arm ................................ ................................ ................................ 93
Table 10 Highl y Effective Contraception Methods ................................ ........................... 108
Table 11 Protocol -Required Safet y Laboratory  Assessments ................................ ........... 117 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 14
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialLIST OF FIGURES
Figure 1 Study  Design ................................ ................................ ................................ ......... 35
Figure 2 Guidance for Dose Decision and Expansion ................................ ........................ 36
Figure 3 Imaging and Treatment for Clinically  Stable Participants Treated With 
Pembrolizumab After First Radiologic Evidence of PD Assessed b y the 
Investigators ................................ ................................ ................................ .......... 77 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 15
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidential1.Synopsis
Protocol Title:  
A Phase II Stud y of Navarixin (MK -7123) in Combination with Pembrolizumab (MK -3475) in 
Participants with Selected Advanced/Metastatic Solid Tumors
Short Title: 
A Phase II Stud y of Navarixin (MK -7123) in Combination with Pembrolizumab (MK -3475) in 
Participants with Selected Advanced/Metastatic Solid Tumors
Objectives/Hypothese s and Endpoints:
Male/female participants of at least 18 years of age with selected advanced/metastatic solid 
tumors will be enrolled in this study .
Objective Endpoint
Primary
Objective: To evaluate the objective 
response rate (ORR) as assessed by  the 
investigator based on Response 
Evaluation Criteria in Solid Tumors 
Version 1.1 (RECI ST 1.1) following 
administration of navarixin in 
combination with pembrolizumab. Objective response is a confirmed 
complete response (CR) or partial 
response (PR) .
Objective: To determine the safet y and 
tolerability  of navarixin in combination 
with pembrolizumab.Dose-limiting toxicity  (DLT)
Adverse event (AE)
Discontinuing study  treatment due to 
an AE.   
Secondary
Objective: To evaluate objective 
response rate (ORR) as assessed by  
investigator based on iRecist (modified 
RECI ST 1.1) ,progression- free survival 
(PFS) as assessed b y RECI ST and 
iRECI ST and overall survival (OS) 
following administration of navarixin 
in combination with pembrolizumab .Objective response is a confirmed CR 
or PR .
PFS is time from the first dose of study  
medication to the first documented 
disease progression or death due to an y 
cause, whichever occurs first.
OS is time from the first dose of study  
medication to death due to any  cause .
Objective: To evaluate the 
pharmacod ynamics as measured b y 
absolute neutrophil counts (ANC) 
following administration of navarixin in 
combination with pembrolizumab.ANC in 109/L 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 16
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialObjective: To evaluate the 
pharmacokinetics of navarixin when 
administered in combination with 
pembrolizumab.Pharmacokinetic parameters including 
area under the curve (AUC) in 
ng·hr/mL , maximum concentration 
(Cmax)in ng/mL , trough concentration 
(Ctrough)in ng/mL
Overall Design:
Study Phase Phase 2
Clinical I ndication Treatment of participants with advanced /metastatic solid 
tumors.
Population Participants with histologically  or cy tologicall y confirmed 
advanced/metastatic solid tumors in 3selected tumor ty pes.
Study Type Interventional
Type of Design This is a stratified, parallel, 2-dose randomized (1:1), 
uncontrolled multicenter study  of navarixin in combination 
with pembrolizumab. The study will use a 2- stage adaptive 
design based on pre- specified criteria for response rate.
Type of Control   No treatment control
Study Blinding Unblinded Open- label
Estimated Duration 
of StudyThe Sponsor estimates that the study will require 
approximately  3years from the time the first participant signs 
the informed consent until the last participant’s last study -
related phone call or visit.   
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 17
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialNumber of Participant s:
Approximately  120participants will be enrolled.
Treatment Groups and Duration :
Treatment Groups Participants will be stratified by  tumor t ype and randomized 
1:1 to either of 2 dose level arms: Arm A will receive 30 mg 
navarixin orally  QD + pembrolizumab 200 mg IV Q3W; 
Arm B will receive 100 mg navarixin orally  QD + 
pembrolizumab 200 mg IV Q3W.
In Stage 1 of the stud y, 30 participants will be randomized to 
each arm. InStage 2, barring earl y termination of the arm, 30 
additional participants will be randomized to each arm.
Duration of 
ParticipationEach participant will participate in the study  from the time 
the participant signs the informed consent form (ICF) 
through the final protocol- specified contact.  
After a screening phase of up to 28 day s, each participant 
will be assigned to receive study  treatment until disease 
progression is radiographically  documented and, when 
clinically  appropriate, confirmed by  the site per modified 
Response Evaluation Criteria in Solid Tumors 1.1 for 
immune -based therapeutics (iRECI ST), una cceptable adverse 
event(s) (AEs), intercurrent illness that prevents further 
administration of treatment, Investigator’s decision to 
withdraw the participant, noncompliance with study  
treatment or procedure requirements ,administrative reasons 
requiring cessation of treatment, or until the participant has 
received 35 administrations (approximately  2 years) of
combination treatment with navarixin and pembrolizumab. 
Monotherap y treatment with pembrolizumab will be allowed 
if navarixin treatment is withheld for ANC or febrile 
neutropenia .  
After the end of treatment, each participant will be followed 
for the occurrence of AEs and spontaneousl y reported 
pregnancy  as described under Section 9.3.  
Participants who discontinue for reasons other than 
radiographic disease progression will have post -treatment 
follow -up imaging for disease status until disease 
progression is documented radiographically  per RECI ST 1.1 
and, when clinically  appropriate, confirmed by  the site per 
iRECI ST, initiating a non- study  cancer treatment, 
withdrawing consent, becoming lost to follow -upor the end 
of the study .  All participants will be followed by  telephone 
for overall survival until death, participant withdrawal of 
consent, becoming lost to follow-up or the end of the study .   
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 18
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialStudy  governance considerations are outlined in Appendix 1. A list of abbreviations used in 
this document can be found in Appendix 6. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 19
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidential2.Schedule of Activities (SoA)
Trial Period:Screening 
PhaseTreat ment Phase  ( 21-day Treatment 
Cycles )End of 
Treat ment 
(EOT) / 
Discon-
tinuationPost-Treatment Phase Notes
Treat ment Cycle/Title:Screening
(Visit 1)1 2 34 to 
35Safety Follow -
upImaging 
Follow -
upSurvival 
Follow -up
Treat ment Days per 
Cycle:1 3 8 1 1 1At tim e of 
treat ment 
discon.30 days post 
last dose study 
medicationEvery 12 
weeksEvery 12 
weeks
Visit Window (Days) -28 to -1 ± 3 ± 3 ± 3 +7 +7 ± 7 ± 7 Procedure windows may vary 
Administrative Procedures
Informed Consent X
Informed Consent for 
Future Biomedical 
ResearchX
Participant Identification 
CardX
Inclusion/Exclusion 
CriteriaX
Demographic and 
Medical History X
Oncology Disease Details 
and Prior Oncology 
Treatment HistoryX
Prior/Concomitant 
Medication ReviewX X X X X X X X X
Treatment 
RandomizationXDose within 3 days of 
randomization   
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 20
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTrial Period:Screening 
PhaseTreat ment Phase  ( 21-day Treatment 
Cycles )End of 
Treat ment 
(EOT) / 
Discon-
tinuationPost-Treatment Phase Notes
Treat ment Cycle/Title:Screening
(Visit 1)1 2 34 to 
35Safety Follow -
upImaging 
Follow -
upSurvival 
Follow -up
Treat ment Days per 
Cycle:1 3 8 1 1 1At tim e of 
treat ment 
discon.30 days post 
last dose study 
medicationEvery 12 
weeksEvery 12 
weeks
Visit Window (Days) -28 to -1 ± 3 ± 3 ± 3 +7 +7 ± 7 ± 7 Procedure windows may vary 
Navarixin
AdministrationNavarixin doses:
ArmA: 30 mg orally QD
or
ArmB: 100 mg orally QD
Pembrolizumab 
Administration  X X X XPembrolizumab dose: 200 mg 
IV Q3W
Efficacy Procedures
Tumor Imaging and 
Response AssessmentX X X XScreening imaging within 28 
days of first dose.  
On-study imaging every 9 
weeks (±7 days) from first 
dose, or as clinically indicated
MSI status testing of 
tumor tissue from CRPC 
participants X**CRPC participants who have 
an objective response
(confirmed or unconfirmed) to 
therapy will complete ,if not 
previously done on an archival 
or newly obtained tumor 
sample.   Testing need only be 
completed once.
Subsequent anti -
neoplastic therapy statusX X X X 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 21
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTrial Period:Screening 
PhaseTreat ment Phase  ( 21-day Treatment 
Cycles )End of 
Treat ment 
(EOT) / 
Discon-
tinuationPost-Treatment Phase Notes
Treat ment Cycle/Title:Screening
(Visit 1)1 2 34 to 
35Safety Follow -
upImaging 
Follow -
upSurvival 
Follow -up
Treat ment Days per 
Cycle:1 3 8 1 1 1At tim e of 
treat ment 
discon.30 days post 
last dose study 
medicationEvery 12 
weeksEvery 12 
weeks
Visit Window (Days) -28 to -1 ± 3 ± 3 ± 3 +7 +7 ± 7 ± 7 Procedure windows may vary 
Survival Status XAfter investigator determined 
PD or start of new anticancer 
treatment. In addition, upon 
Sponsor request, participants 
may be contacted for survival 
status at any time during the 
course of the study.
Clinical 
Procedures /Assessments
Full physical examination X X X
Directed Physical 
ExaminationX X X X
Height X
Weight X X X X X X X
Vital Signs X X X X X X XVS: heart rate, respiratory rate, 
blood pressure, temperature
12-lead ECG XPerform additional test as 
clinically indicated. 
ECOG Performance 
StatusX X X X X X X 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 22
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTrial Period:Screening 
PhaseTreat ment Phase  ( 21-day Treatment 
Cycles )End of 
Treat ment 
(EOT) / 
Discon-
tinuationPost-Treatment Phase Notes
Treat ment Cycle/Title:Screening
(Visit 1)1 2 34 to 
35Safety Follow -
upImaging 
Follow -
upSurvival 
Follow -up
Treat ment Days per 
Cycle:1 3 8 1 1 1At tim e of 
treat ment 
discon.30 days post 
last dose study 
medicationEvery 12 
weeksEvery 12 
weeks
Visit Window (Days) -28 to -1 ± 3 ± 3 ± 3 +7 +7 ± 7 ± 7 Procedure windows may vary 
Laboratory Procedures/Assessments –Analysis by Local Lab
Serum β -Hum an 
Chorionic Gonadotropin 
or Urine Pregnancy Test
(β-hCG; Women of
childbearing potential 
(WOCBP) only)X• Additional urine/serum 
testing may be performed if 
clinically warranted, and/or as 
defined by local regulations.
• If a urine pregnancy test 
cannot be confirmed as 
negative, a serum pregnancy 
test is requ ired. 
• Obtain urine pregnancy test 
within 72 hours prior to first 
dose.
Serum Follicle 
Stimulating Hormone 
(FSH) -(WOCBP only)XIf necessary, to check 
menopausal status
HIV, Hepatitis B and C 
Screen (per site SOP)]XAcceptable to be based on 
history unless testing is 
required by local regulation.
Urinalysis X* X X X X*If screening assessment has 
been performed within 72 
hours prior to initiation of 
dosing, it does not need to be 
repeated on Cycle 1 Day 1.
Perform up to 72 hours before
Day 1 dosing ;  
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 23
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTrial Period:Screening 
PhaseTreat ment Phase  ( 21-day Treatment 
Cycles )End of 
Treat ment 
(EOT) / 
Discon-
tinuationPost-Treatment Phase Notes
Treat ment Cycle/Title:Screening
(Visit 1)1 2 34 to 
35Safety Follow -
upImaging 
Follow -
upSurvival 
Follow -up
Treat ment Days per 
Cycle:1 3 8 1 1 1At tim e of 
treat ment 
discon.30 days post 
last dose study 
medicationEvery 12 
weeksEvery 12 
weeks
Visit Window (Days) -28 to -1 ± 3 ± 3 ± 3 +7 +7 ± 7 ± 7 Procedure windows may vary 
Hematology including 
absolute neutrophil 
count (ANC)X X X X X X X X XNote: visit windows for this 
assessment vary as follows:
As a safety lab, hematology 
(including ANC) will be 
collected on Day 1 of every 
cycle pre -dose as follows:
On days whe nnavarixin 
PK samples are
collected , pre-dose 
ANC should be 
collected within 2 hours 
prior to dosing.
On days whe nnavarixin 
PK is notcollected, pre -
dose ANC can be 
collected within 24 
hours prior to dosing.
In addition, for 
pharmacodynamics 
assessment, a nother sample 
will be collected between 6-
12 hours after dosing on 
Days 1, 3, and 8 of Cycle 1, 
and Day 1 of Cycle 2.
PT/INR and aPTT XParticipants on anticoagulant 
therapy should be monitored
throughout the trial. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 24
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTrial Period:Screening 
PhaseTreat ment Phase  ( 21-day Treatment 
Cycles )End of 
Treat ment 
(EOT) / 
Discon-
tinuationPost-Treatment Phase Notes
Treat ment Cycle/Title:Screening
(Visit 1)1 2 34 to 
35Safety Follow -
upImaging 
Follow -
upSurvival 
Follow -up
Treat ment Days per 
Cycle:1 3 8 1 1 1At tim e of 
treat ment 
discon.30 days post 
last dose study 
medicationEvery 12 
weeksEvery 12 
weeks
Visit Window (Days) -28 to -1 ± 3 ± 3 ± 3 +7 +7 ± 7 ± 7 Procedure windows may vary 
Comprehensive 
Chemistry PanelX X X X X X XNote: visit windows for this 
assessment vary as follows (to 
be collected at same time as
hematology samples):
Chemistry panel will be 
collected on Day 1 of every 
cycle pre -dose as follows:
On days whe nnavarixin 
PK samples are 
collected, pre-dose 
sample should be 
collected within 2 hours 
prior to dosing.
On days whe nnavarixin 
PK is notcollected, pre -
dose sample can be 
collected within 24 
hours prior to dosing. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 25
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTrial Period:Screening 
PhaseTreat ment Phase  ( 21-day Treatment 
Cycles )End of 
Treat ment 
(EOT) / 
Discon-
tinuationPost-Treatment Phase Notes
Treat ment Cycle/Title:Screening
(Visit 1)1 2 34 to 
35Safety Follow -
upImaging 
Follow -
upSurvival 
Follow -up
Treat ment Days per 
Cycle:1 3 8 1 1 1At tim e of 
treat ment 
discon.30 days post 
last dose study 
medicationEvery 12 
weeksEvery 12 
weeks
Visit Window (Days) -28 to -1 ± 3 ± 3 ± 3 +7 +7 ± 7 ± 7 Procedure windows may vary 
Thyroid Function (T3, or 
FT3, T4 or FT4, and 
TSH)X X X XTo be performed every other 
cycle (1, 3, 5, 7 etc.)
Note: visit windows for this 
assessment vary as follows (to 
be collected at same time as 
hematology samples ):
Thyroid testing will be 
collected on Day 1 of every 
cycle pre -dose as follows:
On days whe nnavarixin 
PK samples are collected, 
pre-dose sample should 
be collected within 2 
hours prior to dosing.
On days whe nnavarixin 
PK is notcollected, pre -
dose sample can be 
collected within 24 hours 
prior to dosing
Prostate -Specific Antigen 
(PSA)X X XScreening PSA within 28 days 
of date of allocation.  
In the first year, on -study PSA 
every 9 w eeks (±7 days) from 
date of allocation.
After 1 year, in participants 
remaining on -study, PSA every 
12 weeks (±7 days) 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 26
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTrial Period:Screening 
PhaseTreat ment Phase  ( 21-day Treatment 
Cycles )End of 
Treat ment 
(EOT) / 
Discon-
tinuationPost-Treatment Phase Notes
Treat ment Cycle/Title:Screening
(Visit 1)1 2 34 to 
35Safety Follow -
upImaging 
Follow -
upSurvival 
Follow -up
Treat ment Days per 
Cycle:1 3 8 1 1 1At tim e of 
treat ment 
discon.30 days post 
last dose study 
medicationEvery 12 
weeksEvery 12 
weeks
Visit Window (Days) -28 to -1 ± 3 ± 3 ± 3 +7 +7 ± 7 ± 7 Procedure windows may vary 
AE/SAE review X X
Phar macokinetics/Pharmacodynamics/Future Biomedical Research/Biomarkers –Analysis 
by Central Lab
Blood for Genetic 
AnalysisXCollect pre -dose. 
Peripheral Blood 
Mononuclear CellX X X X XCollect pre -dose (up to 24
hours before dosing) on Day 1 
of Cycles 1-4, 6, and 8, and 
every 4 Cycles thereafter .
Blood for Immune 
Profiling
(immunophenotyping)X X X X XCollect pre -dose (up to 24
hours before dosing) on Day 1 
of each Cycle for Cycles 1 -4, 6 
and 8, and every 4 Cycles 
thereafter .
Serum for 
Pembrolizumab 
PharmacokineticsX X XPre-dose (trough) PK samples 
will be collected within 24 
hours before infusion at Cycles 
1, 2, 4, 6, and 8 and every 4 
cycles thereafter 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 27
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTrial Period:Screening 
PhaseTreat ment Phase  ( 21-day Treatment 
Cycles )End of 
Treat ment 
(EOT) / 
Discon-
tinuationPost-Treatment Phase Notes
Treat ment Cycle/Title:Screening
(Visit 1)1 2 34 to 
35Safety Follow -
upImaging 
Follow -
upSurvival 
Follow -up
Treat ment Days per 
Cycle:1 3 8 1 1 1At tim e of 
treat ment 
discon.30 days post 
last dose study 
medicationEvery 12 
weeksEvery 12 
weeks
Visit Window (Days) -28 to -1 ± 3 ± 3 ± 3 +7 +7 ± 7 ± 7 Procedure windows may vary 
Plasma for navarixin 
PharmacokineticsX X X X X X X XNote: All pre -dose navarixin 
PK samples must be collected 
within 10 minutes prior to 
dosing.
Cycle 1:
Day 1: Pre-dose (0), 1, 2, 4, 
and 6 h, and 1 sample between 
8 -12 h
Day 3: Pre-dose, 1 sample 
between 6 –12 h
Day 8: Pre-dose, 1 sample 
between 6 -  12 h
Cycle 2:
Day 1: Pre-
dose (0), 1, 2, 4, 
and 6 h, and  1 sample between 
8 -12 h
Cycle 3:
Day 1: Pre-dose (trough)
Cycle 4:
Day 1: Pre-dose (trough)
After Cycle 4:
Same scheme as for 
pembrolizumab PK 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 28
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTrial Period:Screening 
PhaseTreat ment Phase  ( 21-day Treatment 
Cycles )End of 
Treat ment 
(EOT) / 
Discon-
tinuationPost-Treatment Phase Notes
Treat ment Cycle/Title:Screening
(Visit 1)1 2 34 to 
35Safety Follow -
upImaging 
Follow -
upSurvival 
Follow -up
Treat ment Days per 
Cycle:1 3 8 1 1 1At tim e of 
treat ment 
discon.30 days post 
last dose study 
medicationEvery 12 
weeksEvery 12 
weeks
Visit Window (Days) -28 to -1 ± 3 ± 3 ± 3 +7 +7 ± 7 ± 7 Procedure windows may vary 
Anti-Pembrolizumab 
AntibodiesX X XAnti-pembrolizumab antibody 
samples will be collected 
within 24 hours before infusion 
at Cycles 1, 2, 4, 6, 8 and every 
4 cycles thereafter
Blood for Serum Protein 
AnalysisX X X XBlood for serum protein 
analysis should be collected 
pre-dose on Day 1 ofeach 
Cycle.
Blood for RNA Analysis X X X XBlood for RNA Analyses 
should be collected pre -dose on 
Day 1 of Cycle 1, Cycle 2, and 
Cycle 5, and at treatment 
discontinuation 
Tumor Tissue Collection
Archival and/or Newly 
Obtained Tissue 
CollectionX X**optional on -treatment biopsy. 
To be performed after 
scheduled blood draws. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 29
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
Confidential3.Introduction
Navarixin (MK- 7123 ,formerly SCH 527123 ),is an orally  bioavailable, potent, and specific 
small molecule antagonist of the CXC G protein -coupled receptor CXCR1/2, with 
substantially  higher affinity  for CXCR2 than CXCR1 . It isin development for once daily 
dosing for use in combination therapy with pembrolizumab for the treatment of advanced 
solid tumors. Three tumor types will be evaluated in this study : PD-(L)1 refractory  non-small 
cell lun g cancer (NSCL C), castrat ionresistant prostate cancer , and microsatellite stable 
(MSS) colorectal cancer (CRC) .
Study Rationale 3.1
Myeloid -derived suppressor cells (MDSCs) are an adverse cancer -wide prognostic 
population of immune infiltrating cells [Gentles, A. J., et al 2015] . MDSCs contribute to 
tumor immune evasion through a variety  of mechanisms that suppress local T -cell activation 
and viability  [Gentles, A . J., et al 2015] [Condamine T, Ramachandran I, Youn JI , 
Gabrilovich DI. 2015] . MDSCs can also influence tumor progression by  promoting tumor 
metastases, angiogenesis and tumor cell invasion [Condamine T, Ramach andran I, Youn J I, 
Gabrilovich DI. 2015] . The relief of my eloid suppression of T cell function could enhance 
pembrolizumab responses and this mechanism is being activel y interrogated to increase the 
number of durable clinical responses.
The CXC G protein -coupled receptor, CXCR2, is highl y expressed on human MDSCs and 
plays a role in the homing of MDSCs in the tumor microenvironment (TME). The CXCR2 
receptor is highl y expressed across tumor t ypes and has been shown to significantly correlate 
with poor surviv al [Steele CW, Karim SA, Leach JDG, Bailey  P, Upstill -Goddard R 2016] 
[Saintigny , P., et al 2013] [L i, L., et al 2015] ; internal Moffitt/TCGA database anal ysis). 
For example, in late stage prostate cancer, CXCR2 -MDSCs have been suggested to play  a 
critical role in prostate tumor progression [Wang G, L u X, Dey  P, Deng P, Wu CC, Jiang S 
2016] . Hormonal therap y and chemotherap y have been s hown to enrich for CXCR2 positive 
cells in prostate cancer patients. I n addition to promoting tumor resistance by  enhancing the 
immunosuppressive TME through MDSC recruitment, reports have shown that the EL RCXC 
chemokine -CXCR1/2 axis can promote angiogenic responses and activate epithelial -
mesench ymaltransition (EMT) differentiation programs which are associated with its role in 
metastasis and stemness [David JM, Dominguez C, Hamilton DH, Palena C. 2016] 
[Acharyy a S, Oskarsson T, Vanharanta S, Malladi S, Kim J 2012] .  
This Phase 2 PO C trial will investigate 3tumor types that express CXCR2, and have a low 
objective response rate to PD -(L)1 inhibitor monotherap y:NSCL C (PD -(L)1 refractory ), 
castration resi stant prostate ,and MSS colorectal cancers , in order to test the   hypothes isthat 
navarixin added to pembrolizumab may improve treatment outcomes .
Background 3.2
Refer to the Investigator’s Brochure (IB)/approved labeling for detailed background 
information on navarixin and the MK -3475 IB/approved labeling for detailed background 
information on pembrolizumab .  
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 30
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialPharmaceutical and Therapeutic Background 3.2.1
Navarixin is a CXCR2 antago nist.
Navarixin Pharmaceutical and Therapeutic Background 3.2.1.1
The EL RCXC chemokine -CXCR1/2 axis mediates pleiotropic effects that impact 
tumorigenesis: 1) promotion of tumor resistance by enhancing the immunosuppressive tumor 
microenvironment (TME) by  recruitm ent of neutrophils/my eloid -derived suppressor cells 
(MDSCs), 2) promotion of angiogenic responses, and 3) activation of epithelial -mesench yme 
transition (EMT), which is associated with metastasis and stemness [David JM, Dominguez 
C, Hamilton DH, Palena C. 2016] [Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim 
J 2012] [Condamine T, Ramachandran I, Youn J I, Gabrilovich DI. 2015] .
CXCR2 antagonists function to inhibit the translocation of granulo cytes (including 
neutrophils) out of the marrow and into circulation (and, inhibit translocation of MDSCs into 
tumors) [Highfill SL , Cui Y, Giles AJ, Smith JP, Zhang H, Morse E 2014] .  As expected, the 
class of CXCR2 antagonists demonstrate sa mechanism -based decrease in circulating 
neutrophils.  Therefore, the neutrophil count serves as an easil y monitorable functional 
biomarker assay .  Navarixin clinical trials have demonstrated a dose -dependent decrease in 
neutrophils, suggesting the molecule is sufficient to test the hypothesis: CXCR2 antagonism, 
in combination with pembrolizumab, improves outcomes for cancer patients relative to 
pembrolizumab alone.
MDSCs are present and active in a number of different tumor types [David JM, Dominguez 
C, Hamilton DH, Palena C. 2016] [Kumar V, Patel S, Tcyganov E, Gabrilovich DI. 2016] .  
Likewise, CXCR2 is expressed in a diverse set of tumor s.  Recent data suggest that CXCR2 
antagonism might reverse tumor immune suppression caused b y MDSCs [Highfill SL , Cui Y, 
Giles AJ, Smith JP, Zhang H, Morse E 2014] [Theivan thiran B, DeVito NC 2017] .  In 
addition, antagonism of CXCR2 has been shown to inhibit tumor metastasis and neo -
angiogenesis in preclinical models. CXCR2 inhibition in combination with immunotherapy 
shows enhanced anti -tumor activity (anti -PD-1/anti -CTL A-4) in a preclinical prostate model
[Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P 2017] . CXCR2 inhibition enhances 
T cell entry , suppresses metastases, and confers sensitivity  to anti -PD-1 treatment in KPC
PDAC model . In addition, disruption of CXCR2 -mediated MDSC tumor trafficking enhances 
anti-PD-1 efficacy in a sy ngeneic RMS tumor models. Moreover, data indicates that 
navarixin treatment can enhance the anti -tumor activity  of PD -1 blockade in a B16 -F10 
syngeneic tumor model that shows modest activity to anti -PD-1 as a monotherapy  (complete 
responses observed in the combination arm). 
No studies with navarixin have been initiated in oncology  indications. However, it was 
previously  developed b y Schering for non-oncology  indications ( chronic obstructive 
pulmonary  disease [ COPD ], asthma, psoriasis).  As a result of this development, over 900 
subjects were treated with navarixin in clinical trials. Several Phase II studies were conducted 
in COPD, asthma, and ps oriasis. No impact of treatment was observed in the psoriasis study . 
Two small asthma studies showed trends to clinically  significant results. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 31
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialThe largest Phase IItrial was a proof of concept ( POC )study  in patients with moderate to 
severe COPD in which navarixin 50 mg was compared with placebo. Navarixin treatment led 
to statistically  significant improvement in forced expiratory  volume (FEV) in patients with 
COPD who were current smokers. Treatment discontinuations for Gr ade2 neutropenia were 
observed.   No increases in infections or fevers were observed in treated patients versus the 
placebo group.   Navarixin development was discontinued due to the modest and restricted 
(current smokers) observed benefit.
Multiple Phase I  studies in healthy  volunteers confirm that navarixin induces a dose 
dependent peripheral reduction in neutrophils ;24% and 48% median ANC decrease for 30 
and 100 mg respectively .  Neutrophil migration from the marrow is inhibited, and no marrow 
hypo-cellularit y was observed.  The neutr ophil reduction is rapidly  reversible on dosing 
cessation, and peripheral neutrophils return to baseline values in 48 -96 hours without 
cytotoxic or my elosuppressive effects on the bone marrow.  
Several CXCR2 antagonists are under development.  AstraZeneca has reported AZD5069 
Phase 1 results in combination with durvalumab [Steele CW, Karim SA, Leach JDG, Bailey  
P, Upstill -Goddard R 2016] .  Thecombination is reported to be well -tolerated, and the 
AZD5069 combina tion with durvalumab does not appear to enhance toxicities observed from 
either AZD5069 or durvalumab monotherapies.
Navarixin development will focus on combinations with immune checkpoint inhibitors 
(pembrolizumab).  The removal of the immune suppression induced b y navarixin , combined 
with immune checkpoint abrogation, is hypothesized to improve cancer therapy outcomes 
relative to either treatment alone.  The mechanistic, dose -dependent, rapidly  reversible, 
decrease in peripheral neutrophils induce dby navarixin (and all CXCR2 antagonists) will 
serve as a readily  monitorable pharmacody namic marker in this trial.
Pembrolizumab (MK -3475) Pharmaceutical and Therapeutic Background 3.2.1.2
Keytruda™ (pembrolizumab) is indicated for the treatment of patients across a n umber of 
indications. For more details on specific indications, refer to the pembrolizumab IB .
Benefit/Risk Assessment 3.3
It cannot be guaranteed that participants in clinical studies will directly  benefit from 
treatment during participation, as clinical studiesare designed to provide information about 
the safet y and effectiveness of an investigational medicine.
Additional details regarding specific benefits and risks for participants participating in this 
clinical study may be found in the accompanyi ng Inves tigators Brochure (IB) and Informed 
Consent documents. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 32
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidential4.Objectives/Hypotheses and Endpoints
Male/female participants of at least 18 years of age with selected advanced/metastatic solid 
tumors will be enrolled in this study .
Objective Endpoint
Primary
Objective: To evaluate the objective 
response rate (ORR) as assessed by  the 
investigator based on Response 
Evaluation Criteria in Solid Tumors 
Version 1.1 (RECI ST 1.1) following 
administration of navarixin in 
combination with pembrolizumab.Objective response is a confirmed 
complete response (CR) or partial 
response (PR) .
Objective: To determine the safet y and 
tolerability  of navarixin in combination 
with pembrolizumab.Dose -limiting toxicity  (DLT)
Adverse event (AE)
Discontinuing study  treatment due to 
an AE.   
Secondary
Objective: To evaluate objective 
response rate (ORR) as assessed by  
investigator based on iRECI ST 
(modified RECI ST 1.1) [Seymour, L., 
et al 2017] , progression- free survival 
(PFS) as assessed b y investigator based 
on RECI ST1.1and iRECI ST,and 
overall survival (OS) following 
administration of navarixin in 
combination with pembrolizumabObjective response is a confirmed CR 
or PR .
PFS is time from the first dose of study  
medication to the first documented 
disease progression or death due to an y 
cause, whichever occurs first.
OS is time from the first dose of study  
medication to death due to any  cause.
Objective: To evaluate the 
pharmacod ynamics as measured b y 
absolute neutrophil counts (ANC) 
following administration of navarixin 
in combination with pembrolizumab. ANC in 109/L
Objective: To evaluate the 
pharmacokinetics (PK) of navarixin
when administered in combination with 
pembrolizumabPK parameters including area under the 
curve (AUC) in ng·hr/mL , maximum 
concentration (C max)in ng/mL , trough 
concentration (C trough)in ng/mL 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 33
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialObjective Endpoint
Tertiary /Exploratory
Objective: To evaluate the 
development of circulating anti -
pembrolizumab antibodies, as 
appropriate, following administration 
of  navarixin in combination with 
pembrolizumabAnti-pembrolizumab antibody  level
Objective: To evaluate the relationship 
between navarixin PKand ANCANC ; navarixin PKparameters 
including AUC, C max, and C trough
Objective: To identify  molecular 
(genomic, metabolic and/or proteomic) 
biomarkers that may  be indicative of 
clinical response/resistance, safet y, 
pharmacod ynamic activity , and/or the 
mechanism of action of navarixin in 
combination with pembrolizumab.Germl ine genetic variation, genetic 
(deox yribonucleic [DNA]) mutations 
from tumor, tumor and blood 
ribonucleic acid (RNA) variation, 
proteomics and immunohistochemistry  
(IHC), and other blood -derived 
biomarkers
5.Study Design 
Overall Design 5.1
This is a stratifie d, parallel, 2-arm(2-dose) , randomized, uncontrolled multicenter stud y of 
navarixin in combination with pembrolizumab in participants with selected 
advanced /metastatic solid tumors. The study  will use a 2
-stage adaptive design based on pre -
specified crite ria.There is no untreated/placebo comparator arm.
Participants with PD -(L)1 refractory  NSCLC, CRPC, or MSS CRC will be randomized into 
one of two dose arms.  In dose Arm A, participants will be treated with 30 mg orallyQD 
navarixin.  I n dose Arm B, participants will be treated with 100 mg orally QD navarixin.  
Participants in both Arms A and B will be treated concomitantly with pembrolizumab 200 
mg IV Q3W.
Per the interim safet y analy sis, if no more than 3 participants in the first 10 evaluable
participants have experienced DLTs during the first cy cle in an arm, this arm may  be 
expanded by  enrolling an additional 20 participants to complete Stage 1. However, during 
Stage 1, if at any time >3 DLTs are observed within the first 10evaluable participants , 
enrollment into an arm will be discontinued. 
In addition, t he following s topping rule is included for excessive toxicity  occurring outside 
the current defined DLT window .If 4or more of the first 10 evaluable participants have a 
DLT per cu rrent protocol definition (either within the first cy cle DLT observation window or 
outside this window) after they  have all finished the first cy cle observation, enrollment into 
the arm may  be discontinued unless totality  of the data (eg, including efficac y) supports a 
favorable risk -benefit trade -off. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 34
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialSafety  and tolerability  will be continuously  monitored throughout the study  duration.  If the 
regimen is deemed intolerable, the arm may  be discontinued even if stopping rule isnot met.
The overall design is an adaptive 2-stage design.  In each arm, up to 30 participants will be 
enrolled in the first stage, and up to 30 participants in the second stage.  In the first stage , 30 
participants (with 10 per tumor ty pe)will be enrolled in each arm(dose level). When all 
participants in a given arm with a given tumor t ype complete the first on -treatment scan at 9 
weeks or when clinicall y indicated (see Section 9.2.1.2) , a futility  anal ysis will be conducted 
to determine whether that tumor ty pe and armwill progress to Stage 2. If atumor ty pe pass es
the futility  anal ysis (see S ection 5.1.4) in Stage 1, at least 10 participants will be enrolled 
with that tumor ty pe in the second stage.
Initial enrollment in each dose armwill be staggered.  The first 3participants in dose Arm A 
or dose Arm B will be enrolled no more frequently  than 1 participant per week, to allow for 
peripheral neutrophil assessment between participants.  Peripheral neutrophil assessment 
(ANC) will occur at baseline, Day  3,and Day  8 during the first cy cle for all participants .  
Decreased ANC counts typically  return to normal in 48- 96 hours following dosing cessation. 
Standard support for oncology  patients with low ANC will be considered as appropriate.  See 
dose reduction algorithm ( Section 7.2.1) for more information.
Specific procedures to be performed during the study , as well as their prescribed times and 
associated visit windows, are outlined in the Study SoA - Section 2. Details of each 
procedure are provided in Section 9 – Study  Assessments and Procedures. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 35
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialStudy Diagram 5.1.1
The study  design is depicted in Figure 1 .
Figure 1Study  Design
 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 36
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialGuidance for dose decision and expansion is depicted in Figure 2 .
Figure 2Guidance for Dose Decision and Expansion
Evaluation of Safety 5.1.2
In order to adequatel y evaluate the safet y of the doses administered, all participants enrolled 
must meet the criteria for evaluability  for Cy cle 1.
Participants are considered nonevaluable for DLT  evaluation if:
They  are randomized but not treated.
They  discontinue from the study  prior to completing all the safet y evaluations in 
Cycle 1 for reasons other than treatment -related adverse events.
They  receive <75% of the total MK -3475 (or pembrolizumab) infusion and/or 
navarixin in Cy cle 1 (eg, if the infusion had to be discontinued due to an infusion 
reaction) and they  did not experience a DLT.
 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 37
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialDose Limiting Toxicity 5.1.3
Formal DLT evaluation will be performed at the interim safet y analy sis, following 
completion of one cy cle of treatment by  10 evaluable participants in each dose arm. DLT 
nonevaluable participants will not be replaced. For example, if one of the first 10 participants 
in anarmis nonevaluable for DLT, then the next DL T evaluable participant enrolled and 
treated in the armwill be included in the interim safet y analysis. The DLT evaluation period 
will be for one cy cle(Day  1 to Day  21.  Day  1 is considered the date a study  drug was first 
administered and not the date of randomization if dosing did not occur on the date of 
randomization ). During this time, supportive treatment with G -CSF will not be allowed.
Anarmdose will be considered intolerable if >3 of 10 evaluable participants experience 
DLTs in C ycle 1. If the armdose is not tolerated at 30 mg (and 100 mg), the arm may be 
discontinued and the protocol may  be amended to include a lower navarixin dose. 
All toxicities will be graded based on investigator assessment (Appendix 4 “Assessment of 
Intensit y”).  
The occurrence of an y of the following to xicities during C ycle 1 will be considered a DLT, if 
assessed b y the investigator to be possibly , probably ,or definitely  related to study  treatment:
1)Grade 4 non -hematologic toxicity  (not laboratory )
2)Grade 4 anemia of an y duration
3)Grade 3 anemia lasting >7days or requiring transfusion
4)Grade 4 hematologic toxicity  (other than anemia) lasting ≥7 day s, except 
thrombocy topenia
a)Grade 4 thrombocy topenia of any  duration
b)Grade 3 thrombocy topenia associated with bleeding
5)Grade 3 non -hematologic toxicity  (not laboratory ) lasting >3 day s despite optimal 
supportive care.
6)Any Grade 3 or Grade 4 non -hematologic laboratory value if:
•Medical intervention is required to treat the participant , or
•The abnormalit y leads to hospitali zation, or
•The abnormalit y persists for >72 hours. 
Exceptions:
•Clinically  non-significant, treatable, or reversible laboratory  abnormalities 
including uri c acid 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 38
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
Confidential7)Any of the following liver test abnormalities are observed (Hy ’s Law) :
•ALT or AST > 3X ULN w ith TBL > 2X ULN with no elevation in alkaline 
phosphatase (AP < 2X ULN) 
•No other reasons can be found to explain the combination of increased 
aminotransferase(s) ( AT)and TBL, such as viral hepatitis, A, B,or C, 
preexisting or acute liver diseases, or another drug capable of causing the 
observed injury
8)Febrile neutropenia Grade 3 or Grade 4:
• Grade 3 is defined as ANC <1000/mm3with a single temperature of >38.3 
degrees C (101 degrees F) or a sustained temperature of ≥38 degrees C 
(100.4 °) for more than one hour.
9)Inability  to administer ≥75% of the planned navarixin dose d ueto drug-related 
tolerability .
10)Delay  in starting Cy cle 2 by  >2 weeks due to toxicity .
Futility Analysis 5.1.4
An interim f utility  analysis for efficacy  will be performed after the first 10 participants for 
each tumor t ypehave at least 1 post -baseline scan assessment in each dose armin Stage 1 . If 
one or more responses (confirmed or unconfirmed) are observed for a tumor ty pe in anarm
(i.e. ≥10% response rate), this tumor ty pe may be expanded to enroll at least additional 10 
participants in Stage 2, for a maximum enrollment of 60 participants in this armacross 3 
tumor ty pes. Otherwise, this tumor ty pe may be stopped earl y for futility . 
If the decision is made t o expand a tumor ty pe in dose Arm A to Stage 2, this tumor ty pe in 
dose Arm B may  be expanded to Stage 2 as well, irrespective of the number of responses as 
long as it has passed the safety evaluation. While the decision rule is mainly based on 
confirmed a nd unconfirmed responses, the totalit y of data w ill also be taken into account.
Number of Participants 5.2
Greater than or equal to 120 participants will be randomized in order to achieve 120
evaluable participants as perSection 10.If no efficacy  is noted in any tumor ty pes the total 
number may  be as low as 60.
Beginning and End of Study Definition 5.3
The overall study begins when the first participant signs the informed consent form (ICF).  
The overall study ends when the last participant completes the last stu dy-related phone -call 
or visit, withdraws from the study or is lost to follow -up (i e,the participant is unable to be 
contacted b y the investigator).    
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 39
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialClinical Criteria for Early Study Termination 5.3.1
Early study termination will be the result of the criter ia specified below:
1.Quality  or quantity  of data recording is inaccurate or incomplete
2.Poor adherence to protocol and regulatory requirements
3.Incidence or severit y of adverse drug reaction in this or other studies indicates a 
potential health hazard to participants
4.Plans to modify  or discontinue the development of the study  drug. In the event of the 
Sponsor decision to no longer supply  study  drug, ample no tification will be provided 
to the sites so that appropriate adjustments to participant treatment ca n be made.
Scientific Rationale for Study Design 5.4
This Phase 2study  is being conducted to evaluate the efficacy , safet y,and tolerability  of 
navarixin in selected solid tumors when administered in combination with pembrolizumab. 
Two different doses of navarixin (30 mg and 100 mg QD) will be evaluated in combination 
with the standard dose of pembrolizumab (200 mg Q3W). 
Rationale for Endpoints 5.4.1
Efficacy Endpoints 5.4.1.1
A primary objective for this trial is to evaluate the antitumor ac tivity  of navarixin in 
combination with pembrolizumab in participants with selected advanced or metastatic solid 
tumors. Tumor response (ORR) in participants with solid tumors will be assessed using 
RECI ST1.1 based on investigator assessment. Images will be collected for p ossible anal ysis 
by blinded, independent central review .
ORR will be used for decision making. A time to event endpoint (e.g., PFS, OS) would 
require a control group (preferably placebo controlled, blinded). Given that the participants in 
this study  have r efractory disease, and have disease that is not responsive to PD -1 
antagonists, ORR is considered evidence of efficacy, and has formed the basis for accelerated 
approval (for oncology  agents) in the US.
Immunotherapeutic agents such as navarixin and pembro lizumab may  produce antitumor 
effects by  potentiating endogenous cancer -specific immune responses. The response patterns 
seen with such an approach may  extend bey ond the ty pical time course of responses seen 
with ty pical cy totoxic agents, and can manifest a clinical response after an initial increase in 
tumor burden or even the appearance of new lesions. Standard response assessment criteria 
may not provide a comprehensive response assessment of immunotherapeutic agents such as 
navarixin and pembrolizumab. Therefore , as a secondary  objective, ORR will also be 
assessed b y iRECI ST. 
Additional secondary objectives include evaluation of PFS by  RECIST 1.1and iRECI ST and 
OS of participants treated with navarixin in combination with pembrolizumab .
For additional details about assessing efficacy  endpoints using RECI ST 1.1 and i RECIST, 
see Appendix 7in Section 12. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 40
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialSafety Endpoints 5.4.1.2
A primary  objective of this trial is to characterize the safet y and tolerability  of navarixin in 
participants with advanced/ metastatic solid tumors when administered in combination with 
pembrolizumab.  The primary safet y analysis will be based on participan tswho experience 
toxicities as defined b y CTCAE Version 4.0.3 criteria. Safety  will be assessed by  quantify ing 
the toxicities and grades of toxicities experienced by participants who have received 
navarixin in combination with pembrolizumab.
Safety  parameters commonly  used for evaluating investigational systemic anti
-cancer 
treatments are included as safet y endpoints for the study  including, but not limited to, the 
incidence of, causalit y to, and outcome of AEs/SAEs; changes in vital signs and laboratory  
values. Adverse events will be assessed as defined by CTCAE, Ve rsion 4.0 .3.
Pharmacokinetic Endpoints 5.4.1.3
A secondary  objective of this study  is to characterize the PK profile of navarixin and 
pembrolizumab following administration of navarixin in combination with pembrolizumab. 
The systemic concentrations of these agents will serve as the primary  readout for the PK, and 
these data will be used to derive PK parameters for these agents when administered in 
combination. Furthermore, the results of these analyses will be used in conjunction with the 
PD, safet y, and explorator y endpoint data to help assess future dosing strategies for 
navarixin .
Pharmacodynamic Endpoints 5.4.1.4
Existing data from prior clinical st udies for respiratory therapies indicate that navarixin
causes a dose -dependent decrease in neutrophils. While this may  limit dosing , its target -
mediated nature (CXCR2 mediates neutrophil trafficking) and existence of available clinical 
data also make it a suitable biomarker for target modulation due to navarixin activity . In 
addition, reports from competitors (AZD5069) [Steele CW, Karim SA, Leach JDG, Bailey  P, 
Upstill -Goddard R 2016] support the mechanism -based observed ANC reduction observed 
after navarixin blockade of CXCR2 signaling. Absolute neutrophil counts (ANC) will be 
used to evaluate target engagement/modulation and its relationship to pharmacokinetics 
endpoints. In addition, ANC levels will be closely monitored during the course of the trial to 
identify  if there are an y instances of neutropenia that may  affect particip ant 
safet y. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 41
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialPlanned Exploratory Biomarker Research 5.4.1.5
Cancer immunotherapies represent an important and novel class of anti -tumor agents.  
However, the mechanism of action of these new therapies is not completel y understood and 
much remains to be learned regarding how best to leverage these new drugs in treating 
patients.  Thus, to aid future patients, it is important to identify novel 
predictive/pharmacod ynamic biomarkers and generate information that will better guide 
therapies with immuno -oncology  drugs. To identify  novel biomarkers, biospecimens (ie, 
blood components, tumor material) will be collected to support anal yses of cellular 
components (eg, protein, DNA, RNA, metabolites) and other circulating molecules.  
Investigations may  include but are not li mited to:
Germline (blood) genetic anal yses (eg, single -nucleotic poly morphism [SNP] analy ses, 
whole exome sequencing, whole genome sequencing)
This research will evaluate whether genetic variation within a clinical study population 
correlates with response to the treatment(s) under evaluation.  If genetic variation is found to 
predict efficacy  or AEs, the data might inform optimal use of therapies in the patient 
population.  Furthermore, it is important to evaluate germline DNA variation across the 
genome in order to interpret tumor -specific DNA mutations.  Finally , microsatellite 
instability  (MSI) may  be evaluated as this is an important biomarker for some cancers (ie, 
colorectal cancer).
Genetic (DNA) analyses from tumor
The application of new technologies, such as next generation sequencing, has provided 
scientists the opportunity to identify  tumor -specific DNA changes (ie, mutations, methy lation 
status, microsatellite instability ).  Key  molecular changes of interest to immune -oncology  
drug develop ment include the mutational burden of tumors and the clonality  of T -cells in the 
tumor microenvironment.  I ncreased mutational burden (sometimes referred to as a ‘h yper -
mutated’ state) may  generate neo -antigen presentation in the tumor microenvironment.  T o 
conduct this ty pe of research, it is important to identify  tumor -specific mutations that occur 
across all genes in the tumor genome.  Thus, genome -wide approaches may be used for this 
effort.  Note that in order to understand tumor -specific mutations; it is necessary  to compare 
the tumor genome with the germline genome.  Microsatellite instability may also be 
evaluated as this is an important biomarker for some cancers (ie, colorectal cancer).
Tumor/blood RNA a nalysis :Both genome -wide and targeted messenger RNA (mRNA) 
expression profiling and sequencing in tumor tissue and/or blood may be performed to define 
gene signatures that correlate to clinical response to treatment with pembrolizumab in 
combination with navarixi nor other immunotherapies. Pembrolizumab induces a response in 
tumors that likely  reflects an inflamed/immune phenoty pe. Specific immune -related gene sets 
(ie, those capturing IFN-γ transcriptional pathways) may  be evaluated and new signatures 
may be iden tified. In addition, expression levels of the targeted receptor CXCR2 and 
correlation to response may  also be investigated. MicroRNA profiling may  also be pursued. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 42
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialImmunohistochemistry  (IHC ) intumor biopsies :Mechanistic studies carried out in 
preclinical models of melanoma (B16 -F10) and colon carcinoma (CT26) showed a 
significant reduction in granulocy tic MDSC infiltration in tumors after navarixin treatment. 
IHC in tumor biopsies will be used to assess c hanges in my eloid and l ymphoid cell content in 
tumo r biopsies as a result of navarixin treatment. In addition ,PD-L1 status by  IHCwill also 
be determined.
Participants will be required to provide an archival tumor tissue sample and/or a fresh biopsy 
of tumor before treatment for these biomarker analy ses. Participant s will also be asked to 
agree to a biops y of tumor after initiation of study  treatment and to provide the acquired 
tissue for these biomarker analys es.
Other blood/serum derived biomarkers :In addition to expression within the tumor tissue, 
tumo r-derived proteins can be shed from tumor and released into the blood.  I n the case of 
proteins, enzy me-linked immunosorbent assay scan measure such proteins in serum and 
plasma and correlate this expression with response to pembrolizumab plus navarixin
combination therap y.Previous clinical trials (P05575) and published competitor data have 
reported concentration changes in the CXCR2 ligands GRO -αand IL -8, and in the 
neutrophil -associated enzy me MMP -9, after pathway  blockade. In addition, c hange s in serum
IL-8 levels have been shown to reflect and predict response to anti -PD-1 treatment in 
melanoma and NSCL C .Changes in IL-8, GRO -a, and MMP -9 concentrations as a result of 
combination therap y will be evaluated by enzy me-linked immunoassay .
Planned Genetic A nalysis 5.4.1.5.1
Genetic variation may  impact a participant’s response to therap y, susceptibility  to, and 
severit yand progression of disease. Variable response to therap y ma y be due to genetic 
determinants that impact drug absorption, distribution, metabolism, and excretion; 
mechanism of action of the drug; disease etiology; and/or molecular subt ype of the disease 
being treated. Therefore, where local regulations and I RB/IEC allow, a sample will be 
collected for DNA anal ysis from consenting participants.
DNA samples will be used for research related to the study treatment(s), the disease under 
study and related diseases. They  may  also be used to develop tests/assay s including 
diagnostic tests related to the disease under study , related diseases and study  drug( s). Genetic 
research may consist of the anal ysis of one or more candidate genes or the anal ysis of genetic 
markers throughout the genome [or anal ysis of the entire genome] (as appropriate).
DNA samples will be analy zed for variation across the entire genom e. Analy ses may  be
conducted if it is hy pothesized that this may  help further understand the clinical data. The 
samples may  be analy zed as part of a multi -study  assessment of genetic factors involved in
the response to understand study  disease or related c onditions.
Future Biomedical Research 5.4.1.6
The Sponsor will conduct Future Biomedical Research on specimens for which consent was 
provided during this study .  This research may  include genetic analyses (DNA), gene 
expression profiling (RNA), proteomics, metabol omics (serum, plasma) and/or the  
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 43
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
Confidentialmeasurement of other analy tes, depending on which specimens are consented for future 
biomedical research.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective of collecting/retaining specimens for 
Future Biomedical Research is to explore and identify  biomarkers that inform the scientific 
understan ding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the correct ti me.  The 
details of this Future Biomedical Research sub -study are presented in Appendix 2  –
Collection and Management of Specimens for Future Biomedical Research.
Justification for Dose 5.5
Starting Dose for This Study 5.5.1
An exposure response (ER) anal ysisfrom previous clinical experience was conducted to 
establish the relationship between navarixin AUC and % reduction in absolute neutrophil 
count (ANC –functional biomarker of navarixin activity ) from baseline. The ER anal ysis 
revealed a dose -dependent decrease in neutrophils. The 30 mg and 100 mg doses were 
chosen as there was a clear differentiation in % ANC reduction between the 2doses and the 
%ANC reduction corresponding to exposures at the 100 mg dose were at the plateau of the 
ER relationship. The low dose (30 mg PO QD ) induced a moderate decrease in circulating 
neutrophils, while the higher dose (100 mg PO QD ) induced a greater reduction . 
The planned dose of pembrolizumab for this trial is 200 mg every 3 weeks (Q3W). Based on 
the totality  of dat a generated in the Key truda development program, 200 mg Q3W is the 
appropriate dose of pembrolizumab across all indications and regardless of tumor type. As 
outlined below, this dose is justified by : 
Clinical data from 8randomized studies demonstrating flat dose -and exposure -
efficacy  relationships from 2 mg/kg Q3W to 10 mg/kg every  2weeks (Q2W)
Clinical data showing meaningful improvement in benefit -risk including overall 
survival at 200 mg Q3W across multiple indicat ions, and
Pharmacology  data showing full target saturation in both systemic circulation 
(inferred from pharmacokinetic [PK] data) and tumor (inferred from ph ysiologicall y 
based pharmacokinetic [PBPK] analy sis) at 200 mg Q3W
Among the 8randomized dose -comp arison studies, a total of 2262 participant s were enrolled 
with melanoma and non -small cell lung cancer (NSCL C), covering different disease settings 
(treatment naïve, previously  treated, PD -L1 enriched and all -comers) and different treatment 
settings (mono therapy  and in combination with chemotherap y). Five studies compared 2 
mg/kg Q3W vs. 10 mg/kg Q3W (KN001 B2, KN001 D, KN002, KN010 ,and KN021), and 3
studies compared 10 mg/kg Q3W vs. 10 mg/kg Q2W (KN001 B3, KN001 F2 and KN006). 
All of these studies demons trated flat dose -and exposure -response relationships across the 
doses studied representing an approximate 5 -to 7.5 -fold difference in exposure. The 2 mg/kg 
(or 200 mg fixed -dose) Q3W provided similar responses to the highest doses studied.  
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 44
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialSubsequently , flat dose -/exposure -response relationships were also observed in other tumor 
types including head and neck cancer, bladder cancer, gastric cancer ,and classical Hodgkin 
Lym phoma, confirming 200 mg Q3W as the appropriate dose independent of the tumor ty pe. 
These findings are consistent with the mechanism of action of pembrolizumab, which acts by 
interaction with immune cells, and not via direct binding to ca ncer cells.
Additionally , pharmacology  data clearl y show target saturation at 200 mg Q3W. First, PK 
data in KN001 evaluating target -mediated drug disposition (TMDD) conclusively  
demonstrated saturation of PD -1 in sy stemic circulation at doses much lower than 200 mg 
Q3W. Secondly , a PBPK anal ysis was conducted to predict tumor PD -1 saturation over a 
wide ra nge of tumor penetration and PD -1 expression. This evaluation concluded that 
pembrolizumab at 200 mg Q3W achieves full PD -1 saturation in both blood and tumor.
Finally , population PK analy sis of pembrolizumab, which characterized the influence of 
body  weig ht and other participant covariates on exposure, has shown that the fixed -dosing 
provides similar control of PK variability as weight based dosing, with considerable overlap 
in the distribution of exposures from the 200 mg Q3W fixed dose and 2 mg/kg Q3W do se. 
Supported by  these PK characteristics, and given that fixed -dose has advantages of reduced 
dosing complexity  and reduced potential of dosing errors, the 200 mg Q3W fixed -dose was 
selected for evaluation across all pembrolizumab protocols.
Maximum Dose/ Exposure for This Study 5.5.2
The maximum pre-planned dose of n avarixin that will be used in this study  is 100 mg QD.
Evidence from the percent ANC reduction v ersus dose data suggest sthat the 100 mg dose is 
near the plateau of the exposure response relationship .  Higher doses may be considered if
supported by clinical PK/PD and efficacy  data.
Rationale for Dose Interval and Study Design 5.5.3
Navarixin
Multiple doses of up to 50 mg navarixin , administered for up to 12 weeks in participants with 
moderate- to-severe COPD, were found to be safe and well -tolerated.  Multiple doses of 
navarixin , 30 mg QD, administered for up to 10 days in participants with mild asthma and up 
to 4 weeks in participants with severe asthma, were found to be safe and well tolerated. The 
effect of navarixin on ANCs was similar following both the single -dose and multiple doses.   
At 24 hours post dosing, the median percent ANC reduction for 30 and 100 mg navarixin 
(orally) was 24 %and 48%, respective ly. There were no oth er significant changes in clinical 
laboratory  parameters, vital signs, and electrocardiograms.  
Navarixin , 30 mg QD, significantly  reduced ANCs and sputum neutrophils in participants 
with COPD, along with early  signs of clinical improvement. Navarixin , 30mg QD, resulted 
in a significant reduction in ANCs and sputum neutrophils in participants with severe asthma 
and demonstrated an improvement in asthma control, as well as a reduction in the rate of 
mild asthma exacerbations. Single dose administration of 100 mg navarixin in healthy  
volunteers was safe and well tolerated in healthy  participants . Multiple doses of 100 mg 
navarixin administered QD for up to 14 days in healthy participants was safe and well  
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 45
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
Confidentialtolerated. There was a significant but reversible dec line in ANCs after both single and 
multiple doses of 100 mg.
While preliminary  signals of clinical benefit were observed in navarixin -treated asthma and 
COPD patients, this efficacy  was not sufficient to warrant continued development in these 
indications.
Following multiple dail y oral administration of 10, 30, 50 , and 100 mg navarixin, plasma 
concentration stead y state was achieved b y Day 11; navarixin minimum observed plasma 
concentration (C min) values were similar on Days 11 through 14. There was little t o no 
accumulation of navarixin observed in plasma on Day  14 with mean accumulation ratio (R) 
values ranging from 1.05 to 1.21. 
Pembrolizumab
The planned dose and dosing interval of pembrolizumab for this study  is 200 mg every  3 
weeks (Q3W). Based on the t otality  of data generated in the Key truda development program, 
200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and 
regardless of tumor ty pes. 
No pembrolizumab dose modifications are planned for this study .
6.Study Population
Male and f emale participants of at least 18 years of age, with selected advanced /metastatic
solid tumors (NSCL C[PD-(L)1 refractory ], CRPC ,and MSS CRC ) will be enrolled in this 
study .
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
Inclusion Criteria 6.1
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Type of Participant and Disease Characteristics –All Participants
1.Have one of the following histologically -or cy tologically -confirmed 
advanced/metastatic (diagnosis of Stage IV [AJCC version 8 or current version as 
applicable] )solid tumor s (NSCL C, CRPC , or MSS CRC )by pathology  report and 
have recei ved, or been intolerant to, or have been ineligible for all treatment known 
to confer clinical benefit.
2.Have Stage III or S tage IV disease that is not surgically  resectable.
3.Have measureable disease by  RECIST 1.1 criteria as assessed b y the local site 
investigator/radiology . Lesions situated in a previously  irradiated area are 
considered measureable if progression has been demonstrated in such lesions.
4.Have supplied tumor tiss ue from either a newl y obtained biopsy  or an archival 
specimen from a site not previously irradiated for biomarker anal ysis. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 46
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialNon-small cell lung cancer (NSCLC) Participants Only
5.Have a histologically or cytologically confirmed diagnosis of Stage IV metas tatic 
NSCL C.
6. Stage IV metastatic NSCLC tumors that are PD-(L) 1 positive (TPS ≥50%), do not 
harbor EGFR -sensitizing mutations and AL K translocations that are amenable to 
treatment with respective ty rosine kinase inhibitor therap y, and who have received 
prior treatment with a PD -(L)1 antagonist
7.Must have progressed on treatment with an anti -PD-(L)1 monoclonal antibody  
(mAb) administered either as monotherap y, or in combination with other 
checkpoint inhibitors or other therapies. PD -1 treatment progression is defined by  
meeting all of the following criteria:
a.Has received at least 2 doses of an approved anti -PD-(L)1 mAb.
b. Has demonstrated disease progression after anti- PD-(L)1 as defined b y 
RECI ST 1.1 The initial evidence of disease progression (PD) is to be 
confirmed b y a second assessment no less than 4weeks from the date of the 
first documentation of PD in the absence of rapid clinical progression. (This 
determination will have been made b y the investigator. Once PD is 
confirmed, the initial date of PD docu mentation will be considered the date 
of disease progression).
c.Progressive disease has been documented within 12 weeks from the last 
dose of anti -PD-(L)1 mAb.
Castrat ion Resistant Prostate Cancer (CRPC) Participants Only
8.Have histologically -or cytologicall y-confirmed (if acceptable according to local
health authority regulations) adenocarcinoma of the prostate .Component sof small 
cell prostate cancer are permitted.  Diagnosis must be stated in a pathology report 
and confirmed b y the investigato r.
9. Have prostate cancer progression on the most recent treatment, as determined
by the investigator, b y means of one of the following:
a.PSA progression using local laboratory  values as defined b y a minimum of 2 
rising PSA levels with an interval of ≥1 week between each assessment where
the PSA value at screening should be ≥2 ng/mL
b.Radiographic disease progression in soft tissue based on RECI ST 1.1 criteria 
with or without PSA progression.
c.Radiographic disease progression in bone defined as the appearance o f 2 or 
more new bone lesions on bone scan with or without PSA progression.
Note: Radiographs must be collected and transmitted to the central imaging
vendor at stud y entr y. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 47
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidential10.Must have progressed on at least one second generation anti- androgen therapy  (e.g. , 
enzalutamide, abiraterone) according to PCWG3 guidelines.
11. Have ongoing androgen deprivation with serum testosterone <50 ng/dL (<2.0 nM).
a.If the participant is currently  being treated with luteinizing hormone-releasing 
hormone a gonists or antagonists ( participants who have not undergone an 
orchiectom y), this therapy  must have been initiated at least 4 weeks prior to 
first dose of trial treatment and treatment must be continued throughout the 
study .
Microsatellite Stable Colorectal Cancer (MSS- CRC) Parti cipants Only
12.Have a histologicall y proven locall y advanced unresectable or metastatic ( Stage IV) 
CRC.
13.Have locally  confirmed microsatellite stable (MSS) CRC; participants with 
microsatellite instability -high (MSI -H) or microsatellite unstable CRC are not 
eligible.
14.Have been previousl y treated with standard therapies, which must include 
fluoropy rimidine, oxaliplatin, and irinotecan.
a.Participants who have withdrawn from standard treatment due to unacceptable 
toxicity  warranting discontinuation of that treatm ent and precluding 
retreatment with the same agent before progression of disease will also be 
eligible.
b.Regimens given with adjuvant intent will be counted as treatment for 
metastatic disease if the participant’s disease had progressed within 6 months 
following treatment.
Demographics –All Participants
15.Men and women who are ≥ 18 years of age.
16.Have an ECOG performance status of 0 or 1.
Male participants:
17. A male participant must agree to use contrac eption as detailed in Appendix 3 of this 
protocol during the treatment period and for at least 120 day safter the last dose of 
study  treatment and refrain from donating sperm during this period. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 48
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialFemale participants:
18. A female participant is eligible to participate if she is not pregnant (see Appendix 
3), not breastfeeding, and at least one of the following conditions applies: 
a.) Not a woman of childbearing potential (WOCBP) as defined in Appendix 3
OR 
b.) A WOCBP who agrees to follow the contraceptive guidance in Appendix 3
during the treatment period and for at least 120 day safter the last dose of study  
treatment.
Informed Consent
19. The participant (or legally  acceptable representative if applicable) provides written 
informed consent/assent for the study .  The participant may also provide 
consent/assent for Future Biomedical Research.  However the participant may  
participate in the main study without participating in Future Biomedical Research.
Laboratory Values – All Participants
20.Demonstrate adequate org an function as defined by  the following table ( Table 1).
Table 1 Adequate Organ Function L aboratory  Values
System Laboratory Value
Hematological
Absolute neutrophil count >1,500/mcL
Plateletsa>100,000/mcL
Hemoglobina≥9 g/dL or ≥5.6 mmol/L 
Renal
Serum creatinine or
creatinine clearance (CrCl) (measured or
calculated) bor
Glomerular Filtration Rate (GFR) in place of 
CrCl≤1.5 X upper limit of normal (ULN) or
≥60 mL/min for participant with creatinine levels 
>1.5 X ULN
Hepatic
Total bilirubin ≤1.5 X ULN or 
Direct bilirubin ≤1.5 X ULN for participants with 
total bilirubin levels >1.5 X ULN ; if there is no 
institutional ULN, then direct bilirubin must be 
<40% of total bilirubin to be eligible. Note: In no 
case can the total bilirubin exceed 3 X ULN.
Aspartate aminotransferase (AST) and Alanine 
aminotransferase (ALT)≤2.5 X ULN or ≤5 X ULN for participants with 
liver metastases
Coagulation
International N ormalized Ratio (INR) or
Prothrombin Time (PT)≤1.5 X ULN unless participant is receiving 
anticoagulant therapy
Activated Partial Thromboplastin Time (aPTT) 
or Partial Thromboplastin Time (PTT)≤1.5 X ULN unless participant is receiving 
anticoagulant therapy as long as PT or aPTT is 
within therapeutic range of intended use of 
anticoagulants 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 49
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialSystem Laboratory Value
a Criteria must be met without packed red blood cell (pRBC) transfusion within last 2 w eeks.  Participants can 
be on stable dose of erythropoietin ( ≥ approximately 3 m onths).
bCreatinine clearance (CrCl) should be calculated per institutional standard. If no local guideline is available, 
creatinine clearance should be calculated using the Cockcroft -Gault Method: CrCl = ([140-age]* weight [kg]* 
[0.85 for females only ])/ (72 * serum creatinine)
Note: This table includes eligibility -defining laboratory value requirements for treatment; laboratory value 
requirements should be adapted according to local regulations and guidelines for the administration of specific 
chemot herapies.
Exclusion Criteria 6.2
Participants are excluded from the study if an y of the following criteria apply:
Medical Conditions
1.Has a known additional malignancy  that is progressing or has required active 
treatment within the past 2years.
Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of 
the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have 
undergone potentiall y curative therap y are not excluded .
2.Has known active CNS metastases and/or carcinomatous meningitis. Participants with 
previously treated brain metastases may participate provided they  are radiologicall y 
stable, ie, without evidence of progression for at least 4 weeks b y repeat imaging 
(note that the repeat imaging should be performed during stud y screening), clinically 
stable and without requirement of steroid treatment for at least 14 days prior to first 
dose of study  treatment.
3.Has had a severe h ypersensitivity  reaction to treatment with anymonoclonal antibody
or compo nents of the study  drug (s).
4.Has an active autoimmune disease that has required sy stemic treatment in the past 2 
years (ie ,with use of disease -modify ing agents, corticosteroids ,or 
immunosuppressive drugs) except vitiligo or re solved childhood asthma/atopy . 
Replacement therap y, such as thyroxine, insulin, or physiologic corticosteroid 
replacement therap y for adrenal or pituitary  insufficiency , is not considered a form of 
systemic treatment and is allowed. Use of nons ystemic steroids is permitted .In 
additio n to active autoimmune disease, participants who have previously  been 
permanentl y discontinued from PD -(L)1 therap y due to immune related side effects 
are not eligible for the study.
5.Has an active infection requiring systemic therapy .
6.Has sy mptomatic ascites or pleural effusion. A participant who is clinically  stable 
following treatment for these conditions (including therapeutic thoracocentesis or 
paracentesis) is eligible.
7.Has interstitial lung disease that required oral or intravenous glucocorticoid s to assist 
with management. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 50
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidential8.Has a history  of (non -infectious) pneumonitis that required steroids or has current 
pneumonitis.
9. Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 
5 years.
Note: Participants who have had a stem cell transplant >5 years ago are eligible as 
long as there are no s ymptoms of graft -versus-host disease (GVHD).
10.Has a known history  of human immunodeficiency  virus (HIV) infection. 
Note: No HIV testing is required unless mandated by  local health auth ority.
11.Has a known history  of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] 
reactive) or known active Hepatitis C virus (defined as HCV RNA [quali tative] is 
detected) infection.
Note: No testing for Hepatitis B and Hepatitis C is required unl ess mandated by  local 
health authority .
12.Has a history  or current evidence of a gastrointestinal (GI) condition (eg, 
inflammatory  bowel disease, Crohn’s disease, ulcerative colitis) or impaired liver 
function or diseases that in the opinion of the Investiga tor may  significantly alter the 
absorption or metabolism of oral medications; any condition, therapy, or laboratory  
abnormality  that might confound the results of the study , interfere with the 
participant ’s participation for the full duration of the study ,make administration of 
the study  drugs hazardous ,or make it difficult to monitor adverse effects such that it 
is not in the best interest of the participant to participate, in the opinion of the treating 
Investigator .
13.Has known ps ychiatric or substance abuse disorders that would interfere with the 
participant ’s ability  to cooperate with the requirements of the study .
14. Is pregnant or expecting to conceive or father children within the projected duration 
of the study .
15.Has undergone major surgery  and has not recovered adequatel y from an y toxicity  
and/or complications from the intervention prior to starting stud y therap y.
16.A WOCBP who has a positive urine pregnancy  test within 72hours before the first 
dose of study  treatment (see Appendix 3 ).  If the urine test cannot be confirmed as 
negative, a serum pregnancy  test is required.  In such cases, the participant must be 
excluded from participation if the serum pregnancy result is positive.
Prior/Concomitant Therapy
17.Participants with CRPC or MSS CRC who have received prior therap y with an anti -
PD-1, anti -PD-(L)1 ,or anti PD L 2 agent . 
18.Have been treated with an agent directed to another stimulatory  or co -inhibitory  T-
cell receptor (eg, CTLA -4, OX 40, CD137). 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 51
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
Confidential19.Has received prior s ystemic anti -cancer therap y including investigational agents or 
has used an investigational device within 28 day s prior to the first dose of study  
treatment. Note: Participants must have recovered from all AEs due to previous 
therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropath y or alopecia 
may be eligible. Participants receiving ongoing replacement hormone therapy for 
endocrine immune -related adverse events (eg, thyroid replacement therap y) will not 
be excluded from participation in this study .
20.Has received prior radiotherap y (not to target lesions) within 2 weeks of start of stud y 
treatment.  Participants must have recovered from all radiation -related toxicities, not 
require corticosteroids, and not have had radiatio n pneumonitis. A 1 -week washout is 
permitted for palliative radiation (≤2 weeks of radiotherap y) to non -CNS disease.
21.Is expected to require any other form of antineoplastic therap y while on study.
22.Has a diagnosis of immunodeficiency or is receiving c hronic systemic steroid therap y 
in excess of replacement doses (prednisone ≤10 mg/day  is acceptable), or on any  
other form of immunosuppressive medication.
Note: The use of ph ysiologic replacement doses of corticosteroids may  be 
approved after consultation with the Sponsor Medical Monitor or designee.
23.Has received a live -virus vaccine within 30 day s prior to first dose of stud y 
medication. Vaccines that do not contain live virus are permitted.
Prior/Concurrent Clinical Study Experience
24.Had been previousl y treated with a CXCR2 inhibitor ( eg,AZD5069, reparixin, 
danirixin, LY3041658 Ab, HuMax -IL8, etc.)
Lifestyle Restrictions 6.3
There are no lifesty le restrictions.
Screen Failures 6.4
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently  randomized .  A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participants to mee t the Consolidated Standards 
of Reporting Trials (CONSORT) publishing requirements and to respond to queries from 
regulatory  authorities. Minimal information includes demograph y, screen failure details, 
eligibility  criteria, and any adverse events or serio us adverse events (SAE) meeting reporting 
requirements as outlined in the data entry  guidelines.
Participant Replacement Strategy 6.5
A participant who discontinues from study treatment orwithdraws from the study will not be 
replaced. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 52
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
Confidential7.Treatments
Study  treatment is defined as an y investigational treatment(s), marketed product(s), placebo ,
or medical device (s)intended to be administered to a study  participant according to the stud y 
protocol.
Clinical supplies [study  treatment(s) provided b y the Sponsor] will be packaged to support 
enrollment.  Clinical supplies will be affixed with a clinical label in accordance with 
regulatory  requirements.
Treatments Administered 7.1
The study  treatments to be used in this study areoutlined below in Table 2Study  
Treatment (s).
Table 2 Study  Treatment(s)
Study 
Treatment Name:Navarixin 
(MK- 7123 )Pembrolizumab 
(MK- 3475)
Dosage Formulation:Oral dry  filled 
capsuleSolution for 
Infusion
Unit Dose Strength(s):Two potencies:
10-mg and 50 -mg 
capsules  100 mg/vial
Dosage Level(s):30 mg QD
100 mg QD200 mg Q3W
Route of 
Administration:Oral IV infusion
Sourcing:Provided centrall y 
by the Sponsor . Provided 
centrall y by the 
Sponsor . 
All supplies indicated in Table 2will be provided per the ‘Sourcing’ row depending upon 
local country  operational requirements.  Every  attempt should be made to source these 
supplies from a single lot/batch number. The study site is responsible for recording the lot 
number, manufacturer, and expiry  date for an y locally purchased product as per local 
guidelines unless otherwise instructed b y the Sponsor.
Refer to Section 9.1.8 for details regarding administration of the study  treatment. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 53
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialDose Modification  7.2
Navarixin Dose Modification 7.2.1
ForGrade 4 ANC, or febrile neutropenia (Gr ade 3 or 4 ANC), navarixin will be held for 1 
week to allow the ANC to recover.  ANC will be measured for recovery  at 1 week (local 
draw is permissible).  If ANC has recovered to Gr ade 1 or better, the participant will be 
restarted at a lower dose of navarixin (ie, from 100 mg to 50 mg or from 30 mg to 20mg), 
depending on the dose arm.  If the participant has not recovered, he/she will return to the 
clinic in one week for a second ANC d raw.  If ANC has recovered to Grade 1 or better, the 
participant will be restarted at a lower dose of navarixin (ie, from 100 mg to 50 mg or from 
30 mg to 20 mg), depending on the arm.   If not recovered, he/she will discontinue navarixin , 
but remain on pem brolizumab treatment.  There will only  be one dose reduction per arm.  If 
the participant experiences G rade 4 ANC or febrile neutropenia while already  dosed reduced, 
the participant will discontinue navarixin treatment (Table 3).
For immune related AEs, see Section 7.2.2 for pembrolizumab dosing instructions.  If 
pembrolizumab dosing is held, navarixin dosing should also be held. If pembrolizumab 
dosing is resumed, navarixin dosing may  be restarted at a lower dose.  If navarixin ha s 
alread y been dose reduced, then navarixin should be discontinue dTable 3and Section 7.2.2).
For DLTs (Section 5.1.3) not encompassed under irAEs ( Section 7.2.2), both navarixin and 
pembrolizumab will be held for 1 week (an additional extension period for recovery  of the 
toxicity  may  be allowed, following consultation with the Sponsor and the investigator). Then, 
if toxicity  has recovered to Gr ade1 or better (or participant’s baseline value), par ticipant will 
be restarted on the standard dose of pembrolizumab and a lower dose of navarixin ( ie, from 
100 mg to 50 mg or from 30 mg to 20 mg), depending on the dose arm.  There will only  be 
one navarixin dose reduction per arm.  Theref ore, if the participant experiences the DLT 
while alread y dosed reduced, the participant will discontinue navarixin, but may restart the 
standard dose of pembrolizumab following recovery  (Table 3 ). 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 54
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTable 3 Navarixin /Study  Drug Dose Modif ications
Toxicities Navarixin Dosing Action
Grade4 ANC Hold navarixin for 1 
week for ANC to 
recover .If ANC recovered to Gr ade1 or 
better, participant will be restarted 
at lower dose of navarixin (ie, from 
100 mg to 50 mg or from 30 mg to 
20 mg ), depending on the arm.
If ANC has not recovered, 
participant will receive a second 
ANC test after an additional 1 week
If ANC recovered to Gr ade1 
or better, participant will be 
restarted at lower dose of 
navarixin (ie, from 100 mg 
to 50 mg or from 30 mg to 
20 mg ), depending on the 
arm.
If ANC has not recovered, 
participant will discontinue 
navarixin treatment, but will 
continue to receive 
pembrolizumab treatment.
Febrile 
neutropenia 
(Grade3 or 4 
ANC)Hold navarixin for 1 
week for ANC to 
recover .If ANC recovered to G rade 1 or 
better, participant will be restarted 
at lower dose of navarixin (ie, from 
100 mg to 50 mg or from 30 mg to 
20 mg ), depending on the arm.
If ANC has not recovered, 
participant will receive a second 
ANC test after an additional 1 week
If ANC recovered to Gr ade1 
or better, participant will be 
restarted at lower dose of 
navarixin (ie, from 100 mg 
to 50 mg or from 30 mg to 
20 mg ), depending on the 
arm.
If ANC has not recovered, 
participant will discontinue 
navarixin treatment, but will 
continue to receive 
pembrolizumab treatment. 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 55
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialToxicities Navarixin Dosing Action
Grade4 ANC or 
febrile 
neutropenia while 
navarixin already 
dosed reducedThere will be onl y 1 
dose reduction per arm .Participant will discontinue 
navarixin .
Study Medication 
Dosing
Immune related 
AEs (irAEs) which 
require 
pembrolizumab
dose modification 
(See Section 7.2.2)Follow Section 7.2.2 
for pembrolizumab 
dosing instructions.
Hold navarixin while 
pembrolizumab is held
to allow irAE to 
recover.Hold/discontinue pembrolizumab 
dosing according to instructions in 
Section 7.2.2
Hold navarixin while 
pembrolizumab is held .
If pembrolizumab is restarted, 
restart navarixin at lower dose of 
navarixin ( ie, from 100 mg to 50 mg 
or from 30 mg to 20 mg ), depending 
on the arm .
If navarixin has alread y been dose 
reduced, discontinue navarixin.
DLT snot 
described above 
(see Section 5.1.3)Hold navarixin for 1 
week *for DLT to 
recover.
Hold pembrolizumab 
while navarixin is held.
*An additional 
extension period for 
recovery  of the toxicity  
may be allowed, 
following consultation 
with the Sponsor and 
the Investigator.If toxicity  has recovered to Gr ade1 
or better (or participant’s baseline 
value), participant will be restarted 
at lower dose of navarixin ( ie, from 
100 mg to 50 mg or from 30 mg to 
20 mg ), depending on the arm.   If 
navarixin has alread y been dose 
reduced, discontinue navarixin. 
Pembrolizumab will be restarted at 
normal dose .
If toxicity has not recovered, 
participant will discontinue study
treatment (discontinue both 
pembrolizumab an d navarixin) . 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 56
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialPembrolizumab Dose Modification 7.2.2
AEs associated with pembrolizumab exposure may represent an immunologic etiology . 
These immune -related AEs (irAEs) may  occur shortly  after the first dose or several months 
after the last dose of pembrolizumab treatment and may affect more than one body s ystem 
simultaneously . Therefore, earl y recognition and initiation of treatment is cr itical to reduce 
complications. Based on existing clinical study data, most irAEs were reversible and could 
be managed with interruptions of pembrolizumab, administration of corticosteroids and/or 
other supportive care. For suspected irAEs, ensure adequate evaluation to confirm etiology  or 
exclude other causes. Additional procedures or tests such as bronchoscop y, endoscop y, skin 
biopsy  may  be included as part of the evaluation .Based on the severity  of irAEs, withhold or 
permanentl y discontinue pembrolizuma b and administer corticosteroids. Dose modification 
and toxicity  management guidelines for irAEs associated with pembrolizumab are provided 
in Table 4 . 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 57
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTable 4 Dose Modification and Toxicity  Management Guidelines for Immune- related AEs Associated with Pembrolizumab
General instructions:
1.Corticosteroid taper should be initiated upon AE improving to Grade 1 or less and continue to taper over at least 4 w eeks.
2.For situations where pembrolizumab has been withheld, pembrolizumab can be resumed after AE has been reduced to Grade 1 or 0 and corticosteroid 
has been tapered. Pembrolizumab should be permanently discontinued if AE does not resolve within 12 w eeks of las t dose or corticosteroids cannot be 
reduced to ≤10 mg prednisone or equivalent per day within 12 weeks. 
3.For severe and life -threatening irAEs, IV corticosteroid should be initiated first follow ed by  oral steroid. Other immunosuppressive treatment sh ould b e 
initiated if irAEs cannot be controlled by corticosteroids.
Immune -related AEsToxicity grade or 
conditions (CTCAEv4.0)Action taken to 
pembrolizumabirAE management with 
corticosteroid and/or 
other therapies Monitor and follow -up 
Pneumonitis Grade 2 Withhold Administer 
corticosteroids (initial 
dose of 1 -2mg/kg 
prednisone or 
equivalent) followed by 
taperMonitor participants for signs and 
symptoms of pneumonitis
Evaluate participants with suspected 
pneumonitis with radiographic 
imaging and initiate corticosteroid 
treatment
Add prophylactic antibiotics for 
opportunistic infectionsGrade 3 or 4, or recurrent 
grade 2Perm anently discontinue
Diarrhea / colitis Grade 2 or 3 Withhold Administer 
corticosteroids (initial 
dose of 1 -2mg/kg 
prednisone or 
equivalent) followed by 
taperMonitor participants for signs and 
symptoms of enterocolitis (i.e. 
diarrhea, abdominal pain, blood or 
mucus in stool w ith or without fever) 
and of bow el perforation (i.e. 
peritoneal signs and ileus).
Participants with ≥ Grade 2 diarrhea 
suspecting colitis should consider GI 
consultation and performing 
endoscopy to rule out colitis. 
Participants with diarrhea/colitis 
should be advised to drink liberal 
quantities of clear fluids.  If sufficient 
oral fluid intake is not feasible, fluid 
and electrolytes should be substituted 
via IV infusion.Grade 4 Perm anently discontinue 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 58
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialGeneral instructions:
1.Corticosteroid taper should be initiated upon AE improving to Grade 1 or less and continue to taper over at least 4 w eeks.
2.For situations where pembrolizumab has been withheld, pembrolizumab can be resumed after AE has been reduced to Grade 1 or 0 and corticosteroid 
has been tapered. Pembrolizumab should be permanently discontinued if AE does not resolve within 12 w eeks of las t dose or corticosteroids cannot be 
reduced to ≤10 mg prednisone or equivalent per day within 12 weeks. 
3.For severe and life -threatening irAEs, IV corticosteroid should be initiated first follow ed by  oral steroid. Other immunosuppressive treatment sh ould b e 
initiated if irAEs cannot be controlled by corticosteroids.
Immune -related AEsToxicity grade or 
conditions (CTCAEv4.0)Action taken to 
pembrolizumabirAE management with 
corticosteroid and/or 
other therapies Monitor and follow -up 
AST / ALT elevation or 
increased bilirubinGrade 2 Withhold Administer 
corticosteroids (initial 
dose of 0.5 -1mg/kg 
prednisone or 
equivalent) followed by 
taperMonitor w ith liver function tests 
(consider w eekly or more frequently 
until liver enzyme value returned to 
baseline or is stable )
Grade 3 or 4 Perm anently discontinue Administer 
corticosteroids (initial 
dose of 1 -2mg/kg 
prednisone or 
equivalent) followed by 
taper
Type 1 diabetes mellitus 
(T1DM) or 
HyperglycemiaNewly onset T1DM or 
Grade 3 or 4 
hyperglycemia associated 
with evidence of -cell 
failureWithhold Initiate insulin 
replacement therapy for 
participants with T1DM 
Administer anti -
hyperglycemic in 
participants with 
hyperglycemia Monitor participants for 
hyperglycemia or other signs and 
symptoms of diabetes.
Hypophysitis Grade 2 Withhold Administer 
corticosteroids and 
initiate hormonal 
replacements as 
clinically indicated.  Monitor for signs and symptoms of 
hypophysitis (including 
hypopituitarism and adrenal 
insufficiency) Grade 3 or 4 Withhold or permanently 
discontinue1 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 59
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialGeneral instructions:
1.Corticosteroid taper should be initiated upon AE improving to Grade 1 or less and continue to taper over at least 4 w eeks.
2.For situations where pembrolizumab has been withheld, pembrolizumab can be resumed after AE has been reduced to Grade 1 or 0 and corticosteroid 
has been tapered. Pembrolizumab should be permanently discontinued if AE does not resolve within 12 w eeks of las t dose or corticosteroids cannot be 
reduced to ≤10 mg prednisone or equivalent per day within 12 weeks. 
3.For severe and life -threatening irAEs, IV corticosteroid should be initiated first follow ed by  oral steroid. Other immunosuppressive treatment sh ould b e 
initiated if irAEs cannot be controlled by corticosteroids.
Immune -related AEsToxicity grade or 
conditions (CTCAEv4.0)Action taken to 
pembrolizumabirAE management with 
corticosteroid and/or 
other therapies Monitor and follow -up 
Hyperthyroidism Grade 2 Continue Treat w ith non -selective 
beta-blockers (e.g. 
propranolol) or 
thionamides as 
appropriate Monitor for signs and symptoms of 
thyroid disorders. 
Grade 3 or 4 Withhold or 
permanently discontinue1
Hypothyroidism Grade 2-4 Continue Initiate thyroid 
replacement hormones 
(e.g. levothyroxine or 
liothyroinine) per 
standard of careMonitor for signs and symptoms of 
thyroid disorders. 
Nephritis and renal 
dysfunctionGrade 2 Withhold Administer 
corticosteroids 
(prednisone 1-2mg/kg or 
equivalent) followed by 
taper.Monitor changes of renal function
Grade 3 or 4 Perm anently discontinue
Myocarditis Grade 1 or 2 Withhold Based on severity of AE 
administer 
corticosteroidsEnsure adequate evaluation to 
confirm etiology and/or exclude other 
causesGrade 3 or 4 Perm anently discontinue 
   04W5XD
07WYDZ
Product:   MK-7123 SCH 527123 60
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialGeneral instructions:
1.Corticosteroid taper should be initiated upon AE improving to Grade 1 or less and continue to taper over at least 4 w eeks.
2.For situations where pembrolizumab has been withheld, pembrolizumab can be resumed after AE has been reduced to Grade 1 or 0 and corticosteroid 
has been tapered. Pembrolizumab should be permanently discontinued if AE does not resolve within 12 w eeks of las t dose or corticosteroids cannot be 
reduced to ≤10 mg prednisone or equivalent per day within 12 weeks. 
3.For severe and life -threatening irAEs, IV corticosteroid should be initiated first follow ed by  oral steroid. Other immunosuppressive treatment sh ould b e 
initiated if irAEs cannot be controlled by corticosteroids.
Immune -related AEsToxicity grade or 
conditions (CTCAEv4.0)Action taken to 
pembrolizumabirAE management with 
corticosteroid and/or 
other therapies Monitor and follow -up 
All other immune -related 
AEsIntolerable/ persistent 
Grade 2Withhold Based on type and 
severity of AE 
administer 
corticosteroids Ensure adequate evaluation to 
confirm etiology and/or exclude other 
causesGrade 3 Withhold or discontinue 
based on the type of 
event.  Events that 
require discontinuation 
include and not limited 
to:  Gullain -Barre 
Syndrome, encephalitis
Grade 4 or recurrent Grade 
3 Perm anently discontinue
1.Withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physician.  
NOTE: 
For participants with Grade 3 or 4 immune -related endocrinopathy where w ithhold of pembrolizumab is required, pembrolizumab may be resumed when AE 
resolves to ≤ Grade 2 and is controlled w ith hormonal replacement therapy or achieved metabolic control (in c ase of T1DM).   
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 61
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialMethod of Treatment Assignment 7.3
Treatment allocation/randomization will occur centrally using an interactive response 
technology  (IRT) system.  There are 2study  treatment arms.  Participants will be assigned 
randomly  in a 1:1ratio to dose Arm A and dose Arm B, respectivel y.
Stratification 7.3.1
Treatment allocation/randomization will be stratified according to the following factors:
Tumor ty pe(NSCL C [PD -(L)1 refractory ], CRPC ,and MSS CRC)
Blinding 7.4
This is an open -label study ; therefore, the Sponsor, investigator and participant will know the 
treatment administered .
Preparation/Handling/Storage/Accountability 7.5
Dose Preparation 7.5.1
Details on preparation and administration of navarixin (and pembrolizumab) are provided in 
the appropr iate Pharmacy /Procedures Manual
Handling, Storage and Accountability 7.5.2
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study treatment received and an y discrepancies are reported 
and re solved before use of the study  treatment.
Only  participants enrolled in the study  may  receive study  treatment and only  authorized site 
staff may  suppl y or administer study treatment. All study treatments must be stored in a 
secure, environmentall y controll ed, and monitored (manual or automated) area in accordance 
with the labeled storage conditions with access limited to the investigator and authorized site 
staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y treatment accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country  Sponsor personnel or designee will provide appropriate 
documentation t hat must be completed for drug accountability  and return, or local discard 
and destruction if appropriate.  Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
docum ented.
The study site is responsible for recording the lot number, manufacturer, and expiry  date for 
any locall y purchased product as per local guidelines unless otherwise instructed b y the 
Sponsor. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 62
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialThe investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution and usage of stud y 
treatments in accordance with the protocol and an y applicable laws and regulations.
Treatment Compliance 7.6
Interruptions from the protocol specified treatment plan for >12 weeks require consultation 
between the investigator and the Sponsor and written documentation of the collaborative 
decision on participant management.
Concomitant Therapy 7.7
Medications or vacci nations specificall y prohibited in the exclusion criteria are not allowed. 
If there is a clinical indication for an y medication or vaccination specifically prohibited , 
discontinuation from study  therapy  or vaccination may  be required. The investigator shou ld 
discuss any  questions regarding this with the Sponsor Clinical Director. The final decision on 
any supportive therap y or vaccination rests with the investigator and/or the participant’s 
primary  physician. However, the decision to continue the participan ton study  treatmen t
requires mutual agreement of the investigator, the Sponsor ,and the participant. 
Participants are prohibited from receiving the following concomitant therap iesand
vaccination s during the screening and treatment periods of the stud y:
Immunotherapy not specified in this protocol
Antineoplastic sy stemic chemotherap y or biological therap ynot specified in this 
protocol
Investigational agents not specified in this protocol
Radiation therap y (radiotherap y for symptom management is allowed )
Live vaccines within 28 days before the first dose of study treatment and while 
participating in the stud y. Examples of live vaccines include, but are not limited to, 
the following: measles, mumps, rubella, chickenpox, y ellow fever, rabies, BCG, and 
typhoid vaccine s. Seasonal influenza vaccines for injection are generall y killed virus 
vaccines and are allowed. Intranasal influenza vaccine s (eg,FluMist®) are live 
attenuated vaccines, and are not allowed.
Glucocorticoids other than to modulate symptoms from an immune -mediated AE . 
Chronic sy stemic replacement doses of steroids andnon-systemic steroids including 
inhaled steroids , topical steroids, intra -nasal steroids, intra -articular, and ophthalmic 
steroids are allowed .
There are no prohibited therapies after the Post -Treatment Safet y Follow -Up v isit.
Rescue Medications andSupportive Care 7.7.1
Participants should receive appropriate supportive care measures as deemed necessary b y the 
treating investigator.  Suggested supportive care measures for the management of AEs with 
potential immunologic etiology  are outlined along with the dose modificati on guidelines in 
Section 7.2, (Table 4).  Where appropriate, these guidelines include the use of oral or IV 
treatment with corticosteroids, as well as additional anti -inflammatory  agents if sy mptoms do  
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 63
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidentialnot improve with administration of corticosteroids.  N ote that several courses of steroid 
tapering may  be necessary  as sy mptoms may  worsen when the steroid dose is decreased.  For 
each disorder, attempts should be made to rule out other causes such as metastatic disease or 
bacterial or viral infection, which might require additional supportive care.  The treatment 
guidelines are intended to be applied when the investigator determines the events to be 
related to pembrolizumab.
Note: If after the evaluation of the event, it is determined not to be related to pem brolizumab, 
the investigator does not need to follow the treatment guidance.  Refer to (Table 4) in Section 
7.2.1 for guidelines regarding navarixin dose modification and supportive care. Refer to 
Section 7.2.2 for pembrolizumab dose modification.
Supporti ve Care Guidelines for Pembrolizumab
Pneumonitis :
oFor Grade 2 events , treat with sy stemic corticosteroids. When sy mptoms improve to 
Grade 1 or less, steroid taper should be started and continued over no less than 4 
weeks.
oFor Grade 3 -4 events , immediately  treat with intravenous steroids. Administer
additional anti -inflammatory  measures, as needed.
oAdd proph ylactic antibiotics for opportunistic infections in the case of prolonged
steroid administration.
Diarrhea/Colitis:
Participant s should be carefull y moni tored for signs and sy mptoms of enterocolitis (such as 
diarrhea, abdominal pain, blood or mucus in stool, with or without fever) and bowel 
perforation (such as peritoneal signs and ileus).
oAll participant s who experience diarrhea/colitis should be advised to drink liberal
quantities of clear fluids. If sufficient oral fluid intake is not feasible, fluid and
electrol ytes should be substituted via I V infusion. For Grade 2 or higher diarrhea,
consider GI consultation and endoscop y to confirm or rule out coliti s.
oFor Grade 2 diarrhea/colitis that persists >3 days, administer oral corticosteroids.
oFor Grade 3 or 4 diarrhea/colitis that persists >1 week, treat with intravenous
steroids followed b y high dose oral steroids.
oWhen sy mptoms improve to Grade 1 or less, steroid taper should be started and
continued over no less than 4 weeks.
Type 1 diabetes mellitus (if new onset, including diabetic ketoacidosis [DKA]) or ≥ 
Grade 3 hyperglycemia, if associated with ketosis (ketonuria) or metabolic acidosis 
(DKA):
oFor T1DM or Grade 3- 4 hyperglycemia
Insulin replacement therapy  is recommended for Ty pe 1 diabetes mellitus and for 
Grade 3 -4 hypergl ycemia associated with metabolic acidosis or ketonuria.
Evaluate patients with serum glucose and a metabolic panel, urine ketones,
glycosylated hemoglobin, and C -peptide. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 64
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialHypophysitis :
oFor Grade 2 events, treat with corticosteroids. When sy mptoms improve to Grade 1 
or less, steroid taper should be started and continued over no less than 4 weeks.
Replacement of appropriate hormones may be required as the steroid dose is tapered.
oFor Grade 3 -4 events, treat with an initial dose of IV corticosteroids followed by oral 
corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be 
started and continued over no less than 4 weeks. Replacement of appropriate 
hormones may  be required as the steroid dose is tapered.
Hyperthyroidism or Hypothyroidism :
Thyroid disorders can occur at any  time during treatment. Monitor patients for changes in
thyroid function (at the start of treatment, periodically  during treatment, and as indicated
based on clinical evaluation) and for clinical signs and sy mptoms of thy roid disorders.
oGrade 2 hyperthy roidism events (and Grade 2 -4 hypothy roidism):
In hyperthyroidism, non- selective beta-blockers (e.g. propranolol) are
suggested as initial therapy .
In hypoth yroidism, th yroid hormone replacement therap y, with levoth yroxine
or liothy ronine, is indicated per standard of care.
oGrade 3 -4 hyperth yroidism
Treat with an initial dose of IV cor ticosteroid followed by  oral corticosteroids.  
When sy mptoms improve to Grade 1 or less, steroid taper should be started
and continued over no less than 4 weeks. Replacement of appropriate
hormones may  be required as the steroid dose is tapered.
Hepatic :
oFor Grade 2 events, monitor liver function tests more frequentl y until returned to
baseline values (consider weekl y).
Treat with IV or oral corticosteroids
oFor Grade 3 -4 events, treat with intravenous corticosteroids for 24 to 48 hours.
oWhen sy mptoms improv e to Grade 1 or less, a steroid taper should be started and
continued over no less than 4 weeks
Renal Failure or Nephritis :
oFor Grade 2 events, treat with corticosteroids.
oFor Grade 3 -4 events, treat with sy stemic corticosteroids.
oWhen sy mptoms improve to Grade 1 or less, steroid taper should be started and
continued over no less than 4 weeks.
Myocarditis:
oForGrade 1 or 2 events, withhold. Based on severity  of AE administer 
corticosteroids. Ensure adequate evaluation to confirm etiology  and/or exclude othe r 
causes. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 65
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialoFor Grade 3 and 4 events, permanentl y discontinue. Based on severity  of AE 
administer corticosteroids. Ensure adequate evaluation to confirm etiology  and/or 
exclude other causes.
Management of Infusion Reactions : Signs and sy mptoms usually  develo p during or shortly  
after drug infusion and generall y resolve completely within 24 hours of completion of 
infusion.
Table 5 shows treatment guidelines for participant s who experience an infusion reaction
associated with administration of pembrolizumab (MK -3475).
Table 5 Pembrolizumab I nfusion Reaction Treatment Guidelines
NCI CTCAE Grade TreatmentPremedication at 
subsequent dosing
Grade 1
Mild reaction; infusion 
interruption not indicated; 
intervention not indicatedIncrease monitoring of vital signs as 
medically indicated until the 
participant is deemed medically 
stable in the opinion of the 
investigator.None
Grade 2
Requires infusion 
interruption but responds 
promptly to symptomatic 
treatment (e.g., 
antihistamines, NSAIDS, 
narcotics, IV fluids); 
prophylactic medications 
indicated for ≤24 hoursStop Infusion and monitor 
symptoms.
Additional appropriate medical 
therapy ma y include but is not limited 
to:
IV fluids
Antihistamines
NSAIDS
Acetaminophen
Narcotics
Increase monitoring of vital signs as 
medically indicated until the 
participant is deemed medically 
stable in the opinion of the 
investigator.
If symptoms resolve within one hour 
of stopping drug infusion, the 
infusion may be restarted at 50% of 
the original infusion rate (e.g., from 
100 mL/hr to 50 mL/hr).  Otherwise 
dosing will be held until symptoms 
resolve and the participant should be 
premed icated for the next scheduled 
dose.
Participant s who develop Grade 2 
toxicity despite adequate 
premedication should be 
permanently discontinued from 
further trial treatme nt 
administration.Participant may be 
premedicated 1.5h (± 30 
minutes) prior to infusion 
of pembrolizumab (MK -
3475) with:
Diphenhydramine 50 mg 
orally (or equivalent dose 
of antihistamine).
Acetaminophen 500-1000 
mg orally (or equivalent 
dose of antipyretic). 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 66
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialNCI CTCAE Grade TreatmentPremedication at 
subsequent dosing
Grades 3 or 4
Grade 3:
Prolonged (i.e., not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of infusion); 
recurrence of symptoms 
following initial 
improvement; 
hospitalization indicated for 
other clinical sequelae (e.g., 
renal impairment, 
pulmonary infiltrates)Stop Infusion.
Additional appropriate medical 
therapy may include but is not limited 
to:
IV fluids
Antihistamines
NSAIDS
Acetaminophen
Narcotics
Oxygen
Pressors
Corticosteroids
EpinephrineNo subsequent dosing
Grade 4:
Life-threatening; pressor or 
ventilatory support 
indicatedIncrease monitoring of vital signs as 
medically indicated until the 
participant is deemed medically 
stable in the opinion of the 
investigator.
Hospitalization may be indicated.
Participant is permanently 
discontinued from further trial 
treatment administration.
Appropriate resuscitation equipment should be available in the room and a physician readily available during 
the period of drug administration. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 67
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialTreatment After the End of the Study 7.8
There is no stud y-specified treatment following the end of the stud y.
Clinical Supplies Disclosure 7.9
This study is open -label; therefore, the participant, the study site personnel, the Sponsor 
and/or designee are not blinded. Study treatment (name, st rength or potency ) is included in 
the label text; random code/disclosure envelopes or lists are not provided.
8.Discontinuation/Withdrawal Criteria 
Discontinuation of Study Treatment 8.1
Discontinuation of study  treatment does not represent withdrawal from the study .
As certain data on clinical events bey ond study  treatment discontinuation may  be important 
to the study , they  must be collected through the participant’s last scheduled follow -up, even 
if the participant has discontinued study  treatment.  Therefore, all pa rticipants who 
discontinue study  treatment prior to completion of the protocol -specified treatment period
will still continue to participate in the study as specified in Section 2 -Schedule of Activities 
and Section 9.11.3 –Post Study .
Participants may  discontinue study  treatment at any  time for any  reason or be dropped from 
the study  treatment at the discretion of the investigator should an y untoward effect occur.  In 
addition, a participant may be discontinued from study  treatment by  the investigator or the 
Sponsor if study  treatment is inappropriate, the study plan is violated, or for administrative 
and/or other safet y reasons.  Specific details regarding procedures to be performed at stud y 
treatment discontinuation are provided in Section 9.1.9 –Disco ntinuation and Withdrawal .
A participant must be discontinued from study treatment but continue to be monitored in the 
study  for an y of the following reasons:
○The participant or participant’s legall y acceptable representative requests to discontinue 
study treatment.
oThe participant interrupts study  treatment administration for more than 12 consecutive 
weeks, unless approved with written documentation from the Sponsor .
oThe participant has a medical condition or personal circumstance which, in the opinion o f 
the investigator and/or Sponsor, placed the participant at unnecessary  risk from continued 
administration of study  treatment.
oThe participant has a confirmed positive serum or urine pregnancy  test (depending on 
local regulation) .
Withdrawal from the Study 8.2
A participant must be withdrawn from the study  if the participant or participant’s legall y 
acceptable representative withdraws consent from the study .
If a participant withdraws from the study , they  will no longer receive study  treatment or be 
follow ed at scheduled protocol visits. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 68
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialSpecific details regarding procedures to be performed at the ti me of withdrawal from the 
study , as well as specific details regarding withdrawal from Future Biomedical Research are 
outlined in Section 9.1.9 –Withdrawal/Discontinuation. The procedures to be performed 
should a participant repeatedly  fail to return for scheduled visits and/or if the study site is 
unable to contact the participant are outlined in section 8.3.
Lost to Follow Up 8.3
If a participant fail s to return to the clinic for a required study  visit and/or if the site is unable 
to contact the participant, the following procedures are to be performed:
●The site must attempt to contact the participant and reschedule the missed visit.  I f the 
particip ant is contacted, the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
●The investigator or designee must make every  effort to regain contact with the 
participant at each missed visit (eg, phone calls and/or a certified letter to the 
participant’s last known mailing address or locally equivalent methods). These 
contact attempts should be documented in the participant’s medical record.
●Note:  A participant is not considered lost to follow -up until the last scheduled visit 
for the individual participant.  The missing data for the participant will be managed 
via the pre- specified statistical data handling and analy sis guidelines.
9.Study Ass essments and Procedures
●Study  procedures and their timing are summarized in the SoA. 
●Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
●The Investigator is responsible for a ssuring that procedures are conducted by 
appropriatel y qualified or trained staff.  Delegation of study site personnel 
responsibilities will be documented in the Investigator Trial File Binder (or 
equivalent).
●All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility  or record 
reasons for screening failure, as applicab le. 
●Procedures conducted as part of the participant’s routine clinical management (eg, 
blood count) and obtained before signing of I CF may  be utilized for screening or 
baseline purposes provided the procedure met the protocol -specified criteria and were
performed within the time frame defined in the SoA. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 69
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
Confidential●Additional evaluations/testing may  be deemed necessary  by the investigator and or 
the Sponsor for reasons related to participant safety . In some cases, such 
evaluation/testing may  be potentially  sens itive in nature (eg, HIV, Hepatitis C, etc.), 
and thus local regulations may  require that additional informed consent be obtained 
from the participant .  In these cases, such evaluations/testing will be performed in 
accordance with those regulations.
The maximum amount of blood collected from each participant over the duration of the 
study , including an y extra assessments that may be required is outlined in the Procedure 
Manual.
Repeat or unscheduled samples may  be taken for safet y reasons or for technical issues with 
the samples.
Administrative and General Procedures 9.1
Informed Consent 9.1.1
The investigator or qualified designee must obtain documented consent from each potential 
participant or each participant’s legally acceptable representative prior to participating in a 
clinical study or Future Biomedical Research . If there are changes to the participant’s status 
during the study (eg, health or age of majorit y requirements), the investigator or qualified 
designee must ensure the appropriate consent is in place. 
General Informed Consent 9.1.1.1
Consent must be documented by  the participant’s dated signature or b y the participant’s 
legally  acceptable representative’s dated signature on a consent form along with the dated 
signature of the person conducting the consent discussion. 
A cop y of the signed and dated consent form should be given to the part icipant before 
participation in the study .
The initial I CF, any  subsequent revised written ICF and an y written information provided to 
the participant must receive the IRB/IEC’s approval/favorable opinion in advance of use.  
The participant or his/her lega lly acceptable representative should be informed in a timely  
manner if new information becomes available that may  be relevant to the participant’s 
willingness to continue participation in the study .  The communication of this information 
will be provided a nd documented via a revised consent form or addendum to the original 
consent form that captures the participant’s dated signature or b y the participant’s legall y 
acceptable representative’s dated signature.
Specifics about a study and the study population will be added to the consent form template 
at the protocol level.  
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations 
and Sponsor requirements. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 70
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialConsent and Collection of Specimens for Future Biomedical Research 9.1.1.2
The i nvestigator or qualified designee will explain the Future Biomedical Research consent 
to the participant, answer all of his/her questions, and obtain written informed consent before 
performing an y procedure related to the Future Biomedical Research sub -study.  A copy  of 
the informed consent will be given to the participant.
Inclusion/Exclusion Criteria 9.1.2
All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee 
to ensure that the participant qualifies for the study .
Participant Identification Card 9.1.3
All participants will be given a Participant Identification Card identifying them as 
participants in a research study . The card will contain study site contact information 
(including direct telephone numbers) to be utilized in the event of an emergency . The 
investigator or qualified designee will provide the participant with a Participant I dentification 
Card immediately  after the participant provides written informed consent. At the time of 
treatment allocation/randomization, site personnel will add the treatment/randomization 
number to the Participant I dentification Card.
The participant identification card also contains contact information for the emergency 
unblinding call center so that a health care provider can obtain inf ormation about study  
treatment in emergency  situations where the investigator is not available.
Medical History 9.1.4
General Medical History 9.1.4.1
A medical history  will be obtained by  the investigator or qualified designee.
Medical history will include all active co nditions, drug allergies, significant medical 
procedures and an y condition diagnosed within the prior 10 y ears that are considered to be 
clinically  significant b y the investigator. Any cancer other than the cancer under study will 
be recorded as medical h istory  even if diagnosed greater than 10 y ears prior to enrollment.  
Details regarding the cancer under stud y will be recorded separately  and not listed as medical
history .
Oncologic Disease Details 9.1.4.2
The investigator or qualified designee will obtain histor ic and current details of the 
participant’s cancer under study .  This information will include ,but is not limited to ,date of 
diagnosis, stage, histology , locations of primary  lesions and location of metastases if 
applicable. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 71
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialPrior and Concomitant Medications Review 9.1.5
Prior Medications 9.1.5.1
The investigator or qualified designee will review prior medication use, including an y 
protocol -specified washout requirement, and record prior medication taken by  the participant 
within 28 day s before the first dose of study  medication.   Any medications taken to treat a 
cancer other than the cancer under stud y will be recorded as a prior medication even if taken 
greater than 28 day s before the first dose of study  medication.  All treatments for the cancer 
under study  will be recorded separatel y and not listed as a prior medication.
Prior Oncologic Treatment 9.1.5.2
The investigator or qualified designee will review and record all treatments for the cancer 
under study  including s ystemic and local treatment, vaccinations, radiation ,and surgeries.  
Additional information collected on these treatments will include, but is not limited to, 
reason for discontinuation, best response ,and date of progression after each treatment as 
applicable.
Concomitant Medications 9.1.5.3
The investigator or qualified designee will record medication, if an y, taken by the participant 
during the study .
All medications related to reportable SAEs and ECI s should be recorded as defined in 
Section 9.3.
Any new anti -cancer therapy  started after the participant’s discontinuation from the treatment 
period will be recorded separately.  Additional information collected on this treatment will 
include, but is not limited to, best response and date of progression.
Assignment of Screening Number 9.1.6
All consente d participants will be given a unique screening number that will be used to 
identify  the participant for all procedures that occur prior to randomization .  Each participant 
will be assigned onl y one screening number.  Screening numbers must not be re -used for 
different participants.
Any participant who is screened multiple times will retain the original screening number 
assigned at the initial screening visit.
Specific details on the screening visit requirements (screening/rescreening) are provided in 
Secti on 9.11.1.  
Assignment of Treatment/Randomization Number 9.1.7
All eligible participants will be randomly allocated and will receive a 
treatment/randomization number.  The treatment/randomization number identifies the 
participant for all procedures occurring af ter treatment allocation/randomization.  Once a 
treatment/randomization number is assigned to a participant, it can never be re -assigned to 
another participant. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 72
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialA single participant cannot be assigned more than 1 treatment/randomization number.
Treatment A dministration 9.1.8
Study  treatment should start on the day  of treatment allocation/randomization or as close as 
possible to the date on which the participant is allocated/assigned.
Timing of Dose Administration 9.1.8.1
Navarixin may  be administered at an y time in relat ion to food intake .  Navarixin should be 
taken at approximately  the same time each day .
Discontinuation and Withdrawal 9.1.9
Participants who discontinue study  treatment prior to completion of the treatment period
shoul d be encouraged to continue to be followed for all remaining study  visits.
When a participant withdraws from participation in the study , all applicable activities 
scheduled for the final study visit should be performed (at the time of withdrawal ).  Any  
adverse events which are present at the time o f withdrawal should be followed in accordance 
with the safet y requirements outlined in Section 9.3 ..
Withdrawal From Future Biomedical Research 9.1.9.1
Participants may  withdraw their consent for Future Biomedical Research.  Participants may  
withdraw consent at an y time by  contacting the principal investigator for the main study .  If 
medical records for the main study are still available, the investigator will contact the 
Sponsor using the designated mailbox (clinical.specimen.management@merck.com).  
Subsequently , the participant's consent for Future Biomedical Research will be withdrawn.  
A letter will be sent from the Sponsor to the investigator confirmi ng the withdrawal. It is the 
responsibility  of the investigator to inform the participant of completion of withdrawal.  An y 
analyses in progress at the time of request for withdrawal or alread y performed prior to the 
request being received by the Sponsor w ill continue to be used as part of the overall research 
study data and results.  No new analys es would be generated after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study records) 
or the specimens have been completel y anon ymized, there will no longer be a link between 
the participant’s personal information and their specimens.  In this situation, the requ est for 
specimen withdrawal cannot be processed.
Participant Blinding/Unblinding 9.1.10
This is an open label study ; there is no blinding for this study .
Domiciling 9.1.11
Participants will not be domiciled. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 73
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialCalibration of Equipment 9.1.12
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinical study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy  parameters shall be suitably  
calibrat ed and/or maintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site.
Efficacy Assessments 9.2
Tumor Imaging and Assessment of Disease 9.2.1
The proc ess for image collection and transmission to the central imaging vendor can be 
found in the Site I maging Manual (SIM).  Tumor imaging is strongly  preferred to be acquired 
by computed tomography  (CT).  For the abdomen and pelvis, contrast -enhanced magnetic 
resonance imaging (MRI) may  be used when CT with iodinated contrast is contraindicated, 
or when mandated b y local practice.  MRI is the strongl y preferred modality for imaging the 
brain.  The same imaging technique regarding modality , ideall y the same scan ner, and the 
use of contrast should be used in a participant throughout the stud y to optimize the 
reproducibility  of the assessment of existing and new tumor burden and improve the 
accuracy  of the assessment of response or progression based on imaging.  No te: for the 
purposes of assessing tumor imaging, the term “Investigator” refers to the local investigator 
at the site and/or the radiological reviewer located at the site or at an offsite facility.
All scheduled images for all study  participants from the s ites will be submitted to the central 
imaging vendor.  In addition, images (including via other modalities) that are obtained at an 
unscheduled time point to determine disease progression, as well as imaging obtained for 
other reasons, but captures radiolo gic progression based on Investigator assessment, should 
also be submitted to the central imaging vendor. 
Initial Tumor Imaging 9.2.1.1
Initial tumor imaging at Screeni ng must be performed within 28 days prior to the da te of 
randomization .  The site study  team must review screening images to confirm the participant 
has measurable disease per RECI ST 1.1.
Tumor imaging performed as part of routine clinical management is acceptable for use as 
screening tumor imaging if it is of diagnosti c quality  and performed with in 28 days prior to 
the date of randomization and can be assessed b y the central imaging vendor .
If brain imaging is performed to document the stability  of existing metastases, MRI  should 
be used if possible.  If MRI  is medicall y contraindicated, CT with c ontrast is an acceptable 
alternative. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 74
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialTumor Imaging During the Study 9.2.1.2
The first on -study  imaging assessment should be performed at 9 weeks (±7 days) from the 
date of randomization. Subsequent tumor imaging should be performed every 9 weeks (±7 
days) or mo re frequently  if clinically  indicated.  Imaging timing should follow calendar day s 
and should not be adjusted for delay s in cy cle starts. I maging should continue to be 
performed until disease progression is identified by the Investigator or the start of ne w 
anticancer treatment, withdrawal of consent, or death, whichever occurs first. All 
supplemental imaging must be submitted to the central imaging vendor. 
Objective response should be confirmed b y a repeat imaging assessment. Tumor imaging to 
confirm PR o r CR should be performed at least 4 weeks after the first indication of a 
response is observed. Participants will then return to regular scheduled imaging, starting with 
the next scheduled imaging time point. Participants who receive additional imaging for
confirmation do not need to undergo the next scheduled tumor imaging if it is less than 4 
weeks later; tumor imaging may  resume at the subsequent scheduled imaging time point.  
Note:  Response does not ty pically need to be verified in real time b y the cen tral imaging 
vendor.
Per iRECI ST (Section 9.2.1.5 ), disease progression should be confirmed b y the site 4 to 8 
weeks after first radiologic evidence of PD in clinically stable participants. Participants who 
have unconfirmed disease progression may  continue on treatment at the discretion of the 
Investigator until progression is confirmed by the site, provided they  have met the conditions 
detailed in Section 9.2.1.5. Participants who receive confirmatory imaging do not need to 
undergo the next scheduled tumor imaging if it is less than 4 weeks later; tumor imaging may  
resume at the subsequent scheduled imaging time point, if clinically stable. Participants who 
have confirmed disease progression b y iRECI ST, as assessed b y the site, will discontinue 
study  treatm ent. Exceptions are detailed in Section 9.2.1.5
End of Treatment and Follow -up Tumor Imaging 9.2.1.3
For participants who discontinue study  treatment, tumor imaging should be performed at the 
time of treatment discontinuation (±4 week window). If previous imaging was obtained 
within 4 weeks prior to the date of discontinuation, then imaging at treatment discontinuation 
is not mandatory . For participants who discontinue study  treatment due to documented 
disease progression, this is the final required tumor imaging i f the investigator elects not to 
implement iRECI ST.
For participants who discontinue study  treatment without documented disease progression, 
every  effort should be made to continue monitoring disease status b y tumor imaging using 
the same imaging schedule used while on treatment every  12weeks (±7 days) until the start 
of a new anticancer treatment, disease progression, pregnancy, death, withdrawal of consent, 
or the end of the stud y, whichever occurs first.
RECIST 1.1 Assessment of Disease 9.2.1.4
RECI ST 1.1 (asse ssed by investigator) will be used as the primary  measure for assessment of 
tumor response, date of disease progression, and as a basis for all protocol guidelines related 
to disease status (eg, discontinuation of study treatment ). 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 75
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialiRECIST Assessment of Di sease 9.2.1.5
The iRECI ST method is based on RECI ST 1.1, but adapted to account for the unique tumor 
response seen with immunotherapeutic drugs. iRECI ST will be used b y the Investigator to 
assess tumor response and progression, and make treatment decisions. When clinically  stable, 
partici pants should not be discontinued until progression is confirmed b y the Investigator, 
working with local radiology , according to the rules outlined in Appendix 7. This allowance 
to continue treatment despite initial radiologic PD takes into account the obse rvation that 
some participants can have a transient tumor flare in the first few months after the start of 
immunotherapy , and then experience subsequent disease response. This data will be captured 
in the clinical database.
Clinical stability  is defined as the following: 
Absence of s ymptoms and signs indicating clinically  significant progression of 
disease
No decline in ECOG performance status 
No requirements for intensified management, including increased analgesia, 
radiat ion, or other palliative care
Any participant deemed clinically  unstable should be discontinued from study  treatment at 
site-assessed first radiologic evidence of PD, and is not required to have repeat tumor 
imaging for confirmation of PD by  iRECI ST.
If the Investigator decides to continue treatment, the participant may continue to receive 
study  treatment and the tumor assessment should be repeated 4 to 8 weeks later to confirm 
PD by  iRECI ST, per Investigator assessment.  Images should continue to be sent i n to the 
central imaging vendor for potential retrospective BICR.
If repeat imaging does not confirm PD per iRECI ST, as assessed b y the investigator, and the 
participant continues to be clinically stable, study treatment may continue and follow the 
regula r imaging schedule.  If PD is confirmed, participants will be discontinued from stud y 
treatment.
If a participant has iRECIST confirmed radiographic progression (iCPD) as defined in 
Appendix 7, study  treatment should be discontinued; however, if the partic ipant is achieving 
a clinically  meaningful benefit, an exception to continue study  treatment may  be considered 
following consultation with the Sponsor.  I n this case, if study  treatment is continued, tumor 
imaging should continue to be performed following the intervals as outlined in Section 2 and 
submitted to the central imaging vendor. 
A description of the adaptations and iRECI ST process is provided in Appendix 7, with 
additional details in the iRECI ST publication  [Seymour, L., et al 2017] .
Guidance for imaging and treatment after first radiologic evidence of progressive disease is 
shown in Table 6and for clinically  stable participants in Figure 3. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 76
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTable 6 Imaging and Treatment AfterFirst Radiologic Evidence of Progressive Disease
Clinically Stable Clinically Unstable
Imaging Treatm ent Imaging Treatm ent
First radiologic 
evidence of PD by 
RECIST 1.1 that 
has been verified 
by BICR]Repeat imaging 
at 4 to 8 weeks to 
confirm PD.May continue study 
treatment at the 
investigator’s 
discretion while 
awaiting 
confirmatory tumor 
imaging by site by 
iRECIST.Repeat imaging 
at 4 to 8 weeks to 
confirm PD per 
investigator’s 
discretion only.Discontinue treatment
Repeat tumor 
imaging confirms 
PD(iCPD) by 
iRECIST per 
investigator 
assessmentNo additional 
imaging required.Discontinue 
treatment (exception 
is possible upon 
consultation with 
Sponsor).No additional 
imaging required.Not applicable
Repeat tumor 
imaging shows 
iUPD by iRECIST 
per inve stigator 
assessmentRepeat imaging 
at 4 to 8 weeks to 
confirm PD.  
May occur at next 
regularly 
scheduled 
imaging visit.Continue study 
treatment at the 
investigator’s 
discretion.Repeat imaging 
at 4 to 8 weeks to 
confirm PD per 
investigator’s 
discretion on ly.Discontinue treatment
Repeat tumor 
imaging shows 
iSD, iPR, or iCR 
by iRECIST per 
investigator 
assessment.Continue 
regularly 
scheduled 
imaging 
assessments.Continue study 
treatment at the 
investigator’s 
discretion.Continue 
regularly 
scheduled 
imaging
assessments.May restart study 
treatment if condition 
has improved and/or 
clinically stable per 
investigator’s 
discretion.  Next tumor 
imaging should occur 
according to the regular 
imaging schedule. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 77
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialFigure 3Imaging and Treatment for Clinically  Stable Participants Treated With 
Pembrolizumab After First Radiologic Evidence of PD Assessed b y the Investigators
iRECIST=modified Response Evaluation Criteria in Solid Tumors 1.1 for immune -based therapeutics; PD=prog ressive 
disease; RECIST 1.1=Response Evaluation Criteria in Solid Tumors 1.1
Prostate -Specific Antigen 9.2.2
The initial Prostate -Specific Antigen (PSA) biomarker assessment at screening must be
performed within 28 days prior to the date of allocation.
In the fi rst year (through Week 54), on study PSA biomarker assessments must be performed
every  9 weeks (63 day s ±7 day s) from the date of allocation. After one y ear, participants who
remain on- treatment will have PSA performed every  12 weeks (84 day s ±7 day s).
MSI Status in CPRC Patients 9.2.3
MSI status will be tested in participants with CRPC who demonstrate an objective response
(either confirmed or unconfirmed) to therapy .  
MSI status can be evaluated using the archival or newly obtained tumor tissue collected at 
screening.
Adverse Events (AE) , Serious Adverse Events (SAE) and Other Reportable Safety 9.3
Events 
The definitions of an adverse event (AE) or serious adverse event (SAE), as well as the 
method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting AE, SAE and other reportable safet y event repo rts can be 
found in Appendix 4.
 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 78
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialProgression of the cancer under study  is not considered an adverse event as described in 
Section 9.3.5 –Disease -Related Events and/or Disease -Related Outcomes Not Qualify ing as 
AEs or SAEs, and Appendix 4.
AE, SAEs, and oth er reportable safety  events will be reported by  the participant (or, when 
appropriate, b y a caregiver, surrogate, or the participant's legally  authorized representative). 
The investigator, who is a qualified ph ysician, and any  designees are responsible fo r 
detecting, assessing, documenting, and reporting events that meet the definition of an AE or 
SAE as well as other reportable safety events. Investigators remain responsible for following 
up AE, SAEs and other reportable safet y events for outcome accordin g to Section 9.3.3.
Adverse events will not be collected for participants during the pre -screening period (for 
determination of archival tissue status) as long as that participant has not undergone an y 
protocol -specified procedure or intervention.  If the participant requires a blood draw, fresh 
tumor biopsy  etc., the participant is first required to provide consent to the main study  and 
AEs will be captured according to guidelines for standard AE reporting.
Time Period and Frequency for Collecting AE, SAE and Other Reportable 9.3.1
Safety Event Information 
All AEs, SAEs and other reportable safet y events that occur after the consent form is signed 
but before treatment allocation/randomization must be reported b y the investigator if the 
participant is receiving p lacebo run -in or other run -in treatment, if the event cause the 
participant to be excluded from the study , or is the result of a protocol -specified intervention, 
including but not limited to washout or discontinuation of usual therap y, diet, or a procedure . 
●All AEs from the time of treatment allocation/randomization through 30 days 
following cessation of study treatment must be reported by the investigator. 
●All AEs meeting serious criteria, from the time of treatment allocation/randomization 
through 90 day s following cessation of study treatment, or 30 day s following 
cessation of study treatment if the participant initiates new anticancer therapy, 
whichever i s earlier must be reported by  the investigator. 
●All pregnancies and exposure during breastfeeding, from the time of treatment 
allocation/randomization through 120 day s following cessation of study  treatment, or 
30 day s following cessation of study  treatment if the participant initiates new 
anticancer therap y must be reported b y the investigator. 
●Additionally , any SAE brought to the attention of an investigator at an y time outside 
of the time period specified above must be reported immediately to the S ponsor if the 
event is considered to be drug -related .
Investigators are not obligated to activel y seek AE or SAE or other reportable safet y events 
in former stud y participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study , and he/she 
considers the event to be reasonably related to the study treatment or study participation, the 
investigator must promptly  notify  the sponsor.
All initial and follow -up AEs, SAEs and other reportable safety  events will be recorded and 
reported to the sponsor or designee within the timeframes as indicated in Table 7. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 79
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTable 7 Reporting Time Periods and Timeframes for Adverse Events and Other 
Reportable Safet y Events
Type of Event Reporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through 
Protocol -
Specified 
Follow -up 
PeriodReporting Time 
Period:
After the Protocol 
Specified Follow -up 
PeriodTimeframe 
to Report 
Event and 
Follow -up 
Inform ation 
to 
SPONSOR:
Non-Serious 
Adverse Event 
(NSAE)Report if:
-due to protocol -
specified 
intervention
-causes 
exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Not required Per data 
entry 
guidelines
Serious Adverse 
Event (SAE)
including Cancer 
and OverdoseReport if:
-due to protocol -
specified 
intervention
-causes 
exclusion
-participant is 
receiving placebo 
run-in or other 
run-in treatmentReport all Report if:
-drug/vaccine related.
(Follow  ongoing to 
outcome)Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
ExposureReport if:
-due to 
intervention
-causes 
exclusionReport all Previously reported –
Follow  to 
completion/termination; 
report outcomeWithin 24 
hours of 
learning of 
event
Event of Clinical 
Interest (require 
regulatory 
reporting)Report if:
-due to 
intervention
-causes 
exclusionReport
-Potential DILI
-Require 
regulatory 
reportingNot required Within 24 
hours of 
learning of 
event
Event of Clinical 
Interest (Do not 
require regulatory 
reporting)Report if:
-due to 
intervention
-causes 
exclusionReport
-non-DILI ECIs 
and those not 
requiring 
regulatory
reportingNot required Within 5 
calendar 
days of 
learning of 
event 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 80
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialMethod of Detecting AE, SAE and Other Reportable Safety Events 9.3.2
Care will be taken not to introduce bias when detecting AE and/or SAE and other reportable 
safet y events. Open -ended and non-leading verbal questioning of the participant is the 
preferred method to inquire about AE occurrence .
Follow -up of AE, SAE and Other Reportable Safety Event Information 9.3.3
After the initial AE/SAE report, the investigator is required to proactivel y follo w each 
participant at subsequent visits/contacts. All AE, SAE and other reportable safet y events 
including pregnancy  and exposure during breastfeeding, ECI, Cancer and Overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 8.3). In addition, the investigator will 
make every  attempt to follow all non -serious AEs that occur in randomized participants for 
outcome.  Further information on follow -up procedu res is given in Appendix 4.
Regulatory Reporting Requirements for SAE 9.3.4
●Prompt notification (within 24 hours) by  the investigator to the sponsor of SAE is 
essential so that legal obligations and ethical responsibilities towards the safety of 
participants a nd the safety  of a study  treatment under clinical investigation are met. 
●The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and 
other regulatory  agencies about the safet y of a study  treatment under clinical 
investigatio n. All Adverse Events will be reported to regulatory  authorities, I RB/IECs 
and investigators in accordance with all applicable global laws and regulations, ie,per 
ICH Topic E6 (R1) Guidelines for Good Clinical Practice.
●Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR) according to local regulatory requirements and sponsor policy and 
forwarded to investigators as necessary .
●An investigator who receives an investigator safety report describing a nSAE or other 
specific safet y information (eg, summary or listing of SAE) from the sponsor will file 
it along with the Investigator’s Brochure and will notify  the IRB/IEC, if appropriate 
according to local requirements.
Disease -Related Events and/or Diseas e-Related Outcomes Not Qualifying as AEs 9.3.5
or SAEs
Efficacy  endpoints as outlined in this section will not be reported to the Sponsor as described 
in Section 9.3.1.  
Specificall y, the suspected/actual events covered in this exception include any event that is 
disease progression of the cancer under stud y.
The Sponsor will monitor unblinded aggregated efficacy endpoint events and safet y data to 
ensure the safety of the participants in the study .  Any  suspected endpoint which upon review 
is not progression of the cancer under study will be forwarded to global safety  as anSAE 
within 24 hours of determination that the event is not progression of the cancer under stud y. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 81
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialPregnancy and Exposure During Breastfeeding 9.3.6
Although pregnancy  and infant exposure during breastfeeding are not considered adverse 
events, an y pregnancy or infant exposure during breastfeeding in a participant (spontaneousl y 
reported to the investigator or their designee), including the pregnancy of a male participant's 
female partner, that occurs during the study are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy . 
Pregnancy  outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth must be reported as 
serious events (Important Medical Events).  If the pregnancy continues to term, the outcome 
(health of infant) must also be reported.
Events o f Clinical Interest (ECI) 9.3.7
Selected non -serious and serious adverse events are also known as Eve nts of Clinical I nterest 
(ECI) and must be reported to the Sponsor.
Events of clinical interest for this study include: 
1.an overdose of Sponsor's product, as defined in Section 9.4 –Treatment of Overdose, 
that is not associated with clinical symptoms or abnormal laboratory results.
2. an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit 
of normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less 
than 2X the upper limit of normal, as determined by  way  of protocol- specified laboratory  
testing or unscheduled l aboratory  testing.*
*Note:  These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that may require 
an additional evaluation for an underl ying etiology. The studysite guidance for 
assessment and follow up of these criteria can be found in the Investigator Trial File 
Binder (or equivalent).
Treatment of Overdose 9.4
For purposes of this study , an overdose will be defined as any  dose exceeding the prescribed 
dose for navarixin ≥200 mg and for pembrolizumab ≥1000 mg (ie, ≥5 times the indicated 
dose) . No specific information is available on the treatment of overdose of navarixin and 
pembrolizumab . In the event of overdose, navarixin and pembrolizumab should be 
discontinued and the participant should be observed closely for signs of toxicity.  
Appropriate supportive treatment should be provided if clinicall y indicated.
Safety 9.5
Details regarding specific safet y procedures/assessments to be performed in this study are 
provided below. The total amount of blood/tissue to be drawn/collected over the course of 
the study (from pre -study to post -study visits), including approximate blood/tissue volumes 
drawn/collected b y visit and by sample type per participant can be found in Section 9.
Planned time points for all safety assessments are provided in the SoA. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 82
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialPhysical Examinations 9.5.1
Full Physical Exam 9.5.1.1
The Investigator or qualified designee will perform a complete ph ysical exam during the 
Screening period. Clinically  significant abnormal findings should be recorded as medical 
history . The time points for full phy sical exams are described in Section 2. After the first 
dose of study  treatment, new clinicall y significant abnormal findings should be recorded as 
AEs.
Directed Physical Exam 9.5.1.1.1
For cy cles that do not require a full ph ysical exam as defined in Section 2, the Investigator or 
qualified designee will perform a directed ph ysical exam as clinically  indicated prior to the 
administration of the study  treatment . New clinically  significant abnormal findings should be 
recorded as AEs.
Vital Signs 9.5.2
The investigator or qualified designee will take vital signs at screening, prior to each 
pembrolizumab infusion, and during the follow -up period as specified in the Sched ule of 
Activities. 
Vital signs will be measured in a semi -supine position after 5 minutes rest and will include 
temperature, sy stolic and diastolic blood pressure, and pulse . 
Electrocardiograms 9.5.3
A standard 12- lead ECG will be performed using local standar d procedures. The timing of 
ECGs is specified in the Schedule of Activities in Section 2.0. Clinically  significant 
abnormal findings at Screening should be r ecorded as medical history . Additional ECG (s)
should be performed when clinically  necessary .
Clinical Safety Laboratory Assessments 9.5.4
Refer to Appendix 5for the list of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency. 
●The investigator must review the laboratory  report, document this review, and record 
any clinically  relevant changes occurring during the study  in the AE section of the 
CRF. The laboratory  reports must be filed with the source documents. Clinically  
signifi cant abnormal laboratory  findings are those which are not associated with the 
underly ing disease, unless judged b y the investigator to be more severe than expected 
for the participant's condition.
●All protocol -required laboratory  assessments, as defined in Appendix 5, must be 
conducted in accordance with the laboratory  manual and the SoA . 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 83
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
Confidential●If laboratory  values from non -protocol specified laboratory  assessments performed at 
the institution’s local laboratory  require a change in study  participant managem ent or 
are considered clinically  significant b y the investigator (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SL AB).
●For an y laboratory  tests with values considered clinically  significantl y abnormal 
during participation in the study  or within 30days after the last dose of study  
treatment, every  attempt should be made to perform repeat assessments until the 
values return to normal or baseline or if a new baseline is established as determined 
by the in vestigator. 
Pharmacokinetics 9.6
To evaluate the immunogenicity  and exposure of pembrolizumab and exposure of navarixin
in this indication, sample collections for analysis of anti -drug antibodies (ADA; anti -
pembrolizumab antibodies) and PK are currentl y planned as shown in the Schedule of 
Activities . Blood samples for PK and ADA collected may  be stored onl y at this time. Further 
analysis may  be performed if required. If ongoing PK and/or ADA sampling is deemed to be 
unnecessary  by the Sponsor, it may  be reduced or discontinued. 
Blood Collection for Plasma Navarixin 9.6.1
Sample collection, storage and shipment instructions for plasma samples will be provided in 
the operations/laboratory manual. 
Note: All pre- dose navarixin PK samples must be collected within 10 minutes prior to 
dosing.
Cycle 1 9.6.1.1
Samples will be collected on:
Day 1: Pre-dose (0), 1, 2, 4, and 6hours , and 1 sample between 8 -12 hours
Day 3:Pre-dose, and 1 sample between 6 -12 hours
Day 8:Pre-dose, and 1 sample between 6 -12 hours
Cycles 2 to 4 9.6.1.2
Samples will be collected on : 
Cycle 2 :
Day 1: Pre-dose (0), 1, 2, 4, and 6hours , and 1 sample between 8 -12 hours
Cycle 3 :  
Pre-dose (trough)
Cycle 4:
Pre-dose (trough) 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 84
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialAfter Cycle 4 9.6.1.3
Samples will collected according to the same schedule as for pembrolizumab PK samples.
Blood Collection for Pembrolizumab 9.6.2
Samples will be collected at pre-dose (trough) within 24 hours before infusion at Cy cles 1, 2, 
4, 6, and 8 and every  4 cy cles thereaf ter.
Pharmacodynamics 9.7
Venous blood samples for safet y and pharmacod ynamics will be collected for measurement 
of neutrophil counts and neutrophil -to-lymphocy te ratios at pre -specified time points as 
outlined in the Schedule of Activities. Sample collection, storage ,and shipment instructions 
for blood samples will be provided in the Procedures Manual.
As a safety  lab, hematology  (including ANC) will be collected on Day  1 of every  cycle pre -
dose as follows:
On day s whe nnavarixin PK samples are collected, pre-dose ANC should be 
collected within 2 hours prior to dosing.
On day s whe nnavarixin PK is notcollected, pre -dose ANC can be collected 
within 24 hours prior to dosing.
In addition, for pharmacody namic assessment, another sample will be collected between 6 -12 
hours after dosing on Days 1, 3, and 8 of Cy cle 1, and Day  1 of C ycle 2.
Biomarkers 9.8
To identify  novel biomarkers, the following biospecimens to support exploratory  analy ses of 
cellular components (eg, protein, RNA, DNA, metabolites) and other circulati ng molecules 
will be collected from all participants in this study as specified in the SoA. Sample 
collection, storage, and shipment instructions for the exploratory biomarker specimens will 
be provided in the laboratory  manual.
Blood for Genetic Analysis
Peripheral Blood Mononuclear Cell
Blood for Immune Profiling (immunophenot yping)
Blood for Serum Protein Analy sis
Blood for RNA Anal yses
Archival and/or Newl y Obtained Tissue Collection
The Planned Genetic Analy sis sample should be drawn for planned anal ysis of the 
association between genetic variants in DNA and drug response. This sample will not be 
collected at the site if there is either a local law or regulation prohibiting collection, or if the 
IRB/IEC does not approve the collection of the sample for these purposes. If the sample is 
collected, leftover extracted DNA will be stored for future biomedical research if the 
participant signs the F uture Biomedical Research consent. If the planned genetic analysis is  
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 85
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
Confidentialnot approved, but F uture Biomedical Researchis approved and consent is given, this sample 
will be collected for the purpose of F uture Biomedical Research .
Future Biomedical Research Sample Collection 9.9
If the participant signs the F uture Biomedical Research consent, the following specimens will 
be obtained as part of Future Biomedical Research:
DNA for future research
Leftover cell s from Peripheral Blood Mononuclear Cell
Leftover serum from Serum Protein Analy sis
Leftover RNA from Blood for RNA Anal yses
Leftover main stud y tumor
Health Economic s 9.10
Patient reported outcomes will not be assessed in this study .
Visit Requirements 9.11
Visit requirements are outlined in Section 2 –Schedule of Activities (SoA).  Specific 
procedure -related details are provided above in Section 9 –Study  Assessments and 
Proced ures.
Screening 9.11.1
Approximately  28 day sprior to treatment randomization, potential participants will be 
evaluated to determine that they  fulfill the entry  requirements as set forth in Section 6.1.  
Screening procedures may be repeated after consultation wit h the Sponsor.
Written consent must be obtained prior to performing an y protocol- specific procedure. 
Results of a test performed prior to the participant signing consent as part of routine clinical 
management are acceptable in lieu of a screening test if p erformed within the specified time 
frame. Screening procedures are to be completed within 28days prior to the first dose of 
study  treatment except for the following:
Laboratory  tests are to be performed within 10 days prior to the first dose of study  
treatment. An exception is hepatitis testing which may  be done up to 28 day s prior to 
the first dose of stud y treatment if required .
Evaluation of ECOG is to be performed within 7 days prior to date of randomization.
For women of reproductive potential, a urin e or serum pregnancy  test will be 
performed within 72 hours prior to the first dose of study treatment. If urine 
pregnancy  results cannot be confirmed as negative, a serum pregnancy  test will be 
required (performed b y the local study  site laboratory ).
Arch ival tumor sample collection is not required to be obtained within 28 days prior 
to the first dose of study treatment. Newly obtained tumor tissue may be obtained 
within 90 day s of treatment initiation. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 86
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialParticipants may  be rescreened after initially  failin g to meet the inclusion/exclusion criteria. 
Results from assessments during the initial screening period are acceptable in lieu of a repeat 
screening test if performed within the specified time frame and the corresponding 
inclusion/exclusion criteria is me t. Participants who are rescreened will retain their original 
screening number.
Treatment Period 9.11.2
Visit requirements are outlined in the SoA (Section 2). Specific procedure -related details are 
provided in Section 9.1.
Post-Stud y 9.11.3
Safety Follow -up Visit 9.11.3.1
The mandatory  Safet y Follow -up Visit should be conducted approximately  30 day s after the 
last dose of study  treatment or before the initiation of a new anticancer treatment, whichever 
comes first. If a participant discontinues from the treatment period appr oximately  30 day s or 
later after the last dose of study  treatment a separate Safety Follow -up visit does not need to 
be completed. The End of Treatment/D iscontinuation visit should be completed only  and 
include any assessments required at the Safet y Follow -up visit but not the discontinuation 
visit.
All AEs that occur prior to the Safet y Follow -Up Visit should be recorded. Participants with 
an AE of Grade >1 will be followed until the resolution of the AE to Grade 0 -1 or until the 
beginning of a new antican cer therap y, whichever occurs first. Serious AEs that occur within 
90 day s of the end of treatment or before initiation of a new anticancer treatment should also 
be followed and recorded. 
Disease Status Follow -up 9.11.3.2
Participants who discontinue study  treatment for a reason other than disease progression per 
RECI ST1.1/iRECIST will move into the Follow -Up Phase and should be assessed as 
outlined in the SoA (Section 2) to monitor disease status. The Sponsor may request survival 
status to be assessed at a dditional time points during the course of the study (not to exceed 
approximately 12 weeks). Every  effort should be made to collect information regarding 
disease status until the start of new anti -cancer therapy , disease progression, death, end of 
study . Information regarding post -study  anticancer treatment will be collected if new 
treatment is initiated.
Survival Follow -up 9.11.3.3
Participants who experience confirmed disease progression or start a new anticancer therap y, 
will move into the Survival Follow -Up Phas e and should be contacted b y telephone 
approximately  every  12 weeks to assess for survival status until death, withdrawal of 
consent, or the end of the trial, whichever occurs first. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 87
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialSurvival Status 9.11.4
To ensure current and complete survival data is available at the time of database locks, 
updated survival status may be requested during the course of the study  by the Sponsor. For 
example, updated survival status may be requested prior to but not limited to an interim 
and/or final analysis. Upon Sponsor notific ation, all participants who do not/will not have a 
scheduled visit or study  contact during the sponsor defined time period will be contacted for 
their survival status (excluding participants that have a previously  recorded death event in the 
collection too l).
10.Statistical Analysis Plan 
This section outlines the statistical analysis strategies and procedures for the primary and 
secondary  anal yses of the study . Exploratory  and other nonconfirmatory  analy ses will be 
outlined in a separate supplemental Statisti cal Analysis Plan (sSAP).
If, after the stud y has begun, changes are made to primary and/or secondary objectives, or the 
statistical methods related to those objectives, then the protocol will be amended (consistent 
with I CH Guideline E9). Changes to explo ratory  or other nonconfirmatory  anal yses made 
after the protocol has been finalized, but prior to final database lock, will be documented in 
the sSAP as needed and referenced in the Clinical Study  Report (CSR) for the study . Post 
hoc exploratory  anal yses will be clearl y identified in the CSR.
Statistical Analysis Plan Summary 10.1
This section contains a brief summary  of the statistical analyses for this trial. Full details are 
in the Statistical Analy sis Plan, Section 10.2 through Section 10.12.
Study Design O verview Phase 2trial of navarixin in combination with 
pembrolizumab in participants with selected 
advanced/metastatic solid tumors .
Analysis Populations Efficacy (Primary and Secondary ): Full Anal ysis Set (FAS)
Safety  (Primary ): All Participant sasTreated (ASaT) and 
DLT evaluable population
PK and PD (Secondary ): Per -Protocol (PP)
Primary Endpoint(s) Efficacy: objective response is a confirmed complete 
response (CR) or partial response (PR) .
Safety : 
Dose-limiting toxicity  (DLT)
Adverse event (AE)
Discontinuing study treatment due to an AE 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 88
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialSecondary Endpoint(s) Objective response is a confirmed CR or PR.
PFS is time from the first dose of study  medication to the first 
documented disease progression or death due to any  cause, 
whichever occurs first.
OS is time from the first dose of study  medication to death 
due to an y cause.
ANC in 109/L
PK parameters of navarixin in combination with 
pembrolizumab andPK parameters of pembrolizumab in 
combination with navarixin , including area under the curve 
(AUC) in ng·hr/mL , maximum concentration (C max)in 
ng/mL , trough concentration (C trough)in ng/mL
Statistical Methods for 
Efficacy/ 
Pharmacokinetic /Pharm
acodynamic AnalysesORR will be estimated using an exact method based on the 
binomial distribution together with its 95% confidence 
interval (Clopper -Pearson interval) . 
Methods for t he secondary  and exploratory efficacy  analy ses 
as well as the comparison between the two arms will be
documented in ansSAP.
PK parameters of study  medicines will be summarized by  
planned visit and time for each arm. 
ANC and percent change from baseline in ANC will be 
summarized by  planned visit and time for each arm
separately .
Treatment Assignment Participants will be randomized centrally  through 
IVRS/I WRS to the 2 arms(doses) of navarixin in 
combination with pembrolizumab, stratified by  tumor ty pes.
Statistical Methods for 
Safety AnalysesSummary  statistics will be provided for the safety  endpoints 
as appropriate (e.g. counts, percentages). Miettinen and 
Nurminen's method will be used to estimate the difference 
between the 2 arms and its 95% confidence interval for 
number of participants wi th a DL T, number of partici pants 
with ≥1 AE and n umber of participants discontinuing study  
treatment due to an AE .
Interim Analyses An interim safety analysis is planned for each armafter the 
first 10 participants across tumor ty pes have finished at least 
one cy cle of therapy  in a given arm. An interim futility
analysis is planned for each tumor ty pe in each armafter the 
first 10 participants in each tumor ty pe have finished the first 
tumor assessment. 
Additional interim analy sis may  be conducted to enable 
future trial planning at the Sponsor’s discretion and data will 
be examined on a continuous basis to allow for timely  
decisions. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 89
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialMultiplicity No multiplicity  adjustment is planned in this Phase 2 trial.
Sample Size and Power For the planning purpose, it is assumed that true objective 
response rates of <1% for MSS CRC and 5% for PDL 1-
refractory  NCSLC and advanced prostate are not considered 
clinically  meaningful, whereas true objective response rates 
of 16% for MSS CRC and 20% for PDL1 -refractory  NCSL C 
and advanced prostate or higher are. With 20 participants in 
each tumor t ype of each armunder the 2-stage adaptive 
design, the probability  that the objective response rate of each 
tumor ty pe is claimed clin ical meaningful is <8% when the 
true response rate is not clinically  meaningful and >75% 
when the true response rate is clinically  meaningful. Thetotal
sample size is 60 participants per arm(20 per each tumor 
type in a narm). No formal hy pothesis testing will be 
conducted. 
Responsibility for Analyses/In -House Blinding 10.2
The statistical anal yses of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor.
The trial is open -label, ie, participants ,investigators, and Sponsor personnel will be aware of 
participant treatment assignment after each participant is enrolled and treatment is assigned.  
Allocation to treatment will be randomized.
Hypotheses/Estimation 10.3
Objectives and h ypotheses of the stud y are outlined in Section 4 –Objectives/Hy potheses 
and Endpoints.
Analysis Endpoints 10.4
Efficacy/Pharmacokinetics /Pharmacodynamic Endpoints 10.4.1
ORR as assessed b y the investigator based on RECI ST 1.1 is the primary  endpoint. ORR as 
assessed b y the investigator bas ed on iRECI ST, PFS as assessed b y investigator based on 
RECI ST 1.1 and iRECI STand OS are the secondary  endpoints in this study . A description of 
efficacy  measures is provided in Section 9.2 –Efficacy  Assessments.
Objective Response rate (ORR) is defined as the proportion of participant s who achieve a
confirmed complete response (CR) or partial response (PR). 
Progression -free Survival (PFS) is defined as the time from the first dose of study medication 
to the first documented disease progression or death due to any  cause, whichever occurs first.
Overall survival (OS) is defined as the time from the first dose of stud y medication to death 
due to an y cause. 
Pharmacokinetic endpoints include serum concentrations of navarixin and pembrolizumab , as 
well as derived PK parameters. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 90
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialPharmacod ynamic endpoint include sANC.
Safety Endpoints 10.4.2
The primary  safet y endpoint is the number/proportion of participants with DL T s(including 
participants with Grade 4 ANC decrease) , and AEs, and who discontinue study  treatment due 
to AE s.  In addition, safety  and tolerability  will be assessed b y clinical review of all relevant 
parameters including adverse events (AEs), laboratory tests, and vital signs.
A description of safet y measures is provided in Section 9.5 -Safet y.
Analys is Populations 10.5
Efficacy Analysis Populations 10.5.1
The Full Anal ysis Set (FAS) population will be used for the anal yses of efficacy  data in this 
study . It consists of all participants with a baseline scan that demonstrated measurable 
disease b y the investigator’ s assessment, and who were administered at least 1 dose of study  
medicine.
Safety Analysis Populations 10.5.2
The All -Subjects -as-Treated (ASaT) population will be used for the analy sis of safet y data in 
this study . The ASaT population consists of all participant s who received at least 1 dose of 
study  treatment. 
The DLT evaluable population includes ASaT participants that meet the criteria for DLT 
evaluability  (e.g., finished Cy cle 1without a DLT or experienced a DLT in Cy cle 1). See 
Section 5.1.3 for details. 
At least 1 laboratory  or vital sign measurement obtained subsequent to at least 1 dose of 
study  treatment is required for inclusion in the analy sis of each specific parameter. To assess 
change from baseline, a baseline measurement is also required.
Pharmac okinetic Analysis Populations 10.5.3
The Per -Protocol (PP) population will be used for the anal ysis of PK and PDdata in this 
study . The PP population consists of the subset of participants who complied with the 
protocol sufficientl y to ensure that their data wil l be likely  to exhibit the effects of treatment, 
according to the underl ying scientific model. Compliance includes such considerations as 
exposure to treatment, availability  of measurements, and the absence of major protocol 
violations. Any participants or data values excluded from the anal yses will be identified, 
along with the reasons for exclusion, in the CSR. At the end of the stud y, all participants who 
were compliant with the study  procedures and have available data from at least 1 treatment 
will be i ncluded in the PP analy sis dataset.
Statistical Methods 10.6
This section describes the statistical methods that address the primary objectives. Methods 
related to secondary  and exploratory  objectives as well as the comparison between the t 2arms 
will be describ ed in the sSAP. The final anal yses will be performed using data from both 
Stage 1 and Stage 2. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 91
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialStatistical Methods for Efficacy Analysis 10.6.1
ORR will be estimated using an exact method based on the binomial distribution together 
with its 95% confidence interva l (Clopper -Pearson interval). 
Methods for the secondary  and exploratory efficacy anal yses as well as the comparison 
between the two arms will be docume nted in the sSAP.
Statistical Methods for Safety Analysis 10.6.2
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters including 
DLTs, AEs, SAEs, laboratory  tests, vital signs, ECG measurements, and phy sical 
examinations.
DLT and adverse events will be summarized by  counts and frequencies for each arm.  
Laboratory  tests, vital signs, and other safet y endpoints will be summarized as appropriate 
(e.g., counts, percentages).
Miettinen and Nurminen's meth od will be used to estimate the difference between the 2arms 
and its 95% confidence interval for n umber of participants with a DLT, number of 
partici pants with ≥1 AE and n umber of participants discontinuing study  treatment due to an 
AE.
Summaries of Baseline Characteristics, Demographics, and Other Analyses 10.6.3
Demographic and Baseline Characteristics 10.6.3.1
Demographic variables and baseline characteristics will be summarized.
Pharmacokinetic and Pharmacodynamic Modeling Analysis 10.6.3.2
Pharmacokinetic parameters of stud y medicines will be summarized by planned visit and 
time for each armseparately . 
ANC and percent change from baseline in ANC will be summarized by  planned visit and 
time for each armseparately .
Pharmacokinetics and pharmacod ynamics modeling anal yses will be documented in the 
sSAP.
Interim Analyses 10.7
There is one planned interim safet y anal ysis and one planned interim futility analysisin this 
trial.
An interim safet y analysis is planned for each armafter the first 10 participants across tumor 
types have finished at least one cy cle of therapy  in a given arm. If no more than 3 
participants in the first 10 participants have experienced DTLs during the first cy cle in a 
given arm, this armmay be expanded by  enrolling 20 additional participants to complete 
Stage 1. Otherwise, this armmay be terminated due to safe ty concern.
An interim futility  analysis is planned for each tumor ty pe in each armafter the first 10
participants in each tumor ty pe have at least 1 post -baseline scan assessment . If 1 or more  
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 92
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
Confidentialresponses (ie, ≥10% response rate) are observed in a tumor ty pe within a narm, this tumor 
type may  be expanded to enroll at least 10 additional participants in Stage 2. Otherwise, this 
tumor ty pe may  be stopped earl y for futility .If the true response rate is 16 %, there is an 82% 
chance to continue the study  at the futility  evaluation . If the true response rate is 20%, there 
is an 89% chance to continue the study  at the futility  evaluation .
Additional interim analy sis may  be conducted to enable future trial planning at the Sponsor’s 
discretion and data will be examin ed on a continuous basis to allow for timely  decisions.
Multiplicity 10.8
There will be no multiplicity  control in this study .
Sample Size and Power Calculations 10.9
For the planning purpose, it is assumed that true objective response rates of <1% for MSS 
CRC and 5 % for PDL 1-refractory  NCSL C and advanced prostate arenot considered 
clinically  meaningful, whereas true objective response rates of 16% for MSS CRC and 20% 
for PDL1 -refractory  NCSL C and advanced prostate or higher are. With 20 participants in 
each tumor t ype of each armunder the 2-stage adaptive design, the probability that the 
objective response rate of each tumor t ype is claim ed clinical meaningful is less than 8% 
when the true response rate is not clinically  meaningful and more than 75% when the true 
response rate is clinicall y meaningful. Thetotal sample size is 60 participants per arm(20 per
each tumor t ype in a narm).No formal h ypothesis testing will be conducted. Table 8 provides 
the p robability  that the objective response rate of each tumor t ype is claimed clinical 
meaningful under different true ORR. Table 9 shows the hy pothetical ORR estimates and the 
CI (Clopper -Pearson interval) based on sample size of 20pertumor t ype. Due to a s mall 
sample size, even an observed response rate as high as 30% ( 6out of 20) could be coming 
from a true signal as low as 14%. A higher observed responses rate such as 8out of 20 would 
be more indicative of a true response rate above 20%.
Table 8 Probability  That ORR is Claimed as Clinical Interest With 20 Participants in Each 
Tumor Type of Each Arm
Tumor 
TypeORR as clinical 
meaningfulTrue 
ORRMinimum Responses 
that ORR is claimed 
as clinical meaningfulProbability that ORR 
is claimed as 
clinical meaningful
CRC 16% 1% 2 1%
16% 2 77%
NSCLC, 
Prostate 20% 5% 3 7%
20% 3 76% 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 93
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialTable 9 The CI of the True ORR Under Different Hypothetical Number of Observed 
Response S cenarios With 20 Participants in Each Tumor Type of Each Arm
Hypothetical number of 
responses (CR or PR)ORR 90% CI of ORR 80% CI of ORR
2 10% (1.8%, 28.3%) (2.7%, 24.5%)
3 15% (4.2%, 34.4%) (5.6%, 30.4%)
4 20% (7.1%, 40.1%) (9.0%, 36.1%)
5 25% (10.4%, 45.6%) (12.7%, 41.5%)
6 30% (14.0%, 50.8%) (16.6%, 46.7%)
7 35% (17.7%, 55.8%) (20.7%, 51.8%)
8 40% (21.7%, 60.6%) (24.9%, 56.7%)
Subgroup Analyses 10.10
Efficacy  endpoints will be anal yzed by armfor each tumor ty pe. Additional s ubgroup 
analyses (e.g., by  age, gender ,and race) may be conducted as needed and will be documented 
in the sSAP. 
Compliance (Medication Adherence) 10.11
Drug accountability  data for study  treatment will be collected during the trial.  Any  deviation 
from protocol -directed administration will be repor ted.
Extent of Exposure 10.12
The extent of exposure will be summarized as duration of treatment in cycles.
11.References
[Acharyy a S, Oskarsson 
T, Vanharanta S, Malladi 
S, Kim J 2012]Acharyya S, Oskarsson T, Vanharanta S, Malladi S, 
Kim J, Morris PG, et al. A CXC L1 paracrine 
network links cancer chemoresistance and 
metastasis. Cell. 2012 Jul 6;150(1):165 -78.04TL N5
[Condamine T, 
Ramachandran I, Youn 
JI, Gabrilovich DI. 2015]Condamine T, Ramachandran I, Youn J I, 
Gabrilovich DI. Regulation of tumor metastasis by 
myeloid -derived suppressor cells. Annu Rev Med. 
2015;66:97 -110.04TL NB
[David JM, Dominguez 
C, Hamilton DH, Palena 
C. 2016]David JM, Dominguez C, Hamilton DH, Palena C. 
The IL -8/IL-8R Axis: A Double Agent in Tumor 
Immune Resistance. Vaccines (Basel). 201 6 Jun 
24;4(3).04TL NF
[Gentles, A. J., et al 
2015]Gentles AJ, Newman AM, L iu CL, Bratman SV, 
Feng W, Kim D, et al. The prognostic landscape of 
genes and infiltrating immune cells across human 
cancers. Nat Med. 2015 Aug;21(8):938 -945.04TR0W 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 94
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidential[Highfill SL , Cui Y, 
Giles AJ, Smith JP, 
Zhang H, Morse E 2014]Highfill SL , Cui Y, Giles AJ, Smith JP, Zhang H, 
Morse E, et al. Disruption of CXCR2- mediated 
MDSC tumor trafficking enhances anti- PD1 
efficacy . Sci Transl Med. 2014 May  
21;6(237):237ra67.04TL NN
[Kumar V, Patel S, 
Tcyganov E, Gabrilovich 
DI. 2016]Kumar V, Patel S, Tcy ganov E, Gabrilovich DI. The 
Nature of M yeloid-Derived Suppressor Cells in the 
Tumor Microenvironment. Trends Immunol. 2016 
Mar;37(3):208-220.04TL NX
[Li, L., et al 2015] Li L, Xu L, Yan J, Zhen ZJ, Ji Y, L iu CQ, et al. 
CXCR2 -CXCL 1 axis is correlated with neutrophil 
infiltration and predicts a poor prognosis in  
hepatocellular carcinoma. J Exp Clin Cancer Res. 
2015 Oct 26;34:129.04TR2B
[Lu X, Horner JW, Paul 
E, Shang X, Troncoso P, 
Deng P 2017]Lu X, Horner JW, Paul E, Shang X, Troncoso P, 
Deng P, et al. Effective combinatorial 
immunotherapy  for castration -resistant prostate 
cancer. Nature. 2017 Mar 30;543(7647):728 -732.04TL P3
[Saintigny , P., et al 2013] Saintigny  P, Massarelli E, L inS, Ahn YH, Chen Y, 
Goswami S, et al. CXCR2 expression in tumor cells 
is a poor prognostic factor and promotes invasion 
and metastasis in lung adenocarcinoma. Cancer Res. 
2013 Jan 15;73(2):571-82.04TR2N
[Seymour, L., et al 2017] Seymour L, Bogaerts J, Pe rrone A, Ford R, 
Schwartz LH, Mandrekar S, et al. iRECI ST: 
guidelines for response criteria for use in trials 
testing immunotherapeutics. Lancet Oncol. 2017 
Mar;18(3):e143 -e152.04P9RV
[Steele CW, Karim SA, 
Leach JDG, Bailey  P, 
Upstill -Goddard R 2016]Steele CW, Karim SA, Leach JDG, Bailey  P, 
Upstill -Goddard R, Rishi L . CXCR2 Inhibition 
Profoundly  Suppresses Metastases and Augments 
Immunotherap y in Pancreatic Ductal 
Adenocarcinoma. Cancer Cell. 2016 Jun 
13;29(6):832 -845.04TL PZ 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 95
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidential[Theivanthiran B, DeVito 
NC2017]Theivanthiran B, DeVito NC, et al.  A HSP -TLR-
Wnt5a Paracrine Signaling Axis Drives CXCR2 
Ligand Recruitment of My eloid- derived Suppressor 
Cells and Represents a Novel Adaptive Resistance 
Mechanism to Anti -PD-1 Antibody  Therap y.  In: 
Society  for Imm unotherapy  of Cancer 2017 
Abstracts; 8-12 November 2017; Baltimore, 
Mary land. 2017.  P385.04TL Q2
[Wang G, L u X, Dey  P, 
Deng P, Wu CC, Jiang S 
2016]Wang G, Lu X, Dey  P, Deng P, Wu CC, Jiang S, et 
al. Targeting YAP -Dependent MDSC I nfiltration 
Impairs Tumo r Progression. Cancer Discov. 2016 
Jan;6(1):80 -95.04TL Q0 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 96
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
Confidential12.Appendices
Appendix 1: Study Governance Considerations 12.1
Merck Code of Conduct for Clinical Trials
Merck*
Code of Conduct for Clinical Trials
I.Introduction
A. Purpose
Merck, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the high est ethical and scientific standards. Protection of participant safety is the overriding concern 
in the design of clinical trials. In all cases, Merck clinical trials will be conducted in compliance with local and/or 
national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by Merck irrespective of the 
party (parties) employed for their execution (eg, contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code 
does not apply to investigator -initiated trials which are not under the control of Merck.
II.Scientific Issues
A. Trial Conduct
1.Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices o f Merck or comparator products.  Alternatively, Merck may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
participant preferences, etc.  
The design (ie, participant population, duration, sta tistical power) must be adequate to address the specific purpose 
of the trial.  Research participants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
Merck selects investigative sites based on medical expertise, access to appropriate participants, adequacy of 
facilities and staff, previous performance in Merck trials, as well as budgetary considerations.  Prior to trial 
initiation, sites are evaluated by Merck personnel to assess the ability to successfully conduct the tria l.
3.Site Monitoring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical 
Practice.  Merck reviews clinical data for accuracy, completeness and consistency. Data are verified v ersus source 
documentation according to standard operating procedures.  Per Merck policies and procedures, if fraud, 
misconduct or serious GCP -non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be clo sed, the responsible regulatory authorities and ethics review committees notified and 
data disclosed accordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, Merck seeks to publish the results of trials it conducts.  Some early phase or 
pilot trials are intended to be hypothesis -generating rather than hypothesis testing.  In such cases, publication of 
results may not be appropriate since the trial may be underpowered and the analyses complicated by statistical issues 
of multipli city.
Merck’s policy on authorship is consistent with the requirements outlined in the ICH -Good Clinical Practice 
guidelines. In summary, authorship should reflect significant contribution to the design and conduct of the trial, 
performance or interpretati on of the analysis, and/or writing of the manuscript.  All named authors must be able to 
defend the trial results and conclusions.  Merck funding of a trial will be acknowledged in publications.  
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 97
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialIII. Participant Protection
A.IRB/IEC review
All clinical t rials will be reviewed and approved by an independent IRB/IEC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by the IRB/IEC prior to implementation, except that 
changes required urgently to protect p articipant safety and well-being may be enacted in anticipation of IRB/IEC 
approval. For each site, the IRB/IEC and Merck will approve the participant informed consent form. 
B.Safety
The guiding principle in decision -making in clinical trials is that par ticipant welfare is of primary importance.  
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a 
minimum, trial designs will take into account the local standard of care.  Participants are never denied access to 
appropriate medical care based on participation in a Merck clinical trial. 
All participation in Merck clinical trials is voluntary.  Participants are enrolled only after providing informed consent 
for participation.  Participants may withdraw from a Merck trial at any time, without any influence on their access to, 
or receipt of, medical care that may otherwise be available to them.
C.Confidentiality
Merck is committed to safeguarding participant confidentiality, to t he greatest extent possible.  Unless required by 
law, only the investigator, sponsor (or representative) and/or regulatory authorities will have access to confidential 
medical records that might identify the research participant by name.  
D.Genomic Resea rch
Genomic Research will only be conducted in accordance with informed consent and/or as specifically authorized by 
an Ethics Committee.
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time -and labor -intensive.  It is Merck’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of Merck trials.  Merck does not pay incentives to 
enroll participants in its trials.  However, when enrollment is particularly ch allenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
Merck does not pay for participant referrals.  However, Merck may compensate referring physicians for time spent 
on chart review to identify potentiall y eligible participants.
B.Clinical Research Funding 
Informed consent forms will disclose that the trial is sponsored by Merck, and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial.  However, the local IRB/IEC may wish to alter 
the wording of the disclosure statement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from Merck trials will indicate Merck as a source of funding.
C.Funding for Trav el and Other Requests
Funding of travel by investigators and support staff (eg, to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by the American Medical 
Association (AMA). 
V. Investigator Commit ment
Investigators will be expected to review Merck’s Code of Conduct as an appendix to the trial protocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "M erck" refers to Merck Sharp & Dohme Corp. and Schering Corporation, each of which is a 
subsidiary of Merck & Co., Inc.  Merck is known as MSD outside of the United States and Canada.  As warranted by 
context, Merck also includes affiliates and subsidiaries of Merck & Co., Inc." 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 98
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialFinancial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54).  I t is the 
Sponsor's responsibility  to determi ne, based on these regulations, whether a request for 
Financial Disclosure information is required.  It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.  
The investigator/subinvestigator(s) agree, if requested by  theSponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements.  
The investigator/subinvestigator(s) fu rther agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by  
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in t he United States for these purposes.  This may  involve the 
transmission of information to countries that do not have laws protecting personal data.
Data Protection
Participants will be assigned a unique identifier by  the sponsor. Any  participant records or
datasets that are transferred to the sponsor will contain the identifier only; participant names 
or an y information which would make the participant identifiable will not be transferred. 
The participant must be informed that his/her personal study -relate d data will be used by  the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authorized personnel appointed by  the sponsor, by  
appropriate IRB/IEC members, and b y inspectors from regulatory authorities.
Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will 
be divulged to the institutional review board, ethics review committ ee (IRB/I EC) or similar 
or expert committee; affiliated institution and employ ees, only  under an appropriate 
understanding of confidentiality  with such board or committee, affiliated institution and 
employ ees.  Data generated by  this study will be considered confidential by the investigator, 
except to the extent that it is included in a publication as provided in the Publications section 
of this protocol.
Confidentiality of Participant Records
By signing this protocol, the investigator agrees that t he Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or copy  study documents in 
order to verify  worksheet/case report form data.  By  signing the consent form, the participant 
agrees to this process.  If study documents will be photocopied during the process of 
verify ing worksheet/case report form information, the participant will be identified by  unique 
code onl y; full names/initials will be masked prior to transmission to the Sponsor. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 99
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialBy signing this prot ocol, the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable privacy  laws, rules 
and regulations.
Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this study .  The Sponsor is also required to document that each I RB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining records of the names 
and qualifications of the IRB/I EC members and to make these records available for 
regulatory  agency  review upon request by  those agencies.
Publication Policy
The results of this study  may  be published or presented at scientific meetings. The sponsor 
will comply  with the requirements for publication of study  results. I n accordance with 
standard editorial and ethical practice, the sponsor will generall y support publication of 
multicenter studies only  in their entiret y and not as individual site data. I n this case, a 
coordinating investigator will be designated by  mutual agreement.
If publication activity  is not directed by  the sponsor, the investigator agrees to submit all 
manuscripts or abstracts to the sponsor before submission.  This allows the sponsor to protect 
proprietary  information and to provide comments.  
Authorship will be determined by  mutual agreement and in line with I nternational Committee 
of Medical Journal Editors authorship requirements.
Compliance with Study Registration and Results Posting Requirements
Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007 
and the European Medicines Agency  (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study is solel y responsible for determining whether the study and its results are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries.  MSD , as Sponsor of this study , will 
review this protocol and submit the information necessary  to fulfill these requirements. MSD
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials.  
Information posted will allow participants to identify  potentiall y appropriate studies for their 
disease conditions and pursue participation b y calling a central contact numb er for further 
information on appropriate study locations and site contact information.  
By signing this protocol, the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive or other locally  mandated regist ries are that of the 
Sponsor and agrees not to submit any  information about this study or its results to those 
registries. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 100
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialCompliance with Law, Audit and Debarment
By signing this protocol, the investigator agrees to conduct the study in an efficient and
diligent manner and in conformance with this protocol; generall y accepted standards of Good 
Clinical Practice (eg, International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use Good Clinical Practice : Consolidated 
Guideline and other generally  accepted standards of good clinical practice); and all 
applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical study .
The Code of Conduct, a collection of goals an d considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored b y MSD , is provided in this appendix 
under the Merck Code of Conduct for Clinical Trials.
The investigator agrees not to seek reimbursement from participan ts, their insurance 
providers or from government programs for procedures included as part of the study
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of any  regulatory  authority  inspection 
conducted for this study .
The Investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection, and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conducting or working o n clinical studies by any court or regulatory  
authority  will not be allowed to conduct or work on this Sponsor’s studie s.The investigator 
will immediately  disclose in writing to the Sponsor if any  person who is involved in 
conducting the study is debarre d or if any  proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator or 
qualified designee is responsible for verify ing that data entri es are accurate and correct b y 
physicall y or electronically  signing the CRF. 
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents. 
Study documentation will be promptly  and ful ly disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the study site upon request for inspection, 
copy ing, review and audit at reasonable times by  representatives of the Sponsor or any  
regulatory  authorities.  The investigator agrees to promptly  take any  reasonable steps that are  
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 101
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidentialrequested b y the Sponsor or regulatory authority as a result of an audit or inspection to cure 
deficiencies in the study documentation and worksheets/case report forms.
The sponsor or desi gnee is responsible for the data management of this study  including 
quality  checking of the data. 
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that the 
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study  agreements, ICH GCP, and all applic able regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or party without written notification to the sponsor. 
Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Study and Site Closure
The sponsor or its designee may  stop the study  or study  site participation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GCP. 
In the event the Sponsor prematurel y terminates a particular study site, the Sponsor will 
promptly  notify  that study site’s IRB/IEC. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 102
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialAppendix 2: Collection and Management of Specimens for Future Biomedical 12.2
Research
1.Definitions
a.Biomarker:  A biological molecule found in blood, other body  fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease.  A biomarker may be 
used to see how well the body  responds to a treatment for a disease or condition.1
b.Pharmacogenomics:  The investigation of variations of DNA and RNA characteristics as 
related to drug/vaccine response.2
c.Pharmacogenetics:  A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug/vaccine response.2
d.DNA:  Deox yribonucleic acid.
e.RNA:  Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this study as outlined in Section 9.9–
Future Biomedical Research Sample Collection will be used in various experiments to 
understand:
oThe biolo gy of how drugs/vaccines work
oBiomarkers responsible for how a drug/vaccine enters and is removed b y the body
oOther pathway s drugs/vaccines may  interact with
oThe biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/ vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health through development of novel treatments targeted to populations 
with the greatest need.  All specimens will be used by the Sponsor or those working for 
or with the Sponsor.
3.Summary of Procedures for Future Bi omedical Research
a.Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in the 
Future Biomedical Research sub -study .
b.Informed Consent
Informed consent for specimens ( ie,DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participants or legal guardians, at a 
study visit by  the investigator or his or her designate.  Informed consent for Future 
Biomedical Research should be presented to the participants on t he visit designated in 
the SoA.  If delay ed, present consent at next possible Participant Visit.  Consent  
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 103
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidentialforms signed b y the participant will be kept at the clinical study site under secure 
storage for regulatory  reasons.  
A template of each study site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository .
c.eCRF Documentation for Future Biomedical Research Specimens
Documentation of participant consent for Future Biomedical Research will be 
captured in the electronic C ase Report Forms (eCRFs). An y specimens for which 
such an informed consent cannot be verified will be destro yed.
d. Future Biomedical Research Specimen(s)
Collection of specimens for Future Biomedical Research will be performed as 
outlined in the SoA. In general, if additional blood specimens are being collected for 
Future Biomedical Research, these will usuall y be obtained at a time when the 
participant is having blood drawn for other study purposes.
4.Confidential Participant Information for Future Biomedical Research 
In order to optimize the research that can be conducted with Future Biomedical Research 
specimens, it is critical to link participant' clinical information with future test results. I n 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like gender, age, medical history  and treatment outcomes ar e 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collected from specimens obtained for Future 
Biomedical Research, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below. 
At the clinical study site, unique codes will be placed on the Future Biomedical Research 
specimens.  This code is a random number which does not contain an y personally 
identify ing information embedded within it. The link (or key ) between participant 
identifiers and this unique code will be held at the study site.  No personal identifiers will 
appear on the specimen tube.  
5.Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for a nalyses using good scientific 
practices.  Anal yses utilizing the Future Biomedical Research specimens may  be 
performed b y the Sponsor, or an additional third party (eg, a universit y investigator) 
designated b y the Sponsor. The investigator conducting the a nalysis will follow the 
Sponsor’s privacy  and confidentiality  requirements. Any  contracted third party anal yses 
will conform to the specific scope of anal ysis outlined in this sub- study . Future 
Biomedical Research specimens remaining with the third part y after specific anal ysis is 
performed will be reported to the Sponsor.
6. Withdrawal From Future Biomedical Research 
Participants may  withdraw their consent for Future Biomedical Research and ask that 
their biospecimens not be used for Future Biomedical Res earch.  Participants may  
withdraw consent at an y time by  contacting the principal investigator for the main study .  
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 104
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialIf medical records for the main study are still available, the investigator will contact the 
Sponsor using the designated mailbox (clinical.specimen.management@merck.com). 
Subsequently , the participant's specimens will be flagged in the biorepository  and 
restricted to main study use only. If specimens were collected from study participants 
specificall y for Future Biomedical Research, these spec imens will be removed from the 
biorepository  and destroyed. Documentation will be sent to the investigator confirming 
withdrawal and/or destruction, if applicable. It is the responsibility  of the investigator to 
inform the participant of completion of the withdrawal and/or destruction, if applicable.  
Any anal yses in progress at the time of request for withdrawal/destruction or already  
performed prior to the request being received b y the Sponsor will continue to be used as 
part of the overall research study data and results. No new analy ses would be generated 
after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required b y regulatory  authorities to retain the mai n study
records) or the specimens have been completel y anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be proc essed. 
7. Retention of Specimens 
Future Biomedical Research specimens will be stored in the biorepository  for potential 
analysis for up to 20 y ears from the end of the main study . Specimens may  be stored for 
longer if a regulatory  or governmental authori ty has active questions that are being 
answered. In this special circumstance, specimens will be stored until these questions 
have been adequatel y addressed.
Specimens from the study site will be shipped to a central laboratory  and then shipped to 
the Sponsor -designated biorepository . If a central laboratory  is not utilized in a particular 
study , the study site will ship directly  to the Sponsor -designated biorepository . The 
specimens will be stored under strict supervision in a limited access facility which
operates to assure the integrity  of the specimens.  Specimens will be destroy ed according 
to Sponsor policies and procedures and this destruction will be documented in the 
biorepository  database.
8.Data Security
Databases containing specimen information and test results are accessible only  to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highl y secure, and is 
accomplished using network securit y policie s and practices based on international 
standards to protect against unauthorized access.
9. Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory  laboratory  studies will be reported to the 
participant, famil y, or phy sicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and concerns regarding misinterpretation. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 105
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialIf important research findings are disco vered, the Sponsor may  publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapidly  report this information to doctors and participants.  Participants will not be 
identified by  name in any publi shed reports about this study  or in any  other scientific 
publication or presentation.
10. Future Biomedical Research Study Population
Every  effort will be made to recruit all participants diagnosed and treated on Sponsor 
clinical studies for Future Biomedical Research.
11.Risks Versus Benefits of Future Biomedical Research 
For future biomedical research, risks to the participant have been minimized and are 
described in the Future Biomedical Research informed consent.
The Sponsor has dev eloped strict securit y, policies and procedures to address participant 
data privacy  concerns.  Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality .  In this highl y unlikely  situation there is risk that the
information, like all medical information, may  be misused.
12.Questions
Any questions related to the future biomedical research should be e -mailed directly  to 
clinical.specimen.management@merck.com.
13.References
1. National Cancer Institute: https://www.cancer.gov/publications/dictionaries/cancer -
terms?cdrid=45618
2.International Conference on Harmonization: DEFINITIONS FOR GENOMIC 
BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC 
DATA AND SAMPLE CODING CATEGORIES -E15; Available from:
http://www.ich.org/products/guidelines/efficacy /efficacy -single/article/definitions -
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics- genomic -data-and-
sample -cod.html
3.Industry  Pharmacogenomics Working Group. Understanding the Intent, Scope and 
Public Health Benefits of Exploratory  Biomarker Research: A Guide for IRBs/IECs 
and Investigational Site Staff. Available at http://i -pwg.org/
4.Industry  Pharmacogenomics Working Group. Pharmacogenomics Informational 
Brochure for IRBs/IECs and Investigatio nal Site Staff. Available at http://i -pwg.org/ 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 106
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialAppendix 3 : Contraceptive Guidance and Pregnancy Testing 12.3
Definitions 
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below) 
Women in the following categories are not considered WOCBP:
● Premenarchal
●Premenopausal female with 1 of the following:
○Documen ted h ysterectomy
○Documented bilateral salpingectomy
○Documented bilateral oophorectom y
Note:  Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.
●Postmenopausal female
○A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. 
▪A high follicle stimulating hormone (FSH) level in the postmenopausal range may 
be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therap y (HRT). However, in the absence 
of 12 months of amenorrhea, confirmation with 2FSH measurements in the 
postmenopausal range is required. 
○Females on HRT and whose menopausal status is in d oubt will be required to use one 
of the non -hormonal highly  effective contraception methods if they wish to continue 
their HRT during the study . Otherwise, they  must discontinue HRT to allow 
confirmation of postmenopausal status before study  enrollment. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 107
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialContraception Requirements
Male Participants
Male participants with female partners of childbearing potential are eligible to participate if 
they agree to one of the following during the protocol defined time frame in Section 6.1: 
●Be abstinent from peni le-vaginal intercourse as their usual and preferred lifesty le 
(abstinent on a long term and persistent basis) and agree to remain abstinent.
● Use a male condom plus partner use of an additional contraceptive method when having 
penile -vaginal intercourse w ith a woman of childbearing potential who is not currentl y 
pregnant.
oThe following are not acceptable methods of contraception:
▪ Periodic abstinence (calendar, s ymptothermal, post -ovulation methods), 
withdrawal (coitus interruptus), spermicides only , and lactational amenorrhoea 
method (LAM).
▪Male condom with cap, diaphragm, or sponge with spermicide .
▪Male and female condom s cannot be used together.
○Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent 
from penile -vagin al intercourse or use a male condom during each episode of penile 
penetration .
Female Participants
Female participants of childbearing potential are eligible to participate if they agree to use a 
highl y effective method of contraception consistently and co rrectly  as described in Table 10
during the protocol
-defined time frame in Section 6.1.  
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 108
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialTable 10 Highl y Effective Contraception Methods
Highly Effective Contraceptive Methods That Are User Dependent a
Failure rate of <1% per year when used consistently and correctly.
●Combined (estrogen- and progestogen - containing ) hormonal contraception b, c
○Oral 
○Intravaginal 
○Transdermal 
○Injectable
●Progestogen -only hormonal contraception b, c
○Oral 
○Injectable 
Highly Effective Methods That Have Low User Dependency 
Failure rate of <1% per year when used consistently and correctly.
●Progestogen - onl y contraceptive implant b, c 
●Intrauterine hormone -releasing s ystem (IUS)b
●Intrauterine device (IUD)
●Bilateral tubal occlusion
●Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. 
If not, an additional h ighly effective method of contraception should be used. 
●Sexual abstinence 
Sexual abstinence is considered a highl y effective method only  if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study  treatment. 
The reliability  of sexual abstinence needs to be evaluated in relation to the duration of the 
study  and the preferred and usual lifesty le of the participant.) 
Notes: 
Use should be consistent with local regulations regarding the use of contraceptive methods 
for participants of clinical studies. 
a) Typical use failure rates are higher than perfect -use failure rates (ie, when used 
consistently  and correctly ). 
b) If horm onal contraception efficacy  is potentially  decreased due to interaction with study  
treatment, condoms must be used in addition to the hormonal contraception during the 
treatment period and for at least 120 day s after the last dose of study  treatment.
c)Iflocally  required, in accordance with Clinical Trial Facilitation Group (CTFG) 
guidelines, acceptable hormonal contraceptives are limited to those which inhibit ovulation.  
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 109
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialPregnancy Testing
WOCBP should only  be included after a negative highl y sensiti ve urine or serum pregnancy  
test.
Aurine pregnancy  test is to be obtained within 72 hours prior to first dose.
If a urine pregnancy  test cannot be confirmed as negative, a serum pregnancy  test is required. 
Following initiation of treatment , additional urine/serum pregnancy  testing may  be 
performed if clinically warranted, and/or as defined by local regulations. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 110
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialAppendix 4: Adverse Events: Definitions and Procedures for Recording, 12.4
Evaluating, Follow -up, and Reporting
Definition of AE
AE Definition
● A n AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally  associated with the use of study  treatment, whether or not considered 
related to the stud y treatment.
●NOTE: An AE can therefore be an y unfavorable and unintend ed sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study treatment.
●NOTE: for purposes of AE definition, study  treatment (also referred to as Sponsor’s 
product) includes an y pharmaceutical product, biological product, vaccine, device, 
diagnostic agent or protocol specified procedure whether investigational (including 
placebo or active comparator product) or marketed, manufactured b y, licensed by, 
provided b y or distributed b y the sponsor for human use in this study.
Events Meeting the AE Definition 
●Any abnormal laboratory test results (hematology , clinical chemistry, or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, or are considered clinicall y significant in 
the medical and scientific judgment of the investigator.
●Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
●New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present before the start of the study .
●Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction .
●Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication. 
●For all reports of overdose (whether accidental or intentional) with an associated 
adverse event, the AE term should reflect the clinical symptoms or abnormal test 
result.  An overdose of study  treatment without any  associated clinical sy mptoms or 
abnormal laboratory  results is reported using the terminology  “accidental or 
intentional overdose without adverse effect.”
●Any new cancer (that is not a condition of the study ). 
Note: Progression of the cancer under study  is not a reportable event. Refer to 
Section 9.3.5 for additional details. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 111
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialEvents NOT Meeting the AE Definition 
●Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
● Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
●Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
●Surgery  planned prior to informed consent to tre at a pre -existing condition that has 
not worsened.
● Refer to section 9.3.5 for protocol specific exceptions
Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met 
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
●The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
● Hospitalization is defined as an inpatient admission, regardless of length of stay, even 
if the hospitalization is a precautionary  measure for continued observation.  (Note: 
Hospitalization for an elective procedure to treat a pre- existing condition that has not 
worsened is not a serious adverse event.  A pre -existing condition is a clinical condition 
that is diagnosed prior to the use of a nMSD product and is documented in the patient’s 
medical history .
d.Results in persistent or significant disability/incapacity
●The term disability  means a substantial disruption of a person’s a bility  to conduct 
normal life functions.
●This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and 
accidental trauma (eg, sprained ankle) whi ch may  interfere with or prevent every day life 
functions but do not constitute a substantial disruption. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 112
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidentiale.Is a congenital anomaly/birth defect
● in offspring of participant taking the product regardless of time to diagnosis
f.Other important medical events:
● Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may not 
be immediately  life-threatening or result in death or hospitalization but may  jeopardize 
the participant or may  require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definition. These events should usually  be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug dependency  
or drug abuse.
Additional Events reported in the same manner as SAE
Additional Events which require reporting in the same manner as SAE
● In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Sponsor in the same 
timeframe as SAEs to meet certain local requirements. Therefore, these events are 
considered serious b y the Sponsor for collection purposes.
●Is a new cancer (that is not a condition of the study);
●Is associated with an overdose.
Recording AE and SAE
AE and SAE Recording
●When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory, and diagnostics reports) 
related to the event.
●The investigator will record all relevant AE/SAE information on the Adverse Event 
case report forms/worksheets at each examination.
●It is notacceptable for the investigator to send photocopies of the participant’s 
medical records to the Sponsor in lieu of completion of the AE CRF page.
●There may  be instanc es when copies of medical records for certain cases are 
requested b y the Sponsor. I n this case, all participant identifiers, with the exception of 
the participant number, will be blinded on the copies of the medical records before 
submission to the Sponsor .
● The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 113
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialAssessment of Intensity
● An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
●The investigator will make an assessment of intensity  for each AE and SAE (and 
other report able safet y event) according to the NCI Common Terminology for 
Adverse Events (CTCAE), version 4.03 ]. Any  adverse event which changes CTCAE 
grade over the course of a given episode will have each change of grade recorded on 
the adverse event case report fo rms/worksheets.
●Grade 1: Mild; as ymptomatic or mil d symptoms; clinical or diagnostic 
observations only ; intervention not indicated.
● Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental ADL.
●Grade 3: Severe or medically significant but not immediately  life-threatening; 
hospitalization or prolongation o fhospitalization indicated; disabling; limiting 
self-care ADL.
● Grade 4: Life threatening consequences; urgent intervention indicated.
●Grade 5: Death related to AE.
Assessment of Causality
● Did the Sponsor's product cause the adverse event?
●The determination of the likelihood that the Sponsor's product caused the adverse 
event will be provided b y an investigator who is a qualified physician.  The 
investigator’s signed/dated initials on the source document or worksheet that 
supports the causalit y noted on the AE form, ensures that a medicall y qualified 
assessment of causality  was done.  This initialed document must be retained for 
the required regulatory  time frame.  The criteria below are intended as reference 
guidelines to assist the investigator in assessing the likelihood of a relationship 
between the test product and the adverse event based upon the available 
information
●The following components are to be used to assess the relationship between 
the Sponsor's product and the AE; the greater the correlation with the 
components and their respective elements (in number and/or intensit y), the more 
likely  the Sponsor's product cause d the adverse event:
●Exposure:   Is there evidence that the participant was actuall y exposed to the 
Sponsor's product such as:  reliable history , acceptable compliance assessment 
(pill count, diary , etc.), expected pharmacologic effect, or measurement of 
drug/metabolite in bodil y specimen?
●Time Course:   Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor's product? I s the time of onset of the AE 
compatible with a drug -induced effect (applies to studies with investigatio nal 
medicinal product)? 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 114
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidential●Likely Cause:   Is the AE not reasonabl y explained by  another etiology  such 
as underl ying disease, other drug(s)/vaccine(s), or other host or environmental 
factors
●Dechallenge: Was the Sponsor's product discontinued or 
dose/expos ure/frequency reduced?
●If yes, did the AE resolve or improve?
●If yes, this is a positive dechallenge. 
●If no, this is a negative dechallenge.
(Note:  This criterion is not applicable if:  (1) the AE resulted in death or 
permanent disability ; (2) the AE resolved/improved despite continuation of 
the Sponsor's product; (3) the study is a single -dose drug study ); or (4) 
Sponsor's product(s) is/are o nly used one time.)
●Rechallenge:   Was the participant re -exposed to the Sponsor's product in this 
study ?
●If yes, did the AE recur or worsen?
●If yes, this is a positive rechallenge. 
●If no, this is a negative rechallenge.
(Note:  This criterion is n ot applicable if:  (1) the initial AE resulted in death 
or permanent disability , or (2) the study is a single -dose drug study ); or (3) 
Sponsor's product(s) is/are used onl y one time.)
NOTE:  IF A RECHALLENGE IS PL ANNED FOR AN ADVERSE EVENT WHI CH 
WAS SERI OUS AND WHI CH MAY HAVE BEEN CAUSED BY THE SPONSOR'S 
PRODUCT, OR IF RE- EXPOSURE TO THE SPONSOR'S PRODUCT POSES 
ADDITIONAL POTENTIAL SIGNIFICANT RISK TO THE PARTI CIPANT THEN 
THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR 
CLINICAL DIRECTOR AS PER DO SE MODIFICATION GUIDELINES IN THE 
PROTOCOL , AND IF REQUIRED, THE INSTITUTIONAL REVIEW 
BOARD/INDEPENDENT ETHI CS COMMITTEE.
●Consistency with Study treatment Profile: Is the clinical/pathological 
presentation of the AE consistent with previous knowledge reg arding the 
Sponsor's product or drug class pharmacology  or toxicology ?
● The assessment of relationship will be reported on the case report forms /worksheets 
by an investigator who is a qualified ph ysician according to his/her best clinical 
judgment, including consideration of the above elements.
● Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor's product relationship).
●Yes, there is a reasonable possibility  of Sponsor's product relationship:
There is evidence of exposure to the Sponsor's product.  The temporal sequence 
of the AE onset relative to the administration of the Sponsor's product is 
reasonable.  The AE is more likely  explained by  the Sponsor's product than by  
another ca use.  
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 115
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidential●No, there is not a reasonable possibility  of Sponsor's product relationship:
Participant did not receive the Sponsor's product OR temporal sequence of the AE 
onset relative to administration of the Sponsor's product is not reasonable OR the 
AE is more likely  explained by  another cause than the Sponsor’s product.  (Also 
entered for a participant with overdose without an associated AE.)
● For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
●There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the Sponsor. However, it is very  
important that the investigator alway s make an assessment of causality  for every  event 
before the initial transmission of the SAE data to the Sponsor.
●The investigator may  change his/her opinion of causality  in light of follow -up 
information and send an SAE follow- up report with the updated causality  assessment.
●The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements
● For studies in which multiple agents are administered as part of a combination 
regimen, the investigator may  attribute each adverse event causality  to the 
combination regimen or to a single agent of the combination.  I n general, causality  
attribution should be assigned to the combination regimen ( ie,to all agents in the 
regimen). However, causality  attribution may  be assigned to a single ag ent if in the 
investigator’s opinion, there is sufficient data to support full attribution of the adverse 
event to the single agent.
Follow -up of AE and SAE
●The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  Sponsor 
to elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This 
may include additional laboratory  tests or investigations, histopathological 
examinations, or consultation with other health care professionals.
●New or updated information will be recorded in the CRF.
●The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
Reporting of AE, SAE, and Other Reportable Safety Events to the Sponsor 
AE, SAE, and Other Reportable Safety Event Reporting to Sponsor via Electronic 
Data Collection Tool
●The primary  mechanism for reporting to the Sponsor will be the electronic data 
collection (EDC) tool.  
● Electronic reporting procedures can be found in the EDC data entry  guidelines (or 
equivalent). 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 116
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
Confidential●If the electronic s ystem is unavailable for more than 24 hours, then the site will 
use the paper AE Reporting form.  
●Reference section 9.3.1 –Time Period and Frequency  for Collecting AE and 
SAE and Other Reportable Safet y Event Information for reporting time 
requirements 
●The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
●After the stud y is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
●If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form or by 
telephone (see next section).
●Contacts for SAE reporting can be found in the Investigato r Trial File Binder (or 
equivalent).
SAE Reporting to the Sponsor via Paper CRF
● If the electronic data collection tool is not operational, facsimile transmission or 
secure e -mail of the SAE paper CRF is the preferred method to transmit this 
information to the Sponsor.
●In rare circumstances and in the absence of facsimile equipment, notification by  
telephone is acceptable with a cop y of the SAE data collection tool sent by overnight 
mail or courier service.
●Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
●Contacts and instructions for SAE reporting and paper reporting procedures can be 
found in the Investigator Trial File Binder (or e quivalent). 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 117
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialAppendix 5: Clinical Laboratory Tests 12.5
The tests detailed in Table 11will be performed by  the local laboratory . 
Protocol -specific requirements for inclusion or exclusion of participants are detailed 
in Section 6.0of the protocol.
Additional tests may  be performed at an y time during the study as determined 
necessary  by the investigator or required b y local regulations.
Table 11 Protocol -Required Safet y Laboratory  Assessments
Laboratory 
AssessmentsParam eters
Hem atology Platelet Count RBC Indices:
•Mean Corpuscular Volume (MCV)
•Mean Corpuscular Hemoglobin (MCH)
•%ReticulocytesWhite Blood Cell (WBC) 
Count with Differential:
•Neutrophils
•Lymphocytes
•Monocytes
•Eosinophils
•BasophilsRed Blood Cell 
(RBC) Count
Hem oglobin
Hem atocrit
Chemistry Sodium Potassium Chloride Phosphorous
Calcium Glucose Bicarbonate / Carbon 
dioxide (CO 2)1Albumin 
Total Protein Blood Urea 
Nitrogen (BUN)2Creatinine ( and 
measured or calculated 
[per institutional 
standard ]creatinine 
clearance [CrCl] ,if 
creatinine is elevated 
above 1.5 times the 
upper limit of normal)3Uric Acid
Alanine 
Aminotransferas
e (ALT) / Serum 
Glutamic -
Pyruvic 
Transaminase 
(SGPT)Aspartate 
Aminotransferase 
(AST) / Serum 
Glutamic -
Oxaloacetic 
Transaminase 
(SGOT)Alkaline PhosphataseTotal Bilirubin (and direct 
bilirubin, if total bilirubin 
is elevated above 1.5times 
the upper limit of normal)
Routine 
Urinalysis•Specific Gravity
•pH, Glucose, Protein, Blood, Ketones by Dipstick
•Microscopic Examination (if blood or protein is abnormal)
Other 
Screening 
Tests•International Normalized Ratio (INR) /Prothrombin Time (PT), Activated Partial 
Thromboplastin Time (aPTT) or Partial thromboplastin time (PTT)4
•Thyroid Function Testing (T4, T3, TSH)5
•Urine Pregnancy Test6
•Serum β -Human Chorionic Gonadotropin (β -hCG)6
•Follicle -Stimulating Hormone (FSH) and Estradiol (as needed in w omen of non -childbearing 
potential only)7
•Serology (human immunodeficiency virus [HIV] Type 1 and Type 2 antibodies; hepatit isB 
surface antigen [HBsAg]/hepatitis B virus antibody; and hepatitis C virus antibody 
ribonucleic acid (HCV RNA)/hepatitis C antibody)8 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 118
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialLaboratory 
AssessmentsParam eters
NOTES:
1. If bicarbonate/CO 2is not done as part of standard of care in your region, these tests do not need to be performed.
2. Blood urea nitrogen is preferred; if not available, urea may be tested.
3. Glomerular filtration rate (GFR) can be used in place of CrCl.
4. Coagulation factors (IN R/PT and aPTT or PTT) should be tested as part of screening procedures for all participants. 
Any participant receiving anticoagulant therapy should have coagulation factors monitored closely throughout the 
study.
5. Total T4 is preferred; if not available, free T4 may be tested. Total T3 is preferred; if not available, free T3 may be 
tested.
6. Women of childbearing potential only. Urine pregnancy test is preferred. If the urine test is positive or cannot be 
confirmed as negative, a serum pregnancy test is requir ed.
7. In women <45 years of age, a high FSH in the postmenopausal range may be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormone replacement therapy. In the absence of 12 months of amenorrhea, 
a single FSH measuremen t is insufficient.
8. Testing is at the discretion of the investigator.
Investigators must document their review of each laboratory  safet y report. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 119
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialAppendix 6: Abbreviations and Trademarks 12.6
Abbreviation/Acronym Definition
ADA Anti-drug antibodies
AE Adverse Event
AJCC American Joint Committee on Cancer, version 8
ALT Alanine aminotransferase
ANC Absolute Neutrophil Count (Peripheral Blood)
AP Alkaline phosphatase
aPTT activated partial thromboplastin time
ASaT All Subjects as Treated
AST Aspartate Aminotransferase
AUC Area Under the Plasma Concentration -Time Curve
BICR Blinded imaging central review
ß-HCG Beta-human chorionic gonadotrophin
BUN Blood urea nitrogen
Cmax Maximum Observed Plasma Concentration
Cmin Minimum Observed Plasma Concentration
Ctrough Trough Observed Plasma Concentration
CNS Central nervous s ystem
COPD Chronic Obstructive Pulmonary Disease
CO 2 Carbon dioxide
CR Complete response
CrCl Creatinine clearance
CRF Case report form
CRPC Castration resistant prostate cancer
CSR Clinical study  report
CT Computed tomograph y
CTCAE Common Terminology Criteria for Adverse Events
CTL A-4 Cytotoxic T -lymphocy te–associated antigen 4
CXCL Cysteine -X-Cysteine Ligand
CXCR1/2 Cysteine -X-Cysteine Chemokine Receptors 1 and 2
DILI Drug -induced liver injury
DLT Dose limiting toxicity
DNA Deox yribonucleic acid
ECG Electrocardiogram
ECI Event of clinical interest
ECOG Eastern Cooperative Oncology  Group
ELRCXC Chemokines containing the sequence glutamate -leucine -arginine 
(ELR) immediately  preceding the cy steine -x-cysteine (CXC) 
motif
EMT Epithelial -mesench ymal transition
EOT End of treatment
FAS Full Anal ysis Set 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 120
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialAbbreviation/Acronym Definition
FEV Forced Expiratory  Volume
FSH Follicle -stimulating hormone
GCP Good Clinical Practice
G-CSF Granulocy te-Colony  Stimulating Factor (Filgrastim)
GFR Glomerular filtration rate
GI Gastrointestinal
GRO -α Growth Related Oncogene-Alpha
HBV Hepatitis B virus
HCV Hepatitis C virus
HIV Human immunodeficiency virus
HRT Hormone replacement therap y
IB Investigator Brochure
ICF Informed consent form
ICH International Council for Harmonisation
iCPD iRECI ST-confirmed progressive disease
iCR iRECI ST-complete response
IHC Immunohistochemistry
IL-8 Interleukin -8
INR International normalized ratio
iPR iRECIST-partial response
irAE immune -related adverse event
IRB/IEC Institutional Review Board/I ndependent Ethics Committee
iRECI ST Modified response evaluation criteria in solid tumor version 1.1 
for immune- based therapeutics
iSD iRECIST-stable disease
IUD Intrauterine device
iUPD iRECI ST-unconfirmed progressive disease
IUS Intrauterine hormone -releasing s ystem
IV Intravenous
IVRS Interactive voice -based registration sy stem
IWRS Interactive web -based registration s ystem
mAb Monoclonal antibody
MCH Mean corpuscular hemoglobin
MCV Mean corpuscular volume
MDSC Myeloid derived suppressor cell
MK-3475 pembrolizumab
MK-7123 navarixin
MMP -9 Matrix Metallopeptidase 9
MPO Myeloperoxidase
MRI Magnetic resonance imaging
MSD Merck Sharp & Dohme Corp.
MSI Microsatellite instability
MSI-H Microsatellite instability -high 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 121
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialAbbreviation/Acronym Definition
MSS CRC Microsatellite stable colorectal cancer
NCI National Cancer Institute 
NSAID Non-sterioidal anti- inflammatory  drug
NSCL C Non small cell lung cancer
ORR Objective response rate
OS Overall survival
PBPK Physiologically  based pharm acokinetic 
PCWG3 Prostate Cancer Working Group 3
PD Progressive disease
PD-1 Programmed cell death protein 1
PD-(L)1 Programmed death ligand 1
PFS Progression free survival
PK Pharmacokinetic s
PO Per os, orall y
POC Proof -of-Concept
PP Per protocol
PR Partial response
PSA Prostate -specific antigen
PT Prothrombin time
PTT Partial thromboplastin time
QD Once Daily
Q3W Once every  3 weeks
RA Accumulation Ratio
RBC Red blood cell
RECI ST 1.1 Response evaluation criteria in solid tumor version 1.1
RNA Ribonucleic acid
SAE Serious Adverse Event
SCH 527123 Navarixin
SAE Serious adverse event
SD Stable disease or standard deviation
SoA Schedule of Activities
sSAP supplemental Statistical Analy sis Plan
SOP Standard operating procedure
SUSAR Suspected unexpected serious adverse reaction
TBL Total bilirubin
T1DM Type 1 diabetes mellitus
TME Tumor microenvironment
TPS Tumor Proportion Score
TSH Thyroid stimulating hormone
ULN Upper limit of normal
WBC White blood cell
WOCBP Woman of childbearing potential 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 122
Protocol/Amendment No.: 034-01 
MK-7123 -034-01 Final Protocol 22-Mar-2018
ConfidentialAppendix 7: Description of the iRECIST Process for Assessment of Disease 12.7
Progression
Assessment at Screening and Prior to RECIST 1.1 Progression
Until radiographic disease progression based on RECI ST 1.1, there is no distinct iRECI ST 
assessment.
Assessment and Decision at RECIST 1.1 Progression
For participants who show evidence of radiological PD by  RECI ST 1.1 as de termined b y the 
Investigator, the Investigator will decide whether to continue a participant on study treatment 
until repeat imaging is obtained (using iRECIST for participant management (see Table 6
and Figure 3). This decision by  the Investigator should be based on the participant’s overall 
clinical condition.
Clinical stability  is defined as the following: 
Absence of s ymptoms and signs indicating clinically  significant progression 
of disease
No decline in ECOG performance status 
No requirements for intensified management, including increased analgesia, 
radiation, or other palliative care
Any participant deemed clinically unstable should be discontinued from study  treatment at 
site-assessed first radiologic evidence of PD, and is not required to have repeat tumor 
imaging for confirmation of PD by  iRECI ST.
If the Investigator decides to continue treatment, the participant may continue to receive 
study  treatment and the tumor assessment should be repeated 4 to 8 weeks later to confirm 
PD by  iRECI ST, per Investigator assessment. Images should continue to be sent in to the 
central imaging vendor for potential retrospective BICR.
Tumor flare may  manifest as any  factor causing radiographic progression per RECI ST 1.1, 
including:
Increase in the sum of diameters of target lesion(s) identified at baseline to ≥20% and 
≥5mm from nadir
oNote: the iRECI ST publication uses the terminology  “sum of measurements”, 
but “sum of diameters” will be used in this protocol, consistent with the 
original RECI ST 1.1 termin ology .
Unequivocal progression of non -target lesion(s) identified at baseline
Development of new lesion(s)
iRECI ST defines new response categories, including iUPD (unconfirmed progressive 
disease) and iCPD (confirmed progressive disease). For purposes of i RECIST assessment, 
the first visit showing progression according to RECI ST 1.1 will be assigned a visit (overall) 
response of iUPD, regardless of which factors caused the progression. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 123
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialAt this visit, target and non- target lesions identified at baseline b y RECIST 1.1 will be 
assessed as usual.
New lesions will be classified as measurable or non-measurable, using the same size 
thresholds and rules as for baseline lesion assessment in RECI ST 1.1. From measurable new 
lesions, up to 5 lesions total (up to 2 per o rgan), may  be selected as New Lesions –Target.  
The sum of diameters of these lesions will be calculated, and kept distinct from the sum of 
diameters for target lesions at baseline.  All other new lesions will be followed qualitativel y 
as New Lesions –Non-target.
Assessment at the Confirmatory Imaging
On the confirmatory  imaging, the participant will be classified as progression confirmed 
(with an overall response of iCPD), or as showing persistent unconfirmed progression (with 
an overall response of iUPD ), or as showing disease stability  or response (iSD/iPR/iCR).
Confirmation of Progression
Progression is considered confirmed, and the overall response will be iCPD, if ANY of the 
following occurs:
Any of the factors that were the basis for the initial iUP D show worsening
oFor target lesions, worsening is a further increase in the sum of diameters of 
≥5mm, compared to an y prior iUPD time point
oFor non -target lesions, worsening is any  significant growth in lesions overall, 
compared to a prior iUPD time point ; this does not have to meet the 
“unequivocal” standard of RECI ST 1.1
oFor new lesions, worsening is an y of these:
An increase in the new lesion sum of diameters by ≥5mm from a prior 
iUPD time point 
Visible growth of new non- target lesions 
The appearance of additional new lesions
Any new factor appears that would have triggered PD by  RECI ST 1.1
Persistent iUPD
Progression is considered not confirmed, and the overall response remains iUPD, if:
None of the progression -confirming factors identified above occurs AND
The target lesion sum of diameters (initial target lesions) remains above the initial PD 
threshold (b y RECI ST 1.1)
Additional imaging for confirmation should be scheduled 4 to 8 weeks from the imaging on 
which iUPD is seen. This may  correspond t o the next visit in the original visit schedule.  The 
assessment of the subsequent confirmation imaging proceeds in an identical manner, with 
possible outcomes of iCPD, iUPD, and iSD/iPR/iCR. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 124
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialResolution of iUPD
Progression is considered not confirmed, and the overall response becomes iSD/iPR/iCR, if:
None of the progression -confirming factors identified above occurs, AND
The target lesion sum of diameters (initial target lesions) is not above the initial PD 
threshold. 
The response is classified as iSD or iPR (depending on the sum of diameters of the target 
lesions), or iCR if all lesions resolve.
In this case, the initial iUPD is considered to be pseudo -progression, and the level of 
suspicion for progression is “reset”. This means that the next visit th at shows radiographic 
progression, whenever it occurs, is again classified as iUPD by  iRECI ST, and the 
confirmation process is repeated before a response of iCPD can be assigned.
Management Following the Confirmatory Imaging
If repeat imaging does not conf irm PD per iRECI ST, as assessed by  the Investigator, and the 
participant continues to be clinically  stable, study  treatment may  continue and follow the 
regular imaging schedule. If PD is confirmed, participants will be discontinued from study  
treatment.
NOTE: If a participant has confirmed radiographic progression (iCPD) as defined above, but 
the participant is achieving a clinically  meaningful benefit ( For those studies in which PFS is 
the primary endpoint, add the following: or if RECI ST 1.1 PD has not be en verified 
centrall y), an exception to continue study  treatment may  be considered following 
consultation with the Sponsor. In this case, if study treatment is continued, tumor imaging 
should continue to be performed following the intervals as outlined in Section 2 and 
submitted to the central imaging vendor.
Detection of Progression at Visits After Pseudo -progression Resolves
After resolution of pseudo-progression (ie, achievement of iSD/iPR/iCR), iUPD is indicated 
by any of the following events:
Target le sions
oSum of diameters reaches the PD threshold ( ≥20% and ≥5 mm increase from 
nadir) either for the first time, or after resolution of previous pseudo -
progression. The nadir is alway s the smallest sum of diameters seen during the 
entire trial, either befor e or after an instance of pseudo -progression.
Non-target lesions
oIf non -target lesions have never shown unequivocal progression, their doing 
so for the first time results in iUPD.
oIf non -target lesions have shown previous unequivocal progression, and this 
progression has not resolved, iUPD results from any  significant further growth 
of non- target lesions, taken as a whole. 
   04W5XD
07WYDZ
Product:  MK-7123 SCH 527123 125
Protocol/Amendment No.: 034-01 
MK-7123-034-01 Final Protocol 22-Mar- 2018
ConfidentialNew lesions
oNew lesions appear for the first time
oAdditional new lesions appear
oPreviously  identified new target lesions show an increase of ≥ 5 mm in the 
new lesion sum of diameters, from the nadir value of that sum
oPreviously  identified non -target lesions show an y significant growth
If any of the events above occur, the overall response for that visit is iUPD, and the iUPD 
evaluat ion process (see Assessment at the Confirmatory  Imaging above) is repeated. 
Progression must be confirmed before iCPD can occur.
The decision process is identical to the iUPD confirmation process for the initial PD, with 
one exception:  if new lesions occu rred at a prior instance of iUPD, and at the confirmatory  
imaging the burden of new lesions has increased from its smallest value (for new target 
lesions, the sum of diameters is ≥5 mm increased from its nadir), then iUPD cannot resolve 
to iSD or iPR. I t will remain iUPD until either a decrease in the new lesion burden allows 
resolution to iSD or iPR, or until a confirmatory  factor causes iCPD.
Additional details about iRECI ST are provided in the iRECI ST publication [Seymour, L., et 
al 2017] . 
   04W5XD
07WYDZ